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Summary 
 
Male factor is the underlying cause in 50% cases of infertility, and is most commonly 
characterised by asthenozoospermia (reduced sperm motility). Incredibly, there is currently no 
known treatment for this condition, and the only option is Artificial Reproduction Technology 
(ART) which is expensive and invasive. The development of a novel treatment would fulfil a 
therapeutic niche that needs to be met. Using calcium as a surrogate for motility, a Flexstation 
high-throughput screening assay (HTS) of 3312 drug discovery ion channel compounds was 
performed. The screen identified 14 hit compounds that increase intracellular calcium in human 
spermatozoa. This project investigated these compounds, along with, 6 hit compounds 
previously identified from a HTS of a Chemogenomics library (246 compounds) for their 
potential to enhance sperm motility. One compound, Trequinsin hydrochloride 
(Chemogenomics library), produced statistically significant increases in progressive motility 
(P=0.02) instantaneously (t=0 min), an effect that was sustained for 3 hrs. Trequinsin 
hydrochloride, a potent class 3 phosphodiesterase inhibitor, along with B1, an ion channel 
compound, produced statistically significant increases in penetrating ability of spermatozoa 
through viscous medium. These compounds were both examined on sub-fertile patient samples, 
with positive results, providing preliminary data on their clinical relevance.  
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1.1 Male infertility  
Infertility is most commonly defined by the failure to conceive after a minimum of 12 
months of regular unprotected intercourse (Rowe, 1993, Irvine, 1998, NICE, 2013). In 
the UK an estimated 3.5 million people suffer from infertility (HFEA 2011). 
Information for prevalence of infertility worldwide is based on data from either 
clinically based, (Thonneau et al., 1991, Hull et al., 1985) or population based, 
(Anderson et al., 2009, Walschaerts et al., 2013) studies and are in agreement that 
approximately one in six couples worldwide will have problems conceiving during their 
reproductive life (Irvine, 1998, Boivin et al., 2007). A common factor in each of these 
studies is that male factor infertility is the single most common diagnostic category 
(Hull et al., 1985, Thonneau et al., 1991, Schmidt et al., 1995), thus, male sub-fertility is 
a significant global problem and its prevalence is continuing to negatively impact on 
artificial reproductive technology (ART) (Barratt et al., 2011, Tomlinson et al., 2013). 
There is an urgent requirement to develop new tests for accurately diagnosing male 
infertility and new treatments that are specific to male factor conditions.        
1.2 Diagnosis of male infertility 
1.2.1 Semen analysis 
It is difficult to diagnose male infertility and the universal approach that is most often 
adopted is using conventional criteria described by the World Health Organisation 
(WHO, 1987, WHO, 1992, WHO, 2010e). This criterion is solely based upon a 
descriptive semen analysis involving the assessment of morphology, motility and sperm 
concentration. However, it has generally been accepted that semen analysis is of little 
clinical value for diagnosing infertility (Tomlinson et al., 1999, Agarwal and Said, 
2011) with the exception of circumstances where the man has very low numbers of 
motile sperm (Macleod and Gold, 1951a).   Many groups have examined the robustness 
of semen analysis as a tool for diagnosing infertility with similar conclusions being 
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ascertained as the first study by Macleod and Gold in 1951 (Macleod and Gold, 1951a, 
Cooper et al., 2010). Since this conclusion that semen analysis is of limited value in the 
prediction of male fertility and fertilising ability, there has been a need to develop 
further assessments for evaluating male fertility. To fill this area methods have been 
developed that evaluate sperm functional competence.  
1.2.2 Sperm Function Assays 
A number of assays have been developed that are capable of assessing sperm function 
which evaluates the capabilities of sperm to progress through the female reproductive 
tract and interact with the oocyte (Aitken, 2006, Lefievre et al., 2007, Barratt et al., 
2011). However, currently these tests have yet to make a significant impact on 
management of infertility in a clinical setting (Lefievre et al., 2007, Barratt et al., 2011).  
 
Sperm motility is one of the most important sperm functions generally analysed through 
semen analysis (Macleod and Gold, 1951a, Curi et al., 2003, Darszon et al., 2011). Ca
2+
 
plays a fundamental role in motility, specifically in hyperactivated motility (Ho, 2001, 
Darszon et al., 2011, Barratt et al., 2011).  Current knowledge on how Ca
2+
 is regulated 
by the cell has increased substantially and although there are still gaps in our 
understanding, clinical research suggests that Ca
2+
 regulation could be used as a means 
of identifying sperm dysfunction (Krausz et al., 1996, Costello et al., 2009, Barratt et 
al., 2011).  Currently there are few options available for diagnosing male infertility both 
clinically and in the laboratory and for this reason semen analysis was used in this 
study, along with functional assays, including the Kremer mucus penetration test, to 
determine fertilising capabilities of spermatozoa.   
 
The Kremer sperm penetration test examines the sperm-mucus interaction in vitro. It 
makes use of a glass-capillary tube filled with cervical mucus or a cervical mucus 
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substitute (methylcellulose) which is placed in contact with a sperm sample (Kremer, 
1965, Ivic, 2002). The test predominantly highlights the proportion of progressively 
motile sperm in a sample identifying the number of sperm capable of mucus penetration 
(Katz et al., 1980). This is a simple and effective in vitro test known to provide 
important information about sperm function (Barratt et al., 1989, Abu-Heija et al., 1996, 
Ivic, 2002).   
 
1.3 Asthenozoospermia 
Asthenozoospermia (low sperm motility),  is defined clinically by a semen analysis 
where the total number of motile cells is less than 40% and/or the percentage of 
progressively motile cells is less than 32% (WHO, 2010b). A large retrospective study 
determined that 81% of infertile men are diagnosed with asthenozoospermia, 19% of 
these men had isolated asthenozoospermia and 63% had asthenozoospermia in 
combination with teratozoospermia (poor sperm morphology) and/or oligozoospermia 
(low sperm concentration) (Curi et al., 2003). A low sperm motility can be caused by 
structural (Chemes et al., 1998, Imai et al., 2001, Visser et al., 2011) or functional 
deficiencies (Makler et al., 1980), by a deleterious effect of seminal plasma (Mortimer 
et al., 1998) or by a combination of these factors. There is currently no drug a man can 
take, nor can be added to sperm in vitro to increase sperm motility (Barratt et al., 2011).  
1.4 The Use of ART 
Currently the main treatment options available for motility dysfunction or sperm 
dysfunction, as a whole, is ART. ART comprises of a range of treatments according to 
the severity of sperm dysfunction, i.e. for mild male factor sub-fertility the treatment is 
IUI (Intra Uterine Insemination), for moderate IVF (In Vitro Fertilisation) and for 
severe ICSI (Intra Cytoplasmic Sperm Injection), all of which are expensive and 
invasive (Tournaye, 2012). The use of ART worldwide is increasing with an estimated 5 
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million babies being born worldwide using artificial reproductive technology (ART) 
(ESHRE, 2012). However, the cost of ART is a major deterrent to couples who need 
treatment in both developing and developed countries (Rauprich et al., 2010). Sperm 
movement characteristics and sperm morphology are significantly, positively correlated 
with fertilisation rates in vitro (Sukcharoen et al., 1995, Sukcharoen et al., 1996) 
suggesting that the ability to develop compounds that could increase sperm movement 
characteristics would have a positive effect on in vitro fertilisation rates.  
1.5 Capacitation 
Capacitation (Austin, 1951, Chang, 1951) is the term given to the processes that sperm 
need to undertake in vivo in the female reproductive tract to acquire the ability to 
fertilise oocytes. Sperm capacitation was first discovered independently by Austin and 
Chang in rats and rabbits (Austin, 1951, Chang, 1951). The process of capacitation is 
poorly defined owing to there being no clear marker to indicate the occurrence of 
capacitation (Breitbart, 2002). However, capacitation has been characterized as a 
complex of changes (structural and functional) that occur in the spermatozoon after a 
period of time spend in the female reproductive tract (De Jonge, 2005). Some of these 
changes in mammals include: increases in intracellular Ca
2+
 and cAMP concentrations 
along with changes in the lipid composition of the plasma membranes resulting in a net 
cholesterol decrease (McLeskey et al., 1998, O'Flaherty et al., 2006, de Lamirande and 
O’Flaherty, 2008, Buzadzic et al., 2014). The removal of cholesterol and other sterols 
(de-capacitating factors) from the sperm plasma membrane, during capacitation, along 
with the non-covalently attached glycoproteins being released from the epididymis, 
produces a more fluid membrane environment that prime the spermatozoa for further 
fertilisation cues (Ikawa et al., 2010). During capacitation changes also occur in 
oxidative metabolism, tyrosine phosphorylation, sperm motility (altering to the 
hyperactivated state) and a drastic reorganisation, removal or modification of proteins 
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within the spermatozoa. Changes in the sperm plasma membrane are essential for the 
initiation of sperm motility, hyperactivation and induction of the acrosome reaction 
(Gadella and Visconti, 2006). The ability of the spermatozoa to hyperactivate and 
undergo the acrosome reaction are essential for fertilisation (Bavister, 2002, Liu et al., 
2007). If spermatozoa are unable to capacitate they will be unable to fertilise an oocyte 
successfully without assistance (Fraser, 1998).  
1.6 Initiation of sperm motility 
Mammalian spermatozoa are not motile in the male body they acquire motility after 
ejaculation (Lindemann and Kanous, 1989, Si and Okuno, 1995, Buzadzic et al., 2014). 
Motility is usually initiated by changes in environmental conditions, such as ionic 
concentrations or osmotic stimulation (Morisawa, 1994). During capacitation, early 
events which are regulated by a HCO3
-
/ soluble adenylyl cyclase (sAC) /cAMP/ protein 
kinase A (PKA) pathways initiate sperm motility (Lee and Storey, 1986, Boatman and 
Robbins, 1991b, Salicioni et al., 2007, Visconti, 2009).  Sperm motility is initiated 
immediately after sperm are released from the epididymis after contact with high 
concentrations of HCO3
-
 in the seminal plasma and female reproductive tract (≥20mM) 
(Chen et al., 2000, Zhou et al., 2005, Xie et al., 2006).  HCO3
-
 plays an important role in 
mediating sperm motility and its actions are determined by activation of sAC, which 
initiate an increase in cytoplasmic cAMP levels (Chen et al., 2000, Xie et al., 2006, 
Battistone et al., 2013). This elevated cAMP level triggers activation of PKA which 
stimulates serine/threonine phosphorylation of target proteins, and ultimately, activates 
tyrosine phosphorylation of proteins located mainly in the flagellum in mammals 
(Carrera et al., 1996, Naz and Rajesh, 2004, Battistone et al., 2013). Knock out studies 
have been conducted on sAC and PKA null mice resulting in infertile males, however, 
addition of cell permeant cAMP reinstates flagella beat and sperm motility (Esposito et 
al., 2004, Xie et al., 2013). This indicates that the motility impairment noted is not due 
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to a structural alteration or defect in the sAC null mice (Esposito et al., 2004, Xie et al., 
2013).   
 
 As previously described, during capacitation, cAMP levels increase resulting in 
tyrosine phosphorylation, which, is one mechanism for maintaining sperm motility. In 
addition to this the membrane potential of the cell becomes hyperpolarised and 
intracellular pH (pHi) along with intracellular Ca
2+
 concentration ([Ca
2+
]i) increases in 
both mice (Visconti et al., 1995b), and humans (Brewis et al., 2000, Visconti et al., 
2002). Mature sperm stored in the epididymis are quiescent due to the male 
reproductive tract having an acidic pH (~5.5 to 6.5). Sperm motility is initiated on 
ejaculation when sperm are mixed with seminal plasma (extracellular pH>7) which 
cause the pHi to increase within the cell to approximately 6.8 (Hamamah et al., 1996), 
subsequently, while traversing the female reproductive tract, the pHi is elevated further 
(Hamamah et al., 1996, Lishko et al., 2012b, Kirichok and Lishko, 2011). Intracellular 
alkalinisation is another important factor that regulates the initiation of sperm motility, 
capacitation and hyperactivation (Hamamah et al., 1996, Suarez, 2008, Lishko and 
Kirichok, 2010).  
1.6.1 Hyperactivation 
Hyperactivation is the term given to the change in sperm swimming and is a 
concomitant event with capacitation in humans, it involves a change from symmetrical 
flagella beats to high amplitude, asymmetrical flagella bending (Suarez, 2008). It was 
first described in sperm from hamsters undergoing capacitation in vitro and similar 
patterns of movement were observed in situ through the walls of the oviductal ampulla 
of golden hamsters at the time of fertilisation suggesting a potential role in fertilisation 
(Yanagimachi, 1970). Hyperactivation has since been observed in vitro in spermatozoa 
from a variety of mammals including; rabbit (Johnson et al., 1981), mouse (Fraser, 
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1977), dog (Mahi and Yanagimachi, 1978), bull (Singh et al., 1983) and human 
(Mortimer et al., 1984). Hyperactivated motility is a property of the flagella although it 
is often measured according to changes in head movement. The changes observed 
between non-hyperactivated and hyperactivated spermatozoa are results of changes in 
the degree of axonemal bending along with changes in the propagation of flagella beats 
(Mortimer et al., 1997). Studies on human sperm capacitation have identified three main 
patterns of movement: (i) forward progressive motility (figure 1-1A), (ii) transition 
motility which is similar to progressive motility but has a more irregular track (figure  
1-1B) and (iii) hyperactivated motility (figure 1-1C) (Mortimer and Mortimer, 1990). In 
vitro, hyperactivated spermatozoa have been described as swimming in ‘circles’ or 
having a ‘starspin’ motion (Ho and Suarez, 2001, Mortimer and Swan, 1995, Burkman, 
1991). The hyperactivated movement pattern of human sperm is ‘biphasic’, similarly to 
rabbit sperm, meaning that the spermatozoa switch between a whiplash (hyperactivated) 
phase and a progressive phase (non-hyperactivated), depending on the environmental 
cues from the female reproductive tract and oocyte vestments, allowing the cell to alter 
its motility according to the requirements of the environment (Pacey et al., 1995, 
Mortimer and Swan, 1995, Mortimer and Mortimer, 1990, Olson et al., 2011).   
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Hyperactivation is crucial to sperm function aiding the sperm to travel along the female 
reproductive tract. The exact role that hyperactivation plays is still debated but, 
evidence suggests, it may facilitate migration through the highly viscous cervical mucus 
and enable penetration of the layers surrounding the oocyte (Suarez et al., 1991, Suarez, 
2008, Ren et al., 2001). Experiments have also shown that hyperactivation may be 
required to detach the sperm from the oviductal epithelium in both animals and humans 
(Demott and Suarez, 1992, Pacey et al., 1995). Clinical studies in humans have 
provided data identifying that the percentage of hyperactivated sperm cells correlates 
with successful fertilisation in vitro (Sukcharoen et al., 1995). The central regulator of 
hyperactivated motility is an elevated [Ca
2+
]i level which is required for both initiation 
and maintaining the hyperactivated state (Alasmari et al., 2013a). There are at least two 
sources of Ca
2+
 that regulate the hyperactivated state in mammalian sperm these are; 
Figure 1-1 Schematic of motility patterns identified during capacitation. (A) forward 
progressive motility, (B) transition phase – moving in a forward direction but with larger ‘whip-
like’ action and (C) hyperactivated motility. Capacitated sperm are biphasic and switch between 
the three patterns of movement. (Mortimer and Mortimer, 1990) 
A 
B 
C 
21 
 
entry through pH dependent CatSper channels located in the plasma membrane of the 
principle piece of the flagella (Ren et al., 2001, Olson et al., 2010, Ren and Xia, 2010) 
and mobilisation of stored Ca
2+
 from the neck/midpiece region of the sperm cell 
(Costello et al., 2009, Ho and Suarez, 2001). 
1.7 The role of Ca
2+
 signalling in sperm motility  
Sperm lack endoplasmic reticulum meaning functional regulation by transcription/ 
translation will be very limited. Therefore, post-translational mechanisms primarily 
control all activities of the cell (Costello et al., 2009).  One such mechanism involves 
changes in intracellular Ca
2+
 concentration. [Ca
2+
]i signalling is achieved through Ca
2+
 
entering the cytoplasm (low Ca
2+
 concentration) from the extracellular space or 
intracellular organelles (Ca
2+ 
concentration four orders of magnitude higher) (Costello 
et al., 2009). It is well established that Ca
2+
 permeable channels exist in the plasma 
membrane of sperm cells. To initiate signalling Ca
2+
 channels need to open to allow the 
flow of ions down their electrochemical gradient (Costello et al., 2009). Regulation of 
protein function through Ca
2+
 signalling plays a central role in controlling activities that 
are vital for sperm function, including motility, hyperactivation, chemotaxis and the 
acrosome reaction (Publicover et al., 2007, Darszon et al., 2011).  
1.7.1 Calcium channels in sperm  
1.7.1.1 Voltage gated Ca
2+ 
channels  
Voltage-gated Ca
2+
 channels (CaV) produce increases in [Ca
2+
]i in response to  
membrane  potential (Em) changes (Darszon et al., 2011). The channels have been 
divided into two separate groups: high voltage activated (HVA), defined as N-type, 
P/Q-type, and R-type Ca
2+ 
currents which require strong depolarisation for activation 
(Tsien et al., 1991, Catterall and Few, 2008) and low voltage activated (LVA) which 
were initially classified as T-type because they open transiently, need weaker 
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depolarisations to open and inactivate faster at more negative potentials (Darszon et al., 
2011).  
 
G-proteins have been found to regulate CaV channels through many different pathways, 
this can be via direct activation with physical interactions between the channel and the 
G-protein or by indirect activation via second messengers and/or protein kinases 
(Dascal, 2001). CaV channels can be stimulated by several protein kinases including 
PKA, protein kinase C (PKC) and Ca
2+
/calmodulin dependent protein kinase II 
(CaMKII) (Welsby et al., 2003, Catterall, 2000, Catterall and Few, 2008, Dai et al., 
2009). Ca
2+
,
 
itself, is known to inactivate CaV channels by associating with CaM. The 
mechanisms are best known for CaV1 and CaV2 channels, however it is possible that 
CaV3 channel functions could also be influenced by CaM (Lopez-Gonzalez et al., 2001). 
RT-PCR experiments have revealed the presence of transcripts for CaV1, 2 and 3 in 
mouse spermatogenic cells and mature human sperm (Goodwin et al., 2000, Park et al., 
2003, Serrano et al., 1999). Patch clamp studies have not been able to reveal CaV1 or 
CaV2 channels in spermatogenic cells however; CaV3 currents have been well 
documented in spermatogenic cells in mice and humans using this technique (Darszon 
et al., 2006, Escoffier et al., 2007, Liévano et al., 1996). These studies suggest that these 
channels could be present in an electrophysiologically inactive state and may become 
activated during sperm maturation (Darszon et al., 2011).    
1.7.1.2 Voltage-gated proton channel HV1  
In mammals the regulation of pHi is fundamental for the initiation of sperm motility, 
capacitation, hyperactivation and the acrosome reaction (Yanagimachi, 1994). The 
proton selective, voltage-gated ion channel (HV1) was cloned in 2006 and it has been 
reported that voltage-gated proton channels are functionally expressed in mammalian 
sperm (Lishko et al., 2010). HV1 is abundantly expressed in human sperm cells and is 
located to the principal piece of the flagellum. This makes it perfectly located to activate 
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pH-dependent proteins of the axoneme and control motility (Ren et al., 2001, Kirichok 
and Lishko, 2011, Lishko and Kirichok, 2010). A role for HV1 in the regulation of 
[Ca
2+
]i homeostasis has been proposed  involving active proton extrusion to maintain 
pHi balance after CatSper activation (Lishko et al., 2012b). Potentially, a depolarizing 
stimulus could also create an increase in pHi via the HV1 channel resulting in activation 
of CatSper and hyperactivated motility (figure 1-2) (Ren and Xia, 2010, Mannowetz et 
al., 2013). 
1.7.1.3 CatSper 
CatSper is a sperm specific cation channel that facilitates the entry of Ca
2+
 into 
spermatozoa (Barratt and Publicover, 2012, Lishko et al., 2011). The CatSper channel is 
located in the principle piece of the flagellum and through this position it is able to have 
a key role in sperm motility (figure 1-2) (Barratt and Publicover, 2012, Ren et al., 
2001).  
 
 
 
 
 
 
 
 
Figure 1-2 Diagram of labelled Human Spermatozoa indicating position of CatSper channel. 
Yellow areas  highlight stores of Ca
2+
 (Barratt and Publicover, 2012) 
 
The CatSper ion channel is comprised of four homologous pore-forming α subunits 
(CatSper 1-4) and three auxiliary subunits, CatSper β, γ and δ (Brenker et al., 2012). 
The Channel was identified through the use of the Patch clamp technique. Research 
using this technique discovered that Ca
2+
 entry into sperm triggered by progesterone is 
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through CatSper (Strunker et al., 2011, Lishko et al., 2011, Barratt and Publicover, 
2012). An influx of Ca
2+
 is crucial for spermatozoa to be capable of fertilisation 
(Publicover et al., 2007) having been shown to play a role in hyperactivation, 
chemotaxis and the acrosome reaction (Publicover et al., 2007, Costello et al., 2009).  
 
CatSper initiated increases in [Ca
2+
]i can be induced by some of the most important 
stimuli in sperm function including cyclic nucleotides, alkaline depolarisation, zona 
pellucida glycoproteins  and bovine serum albumin, although many of the mechanisms 
of action are still not understood (Ren and Xia, 2010). The CatSper channel is pH 
sensitive and physiologically progesterone and prostaglandin have been identified as its 
most potent activators (Strunker et al., 2011, Brenker et al., 2012, Barratt, 2011). 
Progesterone has been shown to have an effect on CatSper in vitro at equivalent 
concentrations to the normal concentrations that the sperm would encounter in vivo (3-
5µM) (reviewed in (Baldi et al., 1998)).  Both high and low concentrations of 
progesterone have been shown to rapidly increase [Ca
2+
]i through Ca
2+
 induced Ca
2+
 
release (CICR) (Sagare-Patil et al., 2012). Activation by progesterone causes an influx 
in Ca
2+
 through the CatSper channel which triggers multiple Ca
2+
 dependent 
physiological responses that are essential for fertilisation (Lishko et al., 2011). It had 
previously been believed that progesterone acted to elevate cAMP levels, which in turn, 
elevated [Ca
2+
]i in human spermatozoa (Ren et al., 2001). However, Strunker et al were 
unable to confirm this suggesting that signalling in human spermatozoa is not through 
G-protein coupled receptor operated cAMP (Strunker et al., 2011).  Strunker et al 
reasoned that the principle voltage gated Ca
2+
 channel in human sperm is CatSper.  
 
Along with progesterone, voltage- sensitive Ca
2+
 selective currents have been shown to 
induce hyperactivation via CatSper. These currents are potentiated by a rise in 
intracellular pH suggesting that the alkalinisation that occurs during capacitation acts to 
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increase CatSper conductance shifting it to a more negative membrane potential (figure 
1-3). This shift increases CatSper mediated Ca
2+
 entry, increasing [Ca
2+
]i, which in turn 
activates hyperactivation (Qi et al., 2007). 
 
Knock out studies on mice identified that disruption to any of the four genes results in 
sperm abnormalities including decreased total motility, progressive motility and an 
inability to undergo hyperactivation rendering them infertile (Qi et al., 2007, Avidan et 
al., 2003). Currently in humans defects have been found on CatSper1, 2, 3 and 4 that 
have been linked to infertility (Visser et al., 2011). Failed fertilisations as a result of 
mutations were attributed to the sperm being unable to evoke a depolarisation, which is 
caused by Ca
2+
 entry, eliminating their ability to become hyperactivated (Hildebrand et 
al., 2010).  
 
The CatSper associated progesterone receptor is sperm specific and structurally differs 
from the genomic form. This enables it to be a specific target for development of drugs 
to aid fertility or as a novel male non-hormonal contraceptive (Lishko et al., 2011, 
Carlson et al., 2009). Functional CatSper is only found in mature spermatozoa 
indicating that there should be no adverse effects anywhere else in the body if targeted 
specifically. HC-056456 (blocks alkaline KCl-evoked increases in [Ca
2+
]i and [Na
+
]i) 
has been shown to be effective at blocking CatSper which resulted in treated sperm 
being unable to hyperactivate. Furthermore, addition of this compound to already 
hyperactivated sperm resulted in a complete reversal from the hyperactivated state back 
to a normal swimming pattern (Carlson et al., 2009). This indicates the importance of 
CatSper and Ca
2+
 in sperm motility.  
1.7.1.4 KSper 
During capacitation sperm cells undergo intracellular alkalinisation, increases in [Ca
2+
]i 
and membrane hyperpolarization (Visconti et al., 2002). These processes are regulated 
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by sperm ion channels including Hv1 (major H
+
 channel) and CatSper (major Ca
2+
 
channel) in human sperm (Ren et al., 2001, Kirichok et al., 2006, Lishko and Kirichok, 
2010, Lishko et al., 2011). However, until recently the identity of the main K
+ 
channel 
in human sperm remained unknown. K
+ 
channels are vital functional components of 
sperm physiology regulating membrane potential and cell motility (Mannowetz et al., 
2013, Mansell et al., 2014). In mice an alkalinisation-sensitive, Ca
2+
 insensitive sperm 
K
+
 channel (Slo3) was found to be essential for male fertility and it had been assumed 
that the principle K
+
 channel in human sperm would have a similar molecular identity 
(Schreiber et al., 1998, Santi et al., 2010). However, recent examination through the 
patch-clamp technique in human ejaculated spermatozoa found that human K
+
 currents 
are insensitive to intracellular alkalinisation but dependent upon [Ca
2+
]i (Mannowetz et 
al., 2013). This suggested that the identity of human KSper (hKSper) may be distinct 
from that of murine and mice KSper which are represented by the Slo3 protein. The 
Slo1 channel contains structural additions allowing these channels to sense changes in 
voltage and [Ca
2+
]i (Schreiber et al., 1999). Staining with anti-Slo1 antibodies 
selectively stained the principle piece of the flagellum which is the same location as 
CatSper and HV1 (Mannowetz et al., 2013, Kirichok and Lishko, 2011). A proposed 
model for KSper channels indicates that KSper may act to coordinate the actions of HV1 
and CatSper during capacitation resulting in elevated levels of [Ca
2+
]i and initiation of 
hyperactivated motility (figure 1-3) (Mannowetz et al., 2013).     
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Figure 1-3 Role of human KSper (Slo1) in sperm physiology and hyperactivation. 
As sperm travel through the uterus and fallopian tube they are exposed to progesterone (P) (pM – nM 
range), intracellular alkalinisation is evoked by Hv1 which partially activates CatSper. However, to fully 
activate CatSper the membrane must become depolarized. This is not achieved until sperm are in the 
proximity of the oocyte exposing them to micromolar concentrations of P which blocks hKSper resulting 
in membrane depolarization. This allows CatSper to become fully activated, triggering sperm 
hyperactivation and making fertilisation possible (Mannowetz et al., 2013). 
 
1.7.2 Calcium stores in sperm 
During the final stages of sperm differentiation, during nuclear volume reduction, 
excess material is packaged into the redundant nuclear envelope (RNE) of which an 
established function is unknown. This structure has been identified in sea urchin and 
mammalian spermatozoa and it has now been proposed that it functions as a Ca
2+
 store 
(Garnier-Lhomme et al., 2009, Darszon et al., 2011).  For an organelle to be classified 
as having Ca
2+
 stores it must have two types of Ca
2+ 
transporters; one enabling loading 
of the store and one enabling Ca
2+
 release from the store on demand (Costello et al., 
2009).  
 
Inositol trisphosphate receptors (IP3Rs) and ryanodine receptors (RyRs) have been 
identified as the major intracellular Ca
2+
 channels located in neck/midpiece region of 
sperm (figure 1-2). The activity of these channels is dependent on the action of second 
messenger pathways such as; inositol triphosphate (IP3), cyclic ADP ribose (cADPR) 
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and nicotinic acid–adenine dinucleotide phosphate (NAADP) (Zhu et al., 2010a, Zhu et 
al., 2010b) and they are believed to play a role in sperm hyperactivation.           
1.8 Flexstation screening assay 
The induction of high- throughput screening (HTS) in the 80’s for drug discovery 
became a significant tool for identifying hits in pharmaceutical research (Terstappen et 
al., 2010). HTS is a well established process for lead discovery that is now being used 
for basic and applied research (Mayr and Bojanic, 2009). The process involves the use 
of automation, miniaturization assays and large scale data analysis to screen chemical 
libraries against a variety of extracellular and intracellular molecular targets in an 
attempt to identify novel chemotypes with a desired mode of action (Mayr and Bojanic, 
2009). Recently the availability of large compound sources and identification of novel 
biological targets has dramatically changed the drug discovery process.  HTS has 
evolved into a mature discipline that acts as a crucial source of chemical starting points 
for drug discovery (Mayr and Bojanic, 2009). 
 
Complex systems such as spermatozoa that rely on post-translational modifications 
make discovery of new drugs for fertility fundamentally challenging. In an attempt to 
meet the unmet need for development of alternate treatment to ART, for male factor 
infertility, HTS offers a novel approach to drug discovery. HTS technology has evolved 
to allow for screening of focused libraries towards specific biological targets (Mayr and 
Bojanic, 2009, Miller, 2006).  A screening library at the University of Dundee (UoD) 
Drug Discovery Unit (DDU) is currently being utilised in projects to identify new 
chemical starting points focused on ion channel targets for male factor infertility (Mok 
and Brenk, 2011). The passage of ions across a cell membrane is tightly regulated by 
ion channels. Ion channels are integral membrane proteins that are encoded by 
approximately 400 ion channel genes in the human genome (Mok and Brenk, 2011). 
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This family of membrane proteins is implicated in many important physiological 
functions in excitable and non-excitable cells and they underlie a wide range of diseases 
(Terstappen et al., 2010, Mok and Brenk, 2011, Lu and An, 2008). As a result, they are 
the third largest class of targets, after G-protein coupled receptors and protein kinases, 
in drug discovery (Lu and An, 2008, Mok and Brenk, 2011).   
 
Martins da Silva et al (2012) developed and optimised a novel high throughput 
screening assay that assessed Ca
2+
 responses evoked by progesterone in human sperm 
(Martins da Silva et al., 2012). This HTS assay utilised a Flexstation microplate reader 
to measure increases in [Ca
2+
]i as a response to progesterone exposure (Martins da Silva 
et al., 2012). This has enabled screening of a chemogenomics library, a novel UoD 
DDU ion channel library and a library targeting GABA A receptors to identify 
compounds that increase [Ca
2+
]i  in human sperm cells. The Flexstation assay uses Ca
2+
 
as a surrogate for motility and is being used as the primary assay for identifying novel 
drugs that have the potential of modulating sperm motility.          
1.9 Chemical stimulation of sperm motility 
Previous attempts at improving ART fertilisation rates through chemical stimulation 
highlighted non-specific inhibitors of phosphodiesterases (PDEIs) e.g. pentoxifylline 
(PTX) as a potential treatment. PDEs hydrolyze the 3’, 5’-phosphodiester bonds of 
cAMP or cGMP to regulate the effects of these important messengers (Lefievre et al., 
2000). In 1990 Yovich et al (1990) released a study that identified significantly 
improved fertilisation rates after using PTX (Yovich et al., 1990).  The use of PTX in 
sperm preparations, for couples undergoing fertility treatment, has also reduced the rates 
of failed fertilisation when dealing with male factor infertility (Yovich, 1993). PTX 
increased hyperactivated motility in human spermatozoa when under conditions that 
support capacitation (Kay et al., 1993). A further study reported higher pregnancy rates 
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after PTX treatment used in combination with IUI (Stone et al., 1999). However, results 
from PTX use were inconsistent with several groups identifying lower fertilisation rates 
in vitro along with the occurrence of a premature acrosome reaction (Tesarik et al., 
1992, Ford et al., 1994, Yovich, 1993). PTX introduced the possibility of chemical 
stimulation for clinical application, although its use was discontinued, the potential for 
specific PDEi’s in treating male factor infertility warrants further study.   
1.10 Computer assisted sperm analysis (CASA) of sperm motility 
Dedicated computer assisted sperm analysis systems have been available commercially 
for 25 years (Mortimer and Mortimer, 2013a) and are capable of measuring sperm 
motility and sperm movement characteristics (kinematics) (Mortimer, 1997).  Technical 
issues concerning their ability to accurately determine sperm concentration in semen 
(Mortimer et al., 1995, Fraser et al., 1997) has discredited their use since the beginning. 
However, in washed preparations CASA is capable of reliably and accurately 
determining sperm kinematics, percentage motility and concentration provided that 
recommended criteria are followed (Fraser and Group, 1998). CASA analysis has 
proved to be invaluable in research and in infertility diagnosis (Mortimer, 2000b). It has 
to be noted that averaged values of sperm kinematic measures from a population alone 
are meaningless and to identify sub-populations that are biologically accurate measures 
have to be determined on a cell-cell basis by combining several kinematic parameters 
(Fraser and Group, 1998, Mortimer and Mortimer, 2013a). The kinematic values 
determined by CASA for each individual sperm cell includes the velocity of movement, 
the width of the sperm head’s trajectory and the frequency of the change in direction of 
the sperm head (David et al., 1981). The velocity parameters determined are the average 
path velocity (VAP), which is the average direction of movement measured for the 
distance travelled by the sperm cell in the observable area, curvilinear velocity (VCL) 
which refers to the total distance covered by the sperm head and straight-line velocity 
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(VSL) which is determined from the straight-line distance between the first and last 
points of the trajectory (figure 1-4). 
  
 
 
 
 
 
The shape of the trajectory influences the velocity values and three further velocities; 
Linearity (LIN), Straightness (STR) and Wobble (WOB) can be calculated from the 
ratios of the velocity values (Mortimer, 2000b). These values are determined as follows: 
LIN = (VSL/VCL) x 100 
STR = (VSL/VAP) x 100 
WOB = (VAP/VCL) x 100  
The CASA also determines the amplitude of lateral head displacement (ALH) from the 
VAP and is calculated as the total width of the lateral movement of the sperm head 
(figure 1-4).  Beat cross frequency (BCF) is calculated by counting the number of times 
the curvilinear path crosses the average path per second. This value is useful when 
estimating the change in the flagella pattern but a limitation of this is the limited number 
of observations that can be made per second, if there are more beats per second than 
images captured per second then the BCF will be underestimated (Mortimer and Swan, 
1999, Mortimer, 2000b). To be able to determine useful information from sperm 
kinematic analysis a range of normal kinematic values for movement need to be 
identified and matched to a proportion of sperm cells in a population that meet the 
Figure 1-4. Schematic identifying motility trajectories as determined by CASA. 
(Mortimer, 2000b)  
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criteria (Mortimer, 2000b). Using this criteria and CASA it is then possible to determine 
the likelihood that a proportion of spermatozoa from a semen sample are capable of 
penetrating his partner’s cervical mucus quickly and without having to obtain cervical 
mucus (Mortimer, 2000b). Motility parameters such as hyperactivated motility which, 
under normal circumstances, is only exhibited under capacitating conditions in human 
sperm, analysed at 60Hz, have to meet the criteria of VCL ≥150 µm/s and LIN ≤50% 
and ALH  ≥7.0 µm (Mortimer et al., 1998). Non-capacitated human sperm cells or 
sperm cells in semen normally portray parameters of motility that are defined by CASA 
under slow (VAP ≤ 5 µm/s), medium (VAP between 5-25 µm/s), rapid (VAP ≥25 µm/s) 
and/ or progressively motile (VAP ≥25 µm/s, STR ≥80%,  ALH ≥ 2.5 µm and <7.0 µm) 
(Mortimer and Mortimer, 2013a). The benefits of CASA analysis, both in research and 
in the clinical laboratory, is diverse and through correct practice is able to give greater 
understanding of the physiological implications of sperm motility. This makes it 
possible to quickly predict the ability of a man’s sperm to penetrate his partner’s 
cervical mucus and to identify sperm showing hyperactivated motility under 
capacitating conditions to help identify the best course of treatment (Mortimer, 2000b, 
Mortimer and Mortimer, 2013a). 
1.11 Thesis Aims 
Previous research has identified the importance of Ca
2+
 signalling for sperm motility. 
Clinical studies have suggested a relationship between low intracellular Ca
2+
 and male 
factor infertility and numerous studies have highlighted the importance of sperm 
motility when correlated to fertilisation success. There are still many questions 
regarding Ca
2+
 signalling and regulation of motility in human sperm especially 
regarding the central role that Ca
2+
 signalling plays in sperm function. Ca
2+
 channels 
have been identified as potentially important targets for pharmacological interventions, 
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therefore, a series of experiments were designed and conducted with the following aims 
in mind: 
1. To identify a sub-group from donor spermatozoa that can be used as a surrogate 
for patient samples.  
2. To develop a standard operating procedure for screening compounds identified 
from the Flexstation high throughput screen to identify compounds that enhance 
motility.  
3. To examine the effects of novel compounds mediating sperm motility on 
research sperm donors and sub-fertile patients. 
4. To determine, by assessing data from two established clinics the incidence of 
asthenozoospermia in isolation and combination with other sperm parameters to 
identify patients who would benefit from treatment from therapeutic 
advancements and relate this to fertilisation success.     
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CHAPTER 2 
Methods and Materials 
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2.1 Reagents and Stocks 
Stock solutions of 1% dimethyl sulfoxide (DMSO) in distilled water were prepared on a 
monthly basis and stored at room temperature until use. 
 
To make the stocks for PHA665752, inhibitor of MET kinase and Leelamine 
hydrochloride (CB1
 
agonist), each were dissolved in DMSO to a concentration of 80mM 
and stored in the freezer (-20
o
C) (source and catalogue numbers see appendix). These 
80mM stocks were further diluted in dH2O to make aliquots with a final concentration 
of 4mM. The final concentration of PHA665752 and Leelamine hydrochloride when in 
the sperm suspension was 40µM, which is the same concentration the compounds were 
screened at through the Flexstation assay screen, with final concentration of DMSO not 
exceeding 1%.     
 
Stock solutions for GP1a (CB2 agonist), JX401 (inhibitor of p38α), EO1428 (inhibitor 
of p38α and p38β) and Trequinsin hydrochloride (inhibitor of cGMP-inhibited 
phosphodiesterase, PDE3) were prepared by dissolving in DMSO (GP1a, EO1428 and 
Trequinsin hydrochloride 80mM, JX401 70mM), and stored in the freezer (-20
o
C) 
(source and catalogue numbers see appendix). Aliquots of these stocks were further 
diluted in DMSO to a final volume of 4mM, and stored in the freezer (-20
o
C) for no 
longer than 4 months. The final concentration of each; GP1a, JX401, EO1428 and 
Trequinsin hydrochloride, in sperm suspension was 40µM to ensure it matched the 
concentration of the compounds in the Flexstation assay screen, with a final 
concentration of DMSO not exceeding 1%.    
 
Stock solutions for A1-H1 and A2-G2 were produced by the UoD DDU at a 
concentration of 10mM made up in 100% DMSO and further diluted in dH2O to a 
concentration of 1mM and stored at 4
o
C. The final concentration of each of these 
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compounds in sperm suspension was 10µM (same concentration as used in the 
Flexstation screen) with a final concentration of DMSO not exceeding 1%.  
2.2 Media used for donor samples 
A non- capacitating HEPES-buffered medium (NCM) was used to measure samples 
under a non-capacitated state, consisting of: 1.8mM CaCl2, 5.4mM KCl, 0.8mM 
MgSO4.7H2O, 116.4mM NaCl, 1.0mM NaH2PO4.2H2O, 5.55mM D-glucose, 2.73mM 
sodium pyruvate (C3H3NaO3), 41.75mM sodium lactate (NaC3H5O3), 25mM HEPES, 
0.3% BSA  dissolved in 10mls H2O (total volume: 50ml) (Matson and Tardif, 2012, 
Alasmari et al., 2013a). The pH was adjusted to 7.4 by the addition of 1M NaOH with 
an osmolarity of 290-320mOsm/kg. A synthetic tubal fluid (STF) was used as a 
capacitating medium (CM) (adapted from NCM). This was used to measure samples 
under capacitating conditions derived similarly to NCM but containing 26mM sodium 
bicarbonate (NaHCO3) instead of HEPES and 25mM NaC3H5O3 instead of 41.75mM 
(in NCM). The STF was adjusted to pH 7.4-7.6 by the addition of 1M NaOH with an 
osmolarity of 290-320mOsm/kg (source and catalogue numbers see appendix).  
2.3 Samples 
2.3.1 Ethical Approval  
Volunteer sperm donors (healthy men selected at random from the general public 
(mainly students) with no known fertility problems) were recruited in accordance with 
the Human Fertilisation and Embryology Authority (HFEA) Code of Practice (version 
8) (covers donor recruitment) under local ethical approval (08/S1402/6). Written 
consent was obtained from patients in accordance with the HFEA Code of Practice 
(version 8) under the same ethical approval as stated above from the Tayside Committee 
of Medical Research Ethics B (patient and donor participation, see appendix for consent 
forms).  
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2.3.2 Semen Samples 
Volunteer donor semen samples were produced by masturbation into a sterile plastic 
container following 2-3 days sexual abstinence. Samples were produced in the morning 
and brought to the lab within 1 hour (hr) of production. The samples were left to liquefy 
at 37
o
C for approximately 30 min before being analysed. 
Semen samples collected from patients were produced in the Assisted Conception Unit 
(ACU) by masturbation into a sterile container, following 2-3 days abstinence, on the 
morning of treatment, and prepared by the ACU laboratory by density gradient 
centrifugation. 1.5ml gradients were layered using 40% and 80% PureSperm
®
 with 2ml 
semen overlaid on top. After centrifuging at 300g for 20 min the 80% fraction was 
recovered and washed in 5ml SAGE
®
 gamete buffer which was centrifuged at 500g for 
10 min. If the sample was used in an ICSI procedure the required amount of 80% 
fraction was left in 100μl SAGE® gamete buffer. If used for IVF the 80% fraction was 
re-suspended in Quinn’s Advantage® fertilisation medium supplemented with human 
serum albumin (HSA). Surplus sample not required for treatment were used in research. 
‘Morning’ samples were prepared in the ACU laboratory by PureSperm® DGC 
(described above) (source and catalogue numbers see appendix). A proportion of the 
80% fraction is removed to be used for treatment whilst the remainder of the 80% and 
the 40% fraction are combined back together and made available for research. The 
sample is then re-prepared in the research laboratory (to re-separate sperm into 40% and 
80% fractions), by Percoll
®
 density gradient (described below), and the 80% fraction 
collected. Samples used in chapter 3 represent patient samples donated to research 
following ACU embryologist preparation that were then re-prepared in the research 
laboratory. ‘Afternoon’ samples were prepared by embryologist preparation in the ACU 
(same as morning samples described above) however; these prepared samples were 
capacitated for a minimum of 3 hrs because they had been placed in the CO2 incubator 2 
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hrs prior to being used for insemination (IVF) in the ACU lab. Following treatment, any 
remaining sample was made available for research but unlike the ‘morning’ samples it 
was not re-prepared before use (samples used in chapters 6&7).  
Semen samples from patients attending the ACU are from couples attending for ART 
and are not necessarily all men with male factor infertility.  
2.4 Sperm preparation 
Semen samples from donors were prepared using the density gradient centrifugation 
(DGC) method to isolate spermatozoa from seminal plasma. A maximum of 1.5ml of 
semen was gently added to the top layer of the density gradient (2ml 40% Percoll
®
 with 
an underlay of 2ml 80% Percoll
®
) and centrifuged at 300g for 20 min. The supernatant 
was discarded followed by collection of the 40% layer and 80% pellet into separate 
wash tubes. Samples were washed in 5ml NCM (centrifuged at 500g for 10 min) 
(Mortimer and Mortimer, 2013b). After centrifugation, the supernatant was discarded 
and the pellet was re-suspended in NCM or CM (source and catalogue numbers see 
appendix).  
2.5 CASA parameters adopted in all experiments 
Samples were diluted in NCM or CM to between  ≥2x106/ml (lower limit, too few cells 
for CASA to distinguish between debris and sperm cells resulting in an increased error) 
(Garrett et al., 2003) and ≤50x106/ml (upper limit, measurement made above 50x106/ml 
are at a higher risk of collisions increasing error) (WHO, 2010c) allowing accurate 
reading on the CASA. Unless otherwise stated, motility was measured after 
centrifugation at time 0 min (time 0 min = addition of NCM/ CM to sample and motility 
measured instantly) then every 30 min for 3 hrs. Samples were kept in the appropriate 
incubator (5% CO2 or normal) between readings. The slides used for readings were 4 
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chambered 20µM depth slides that incur no known drift (MicroCell counting chambers, 
Vitrolife, Inc. San Diego, CA, USA). 
A minimum of 200 cells were counted per frame, with a minimum of 2 frames counted 
per chamber, to give a minimum total of 800 motile spermatozoa counted (unless 
otherwise stated) in every experiment. This number was chosen in order to achieve an 
acceptably low sampling error when evaluating motile cells (WHO, 2010d). 
2.6 Gradient experiment (Chapter 3) to determine most suitable fraction to 
be used as a surrogate for patients  
Gradients were compiled from 1ml 80% Percoll
®
 with an underlay of 1ml 90% 
Percoll
®
, followed by overlaying 2ml of 60%, 40% and 20% Percoll
®
  (2ml of each 
added to reduce contamination between layers when collecting sample) with 1ml sperm 
added and then centrifuged at 300g for 20 min, as described previously. The supernatant 
was discarded followed by collection of each layer into separate wash tubes containing 
5ml NCM. Each wash was centrifuged for 10 min at 500g. Samples were diluted in CM 
and readings taken at 0 min then every 60 min for 5 hrs. 400 cells counted per frame, 4 
frames counted for each chamber giving a minimum total count of 1600 motile cells.  
2.7 Assessment of calcium and motility induced by novel compounds 
2.7.1 Flexstation Assay Screen (experiments conducted by Sarah Matins da Silva in 
combination with the Dundee Drug Discovery Unit (DDU))   
Sperm samples were collected and prepared as previously described.  Following 
preparation by DGC sperm cells were subjected to capacitating conditions for 2 hrs 30 
min. Media and supernatant were removed and cells re-suspended in Flexstation assay 
buffer (1XHBSS, 20mM HEPES, 0.5mM probenecid, pH7.4) and concentration and 
volume ascertained. Approximately 110 million cells constituted in a 5ml volume were 
added to an equal volume of the Ca
2+
 sensitive dye, Calcium 3, which had been made up 
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to twice the manufacturer’s recommended concentration.  Following an incubation at 
37ºC for 60 min, the sperm cells were recovered by centrifugation at 700g for 5 min at 
room temperature and re-suspended in Flexstation assay buffer at a concentration of 5 x 
10
6
 cells / ml.  The cells were plated out onto 384 well clear bottom, black wall plates at 
a concentration of 2.5 x 10
5
 cells / 50µl /well.  The plates were then centrifuged at 700g 
for 5 min at room temperature to ensure the cells were at the base of each well. A plate 
was made up to contain test compounds at a 5x final concentration, with the use of 
10µM progesterone as a control (plated by robotics at DDU).  Both the assay and the 
plates containing compounds along with FLIPR tips were placed into the appropriate 
compartment of the Flexstation. The Flexstation recording was started and 12.5µl of test 
compound was added after 18 seconds (s). Ca
2+
 dependent fluorescence of the Calcium 
3 dye was measured for 100s as recommended by the manufacturer (excitation 
wavelength = 485nm, emission wavelength = 525nm, cut-off = 515nm). Hit compounds 
were identified by software analysis of the area under the curve function when 
compared to progesterone (positive control).  These compounds were then examined for 
any effect they may have on motility (see below).   
2.7.2 Preparation for motility assessment of novel compounds 
Following DGC preparation, each sample was diluted to a final concentration of 
20million/ml. Samples were placed in appropriate incubators NCM-samples in normal 
(37
o
C, 15 min), CM-samples in 5% CO2 (37
o
C, 2 hrs 30 min). 99µl of semen sample 
was then placed in labelled round bottom tubes with the addition of 1µl of appropriate 
drug. 1µl 1% DMSO was added to control tube as a vehicle control. 3µl of sperm 
suspension was then loaded onto preheated fixed chamber Microcell slides and CASA 
analysis conducted (described previously).  
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2.7.3 Sperm penetration into artificial viscous medium (Kremer test) 
Kremer penetration tests were carried out using methylcellulose (an artificial mucus 
substitute) with a viscosity of 4000 cp (MC4000). This was prepared in NCM 
containing 0.3% BSA at 10mg/ml. As previously described (Ivic 2002), 5 cm long, 
rectangular, flattened capillary tubes with a depth of 0.4mm (Camlab Limited 
Cambridge UK) were placed into the methylecellulose for 30 min at 37
o
C to allow the 
tubes to fill. Excess methylcellulose was gently wiped from the tubes and the upper 
ends of the capillary tubes sealed with plasticine. The open end of the tube was placed 
into the prepared sperm at a concentration of ~ 20x10
6
/ml for donor samples. Patient 
samples were capacitated in the ACU lab for a minimum of 3 hrs (as described above) 
they were then diluted in clinic media to a concentration of ~ 2x10
6
/ml.  1µl of 
compound was added to 99µl of sperm suspension, giving a final concentration in each 
case of 10μM A1 - E1, 40µM Trequinsin and 3.6µM progesterone. Controls contained 
1% DMSO to account for any effects produced by DMSO itself. Sperm preparations 
and capillary tubes were then incubated in appropriate incubators (see above) for 1 hr. 
The capillary tubes were then removed and wiped to remove residual spermatozoa from 
the surface of the tubes. The open ends of the tubes were sealed with plasticine, and 
marks were made on the tubes at 1 cm and 2 cm. The tubes were then viewed on an 
Olympus CX41 microscope (20X objective final magnification x200) (Olympus 
Corporation, Tokyo, Japan), with the number of cells being counted at 1 and 2 cm 
distances from the base of the tubes (figure 2-1). Three fields of view were counted for 
three separate planes between the upper and lower wall of the capillary tube and an 
average obtained. Results were normalised to parallel untreated 1% DMSO controls to 
allow comparison between different experiments (source and catalogue numbers see 
appendix). 
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2.8 Assessment of the Acrosome Reaction 
Sperm obtained from donors was prepared by DGC as described previously. Sperm 
acrosomes were studied by staining with lectin from Pisum sativum (pea) (PSA) 
labelled FITC, as described by Liu et al (Liu and Baker, 1988). Prepared sperm were 
capacitated for 2 hr 30 min before being exposed to C1 or D1 at a final concentration of 
10µM for 1 hr. A negative control was exposed only to CM (1 hr), a vehicle control was 
exposed to 1% DMSO (1 hr) and a positive control where sperm were induced to 
undergo the acrosome reaction using Ca
2+
 ionophore (A23187) at a final concentration 
of 10µM for 15 min (Aitken et al., 1993, WHO, 2010a). Sperm were washed twice with 
10ml 0.9% sodium chloride by centrifugation at 600g for 10 min. The sperm pellets 
were re-suspended in 20-30µl sodium chloride and smeared on microscope slides, 
allowed to air dry. The smear was fixed in 95% (v/v) ethanol for 30 min at 4
o
C.  
After some initial experiments to optimise conditions, the final protocol involved using 
12.5µg/ml PSA labelled with FITC in phosphate buffered saline (PBS) (PSA (FITC)) 
for 1 hr at 4
o
C in the dark. The slides were washed in PBS three times and mounted 
Figure 2-1 Model depicting sperm penetration into artificial viscous medium (Kremer test). 
Kremer capillary tubes filled with viscous medium were immersed in sperm suspensions in the 
presence or absence of compounds, and left at 37°C in a 5% CO2 incubator for 1 hr to allow the 
migration of motile spermatozoa. Red lines on the tube show the locations at which sperm numbers 
were counted, i.e. 1 and 2cm from the base of the tube. (Alasmari, 2013)  
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using hydromount (source and catalogue numbers see appendix). At least 200 sperm 
were counted from each slide with 2 slides per treatment, 400 sperm counted total per 
compound, on an EVOS xl digital inverted microscope (Advanced Microscopy Group) 
using fluorescence setting with 400x magnification. Images were captured on the EVOS 
fully integrated colour camera. When more than half a sperm head was brightly 
fluorescing the acrosome was considered to be normal and intact (figure 2-2)       
 
 
 
 
 
 
Figure 2-2. Image depicting acrosome intact (AI) and acrosome reacted (AR) spermatozoa. 
Acrosome intact spermatozoa were identified by more than half the sperm head brightly fluorescing 
whereas acrosome reacted spermatozoa were identified by having a fluorescing equatorial segment and no 
fluorescence elsewhere in the sperm head (Image courtesy of Jones et al.,2010).      
 
2.9 Hypo-osmotic swelling (HOS) test 
Agonists were examined to measure if they significantly compromised sperm viability 
by use of the hypo-osmotic swelling (HOS) test (Jeyendran et al., 1984). The HOS test 
measures sperm membrane integrity and for this test spermatozoa incubated with or 
without agonists were further incubated with hypo-osmotic medium (75 mmol D-
fructose l
−1
 and 25 mmol sodium citrate dihydrate l
−1
) at 37
o
C in 5% CO2 for 30 min 
(source and catalogue numbers see appendix). Sperm with coiled tails were counted as 
viable and were counted from 2 separate aliquots with a minimum of 200 cells counted 
per replicate to reduce sampling error. 
AR 
AI 
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2.10 Statistical analysis 
Normality of data (the supposition that the underlying random variable of interest is 
distributed normally, or approximately so) was assessed according to frequency 
distributions and the Kolmogorov-Smirnov test. Results are expressed as the mean ± SD 
(standard deviation), mean ± SE (standard error). Statistical comparisons were made 
using T-test and the analysis of variance (ANOVA) if the data were either originally 
normally distributed or normalised after transformation. However, some data sets were 
not able to be normalised following transformation thus; the statistical analysis of this 
data was performed using non-parametric tests including Mann Whitney U test and 
Kruskal – Wallis one way analysis of variance on ranks. Pearsons Chi squared analysis 
was conducted when analysing results from the Hypo-osmotic swelling (HOS) test. 
Linear regression analysis was employed when analysing semen data from two separate 
clinics. Significance was considered to be P≤0.05. All statistical analysis was performed 
using SPSS statistics 18.   
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CHAPTER 3 
Identification of a sub-group of donor 
spermatozoa after density gradient 
centrifugation that is comparable to a 
patient sample 
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3.1 Introduction 
The availability of sub-fertile patient semen samples for research purposes is very 
limited and for this reason it would be invaluable to research to be able to isolate a sub-
group of spermatozoa from donor samples that is similar to sub-fertile patients. Patient 
samples can be very variable having problems with low concentration, poor 
morphology, poor motility or combinations of these factors (Curi et al., 2003) making 
this task a difficult one. In an attempt to identify a ‘surrogate’ patient sample from 
normozoospermic donors density gradient centrifugation was used to separate donor 
samples into 6 fractions; 20%, 40%, 60%, 80% and 90%. Each fraction was then 
compared to the 80% fraction procured from sub-fertile patients for their motility 
characteristics. Motility is an important functional characteristic that is related to a 
spermatozoa’s ability to successfully fertilise in IVF (Donnelly et al., 1998). Clear 
differences have been noted in sperm motility between sub-fertile and fertile men 
(Macleod and Gold, 1951b, Barratt et al., 2011) which corroborates the importance of 
identifying a surrogate population of donor sperm to be used in research if sub-fertile 
samples are not available. Poor sperm motility has been associated with defective 
mitochondrial DNA (Oaconnell, 2003) meaning that testing new drug therapies or 
preparation techniques on normozoospermic donors as a substitute for sub-fertile 
patients may give inaccurate results. To be able to accurately determine the effect of a 
new treatment on spermatozoa you need to be able to test on sperm that have similar 
qualities to that seen in patient samples. 
 
 DGC is currently the sperm preparation technique employed by assisted conception 
clinics for preparing spermatozoa before procedures. DGC was initially suggested to be 
used to enhance motility in cases of asthenozoospermia (Berger et al., 1985) and in the 
late 80’s this technique was shown to enhance sperm penetration into human oocytes 
(Guerin et al., 1989). Previous studies have discovered that spermatozoa recovered from 
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different Percoll
®
 fractions and incubated in capacitating media have the ability to 
maintain motility to different extends regarding which fraction the cells are recovered 
from  (Saad and Guerin, 1992). Using this information this study attempted to isolate 6 
different fractions (20%, 40%, 60%, 80% and 90%) from normozoospermic donor 
spermatozoa and compare the motility parameters from the spermatozoa recovered from 
each fraction to that of sub-fertile patient spermatozoa recovered from the 80% fraction. 
Previous studies have examined and analysed motility parameters from spermatozoa 
recovered from different fractions after DGC however, these studies were attempting to 
identify the fraction that contains the ‘best’ spermatozoa to be used clinically in ART 
(Saad and Guerin, 1992, Moohan and Lindsay, 1995, Forster et al., 1983, Yao et al., 
1996). We have been unable to locate a study that compares fractions from donor 
spermatozoa with that of sub-fertile patients. 
 
The main aim of this chapter is to isolate and identify a sub-group of spermatozoa from 
normozoospermic donors that has similar motility characteristics to spermatozoa 
recovered from patients undergoing fertility treatment.       
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3.2 Results 
3.2.1 Comparison between sperm movement characteristics from 
normozoospermic donors after migration through 20%, 40%, 60%, 80% and 90% 
Percoll
®
 gradients, with patient samples after an 80% Percoll gradient
® 
3.2.1.1 Movement of spermatozoa recovered from different fractions of Percoll
®
 
(donor) compared to 80% fraction (patient) 
In the motility assay the motility parameters measured were VCL, ALH, LIN, total 
motile, progressive motile and hyperactivation for each fraction acquired from donor 
samples.  This information was then compared to the information obtained for the same 
parameters from the 80% fraction of sub-fertile patients. In this study we are looking for 
the donor fraction that most closely reflects the motility parameters of the sub-fertile 
sample meaning we are looking at fractions where there is not a significant difference. 
The 20% fraction showed significant differences to the sub-fertile sample concerning 
VCL across all time points (0 min P˂0.01, 60, 120, 240 and 300 min P˂0.05) excepting 
after 180 min where no significant difference was noted (figure 3-1A and appendix).  
The 40% fraction was significantly decreased compared to the sub-fertile sample at 0 
min (P˂0.05) with no significant differences in VCL at any other time point (figure 3-
1A and appendix). No significant difference was noted in the 60%, 80% and 90% 
fraction regarding VCL at 0, 120, 180, 240 or 300 min however, VCL was significantly 
increased in donor samples in all three fractions after 60 min (60%, 80% P˂0.05, 90% 
P˂ 0.01) (figure 3-1A, and appendix).  
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Values for ALH were found to have no significant differences when compared to sub-
fertile patient samples for any of the donor fractions analysed across the entirety of the 
300 min time course (figure 3-1B and appendix). 
 
Maximum linearity values were identified from spermatozoa recovered from the 60%, 
80% and 90% fractions from donors and no significant difference was noted across the 
300 min time course of each of these fractions when compared to the sub-fertile patient 
sample (figure 3-1C and appendix). The linearity values for the 20% and 40% fractions 
were similar (figure 3-1C) and significant decreases were found at time 0 min (20% 
P˂0.005, 40% P˂0.05), 60 min (20% P˂0.05) and 180 min (20% and 40% P˂0.05) in 
donor samples compared to patients (figure 3-1C and appendix). 
 
The percentage of total motile spermatozoa recovered were maximal in the 60%, 80% 
and 90% donor fractions but owing to the huge variation in the percentage of total 
motile spermatozoa recovered from the sub-fertile patients. Significant increases in 
motility from donor spermatozoa were noted at time 0 and 60 min in the 90% fraction 
(P˂0.05) compared to the 80% sub-fertile patient (figure 3-1D and appendix). The 
percentage of total motile in the 20% fraction were significantly lower than the sperm 
recovered from the sub-fertile patient sample at time 0 and 180 min (P˂0.05) but no 
significant differences were identified at any of the other time points (60, 120, 240 or 
300 min) (figure 3-1D and appendix). The 40% fraction showed no significant 
differences at any time points when compared to the sub-fertile sample (figure 3-1D and 
appendix).      
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Figure 3-1 Comparison between donor and sub-fertile samples in Percoll
®
 fractions relative to 
incubation time under capacitating conditions. Overview of 20%, 40%, 60%, 80% and 90% donor 
fraction compared to 80% sub-fertile fraction  for VCL (A), ALH (B), LIN (C) and total motile (D). The 
result shown is the mean ± SEM. N= 5 for both donors and patients, * indicates significant difference 
(P˂0.05),  indicates P˂0.01, indicates P˂0.005 between each individual fraction and the patient sample 
(T-test and Kruskall-Wallace test).  
   * * * 
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The percentage progressively motile spermatozoa recovered from the 20% fraction were 
significantly lower than that of the sub-fertile patients at time 0 and 180 min (P˂0.05) 
(figure 3-2A and appendix). Again there was a large variation in the percentage 
progressively motile cells recovered from the patient samples resulting in no significant 
difference being noted between the 40%, 60%, 80% or 90% fractions in comparison to 
the patient samples at any time point examined (figure 3-2A and appendix). 
 
The percentage of hyperactivated spermatozoa was significantly lower in the 20% 
fraction at time 0 min in comparison to the sub-fertile sample (P˂0.05) (figure 3-2B and 
appendix). A significant increase in the percentage of hyperactive spermatozoa was 
found in the 60%, 80% and 90% fractions after incubation for 60 min (P˂0.05) 
compared to those recovered from the sub-fertile 80% fraction (figure 3-2B and 
appendix).  There were no significant differences identified at any other time points (0, 
120, 180, 240 or 300 min) for the 60%, 80% and 90% fractions. The 40% fraction 
showed no significant differences at any time point across the 300 min time course 
when compared to the sub-fertile samples (figure 3-2B and appendix). 
 
Kruskall-Wallace statistical analysis showed that there was no significant difference in 
any of the parameters measured when looking independently at samples from 20%, 
40%, 60%, 80%, 90% or patients across 300 min time course. This showed that 
incubation time didn’t have an effect either positive or negative on the motility 
parameters measured (VCL, ALH, LIN, total motile, progressively motile and 
hyperactivation).  
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Figure 3-2 Comparison between donor and sub-fertile samples in Percoll
®
 fractions 
relative to incubation time under capacitating conditions. Overview of 20%, 40%, 60%, 
80% and 90% donor fraction compared to 80% sub-fertile fraction  for progressively motile 
(A) and hyperactivation (B). The result shown is the mean ± SEM. N= 5 for both donors and 
patients, * indicates significant difference (P˂0.05) between each individual fraction and the 
patient sample (T-test and Kruskall-Wallace test).  
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3.3. Discussion  
Density gradient centrifugation is a useful sperm preparation technique that allows for 
collection of motile sperm by separation into separate fractions even in cases of 
asthenozoospermia (Berger et al., 1985). This technique is currently used clinically to 
obtain the 80% fraction containing the ‘best’ portion of spermatozoa to be used for 
fertilisation in artificial reproductive technology (Forster et al., 1983, Yao et al., 1996, 
Oaconnell, 2003). The data in this chapter corroborates that of other studies identifying 
that the proportion of spermatozoa collected after density gradient centrifugation from 
the higher percentage Percoll
®
 fraction i.e. 90%, gives you the better overall motility 
parameters (Forster et al., 1983, Saad and Guerin, 1992, Yao et al., 1996). Although, the 
data in this study noted that there were no significant differences across any of the 
parameters measured between the 80% and 90% Percoll
®
 gradient suggesting that an 
80% gradient is of a high enough density to retrieve highly motile spermatozoa. In this 
study the patient samples did undergo a second Percoll
® 
gradient before comparison 
with the donor samples. This could have had a detrimental effect on the motility of 
these samples however previous work in our laboratory has suggested that the effects of 
a second Percoll
® 
gradient are negligible on motility. Previous studies available have 
compared motility parameters (Berger et al., 1985, Forster et al., 1983, Moohan and 
Lindsay, 1995, Saad and Guerin, 1992), morphology (Yao et al., 1996, Forster et al., 
1983), vitality, interaction with zona-free hamster eggs (Forster et al., 1983) and DNA 
damage (Oaconnell, 2003, Ghaleno et al., 2013) between differing fractions obtained 
after density gradient centrifugation from the same sample, however, we have been 
unable to identify any studies that compare fractions taken from normozoospermic 
donors with sub-fertile patient samples.  
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The results from this study show that, concerning VCL, the variability in the patient 
samples means it is not possible to discern which fraction is most similar with 40%, 
60%, 80% and 90% all having values similar to that of the patient sample. With regard 
to ALH, it was again not possible to determine which fraction was comparable to sub-
fertile samples with all fractions expressing similar values (including patients) reflecting 
findings of previous groups (Saad and Guerin, 1992). The data presented in this chapter 
identifies significant differences in more than one parameter and at more than one time 
point for both the 20% and 90% donor fractions when compared to the 80% sub-fertile 
fraction suggesting that they are not suitable comparable fractions to patient samples. 
The 40%, 60% and 80% fractions are all showing similarities to the 80% sub-fertile 
patient samples and from the data available in this study it is not possible to determine 
which of these three fractions is most similar to patients. However, in this study it was 
decided to use the 40% fraction as our poor motility group.  
 
This study has looked specifically and solely at motility parameters and we are aware 
that to be able to accurately determine a sub-population of donor spermatozoa that is 
similar to that of sub-fertile patients, further in-depth analysis would need to be 
completed looking at morphology, DNA damage, vitality, penetration ability, acrosome 
reaction and also account for bacteria/debris (Aitken et al., 1995). This may be the 
reason that this study has not been attempted previously due to the many variables that 
need to be accounted for to make it a valid study. Another factor that may discourage 
people from completing this study could be the knowledge that variation between 
patient samples is large (Macleod and Gold, 1951b) and the ability to identify any 
useful data would depend on having a large sample size, which can be difficult to 
obtain.  
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CHAPTER 4 
Development of Standard Operating 
Procedure for Drug Screening 
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4.1 Introduction 
 In vitro and in vivo sperm motility can be affected by a variety of factors some of which 
can be more easily controlled in an in vitro environment such as; temperature (37
o
C) 
(Esfandiari et al., 2002, WHO, 2010f), exposure to non-capacitating or capacitating 
conditions and types of apparatus used. As an attempt to increase the repeatability and 
reliability of any results obtained within this project, preliminary investigations were 
performed and environmental factors systematically examined thereby producing a 
protocol that limits/accounts for variation in results.  
 
The focus of this chapter was to examine sperm motility under a variety of conditions 
addressing six key questions:  
1. Given the variability within a prepared human sperm population, is it more 
accurate to assess motility parameters in 200 cells from 4 different aliquots 
compared to 400 cells from 2 different aliquots?   
2. Does the use of slides with fixed coverslips give a more accurate representation 
of motility when compared to reusable slides and coverslips?  
3. What is the effect of NCM and CM on sperm motility?  
4. Do CM and NCM have a detrimental effect on sperm motility when incubated at 
37
o
C for long periods of time?  
5. Are motility responses consistent within and between ejaculates?  
6. Does 1% DMSO have a detrimental effect on sperm motility under non-
capacitating and/or capacitating conditions?  
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4.1.1 Minimum number of cells counted to reduce sampling error  
Spermatozoa are erratic and changeable and therefore huge variation in motility within a 
single sample can occur. Standard procedure describing analysis of motility parameters 
using CASA recommends that a minimum of 200 cells per frame from each replicate is 
measured to reduce sampling error (WHO, 2010d, Fraser and Group, 1998). However, it 
is not only important to identify a reliable method of evaluating motility, but to do so in 
the most economical way. To determine whether it was possible to read more than 200 
cells from one replicate whilst maintaining similar variability within results, an 
investigation was devised using a sample split into two groups: 1) four separate aliquots 
of 200 cells measured per time-point and 2) two separate aliquots where 400 cells were 
measured per time-point (see chapter 2).  Semen samples were prepared in the same 
way and cells diluted to the same concentration.  
4.1.2 Variation in motility assessed by different slide types 
When assessing sperm parameters using CASA, there is large variation in sperm 
concentration and motility according to slide type used (Tomlinson et al., 2001). A 
comparison of CASA motility parameters was performed to assess differences between 
the two slide types available in our lab, which could account for variation within results, 
2xCell Hamilton Thorne slides (20μm) with separate coverslips (figure 4a) and 
Microcell 4 fixed chamber slides (20μm) (figure 4b) were evaluated. The Hamilton 
Thorne slides are reusable and therefore washed and recycled, whereas the Microcell 
slides are disposable, single use only.  
 
 
 
Figure 4 Examples of slide types examined. (a) 2xcell Hamilton Thorne slide with manual cover-slips (b) 
Microcell 4 fixed chambered slides. Image adapted from  Spermatogenesis (Mortimer and Mortimer, 2013b). 
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4µl of prepared sperm was added to each chamber of the Hamilton Thorne slides and 
coverslips overlaid thereafter, whereas 3µl per chamber was added to the Microcell 
fixed chamber slides. A time-course experiment was run using a control sample in 1% 
DMSO. Samples were split and motility measured on each different slide type and 
results analysed. The hypothesis was that the Hamilton Thorne slides with the 
coverslips that are manually placed would have an increased chance of causing cells to 
stick to the slide resulting in a decreased total motility and progressive motility 
compared to the fixed chamber slides.  
4.1.3 Between-donor and within- donor biological variation 
If a series of samples are taken from the same person for semen analysis, the results of 
each of the independent deposits will not be exactly the same (Alvarez, 2003). The 
results may vary over time due to a variety of factors including; sexual abstinence 
period, transport of the sample to the laboratory and inherent biological variation 
(Alvarez, 2003).  Spermatogenesis in mammals can range from 30 to 78 days and in 
humans the process takes over 70 days (Hess and Renato de Franca, 2008). To be able 
to account for any within-donor variability as a result of variation in spermatogenesis, 
repeat experiments were performed to compare the same sample over a 4 month period.  
Samples were subjected to capacitating conditions (2 hr 30 min, 37
o
C, 5% CO2) before 
motility assessments (CASA) were performed. Each sample was subjected to the same 
conditions to reduce variation from the external environment.  
 
When the same tests are performed on different individuals the results once again would 
not be the same (Alvarez, 2003). In order to obtain robust and reliable results it is 
important to also be aware of between-donor variability. To be able to account for this a 
comparison in motility parameters between the same 5 donors examined for within-
donor variability was conducted.   
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4.1.4 Effect of DMSO on sperm motility  
DMSO is a solvent used to solubilise and stabilise compounds generated by UoD DDU. 
In future experiments we planned to examine motility effects of DDU library 
compounds, and therefore investigated the effects of DMSO on human sperm. All DDU 
compounds were provided in solution in 100% DMSO, and these were further diluted to 
concentrations of 4mM or 1mM respectively (chapter 2). These prepared stocks were 
diluted 1:100 with the prepared sperm sample making final concentration of DMSO in 
solution no more than 1% (known non-toxic concentration (de Lamirande and Gagnon, 
2002)). To ensure that 1% DMSO had no detrimental effect over time, serial motility 
assessments were made and compared with control (either NCM or CM alone) over a 
3hr time course.  
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4.2 Results 
4.2.1 Development of methods for motility assessment by CASA 
4.2.1.1 Determination of the number of aliquots from a single sample that need to be 
taken to assess motility parameters     
To determine the number of aliquots that need to be taken from a single sample in order 
to reliably assess motility parameters, a total of 800 motile cell counts were taken from 
either two aliquots from the same sample or four aliquots from the same sample. 
Motility parameters were measured from 40% and 80% fractions under non-capacitating 
and capacitating conditions to allow for any variation between fractions and types of 
media used. Figure 4-2 A&B shows the range for 800 motile cell counts in NCM and 
CM for 40% and 80% fractions. The range of results for reading cells from only two 
aliquots compared to four aliquots are very similar for both total motility and 
progressive motility (appendix). There is also no clear difference seen in ranges of total 
and progressive motility when reading 800 motile cells following incubation under 
capacitating conditions in either 40% or 80% fractions (figure 4-2 C&D and appendix). 
Results recorded for all variables also indicate that there is no statistical difference in 
range of all parameters measured at all time points (VCL, ALH and hyperactivation 
(appendix)). 
  
 
 
 
 
 
Figure 4-1 Key for identifying features in Box Plots (figures 4-2 & appendix). 
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Figure 4-2. Variation in range of results 4 aliquots vs 2 aliquots in non capacitating and capacitating 
buffer for % total motile (A) 40% NCM (B) 80% NCM (C) 40% CM (D)  80% CM. The result shown is 
the mean (blue diamond) ± the range for A-D, see figure 4-1 for identifying features of box plots. Motility 
parameters were measured over a period of 180 min under non-capacitating and capacitating conditions 
comparing the number of replicates needed to produce a low sampling error when measuring sperm 
motility. Dark Grey boxes = 2 aliquots, 400 cells per aliquot, Light Grey boxes = 4 aliquots, 200 cells per 
aliquot. N= 3 for both parameters. Results show no significant differences (Mann Whitney test) 
 
0 
20 
40 
60 
80 
100 
0 60 120 180 
 %
 T
o
ta
l M
o
ti
le
 
Time (Mins) 
40% NCM 
 A 
0 
20 
40 
60 
80 
100 
0 60 120 180 
 %
 T
o
ta
l M
o
ti
le
 
Time (Mins) 
80% NCM 
 B 
0 
20 
40 
60 
80 
100 
0 60 120 180 
 %
 T
o
ta
l M
o
ti
le
 
Time (Mins) 
40% CM 
 C 
0 
20 
40 
60 
80 
100 
0 60 120 180 
 %
 T
o
ta
l M
o
ti
le
 
Time (Mins) 
80% CM 
 D 
       0                         60                     120                    180 
       0                         60                     120                    180 
       0                         60                     120                    180 
       0                         60                     120                    180 
62 
 
0 
10 
20 
30 
40 
50 
60 
70 
80 
90 
100 
Time (Mins) 
%
 T
o
ta
l M
o
ti
le
 
Time (Mins) 
Manual Coverslips 
Fixed Coverslips 
0 
10 
20 
30 
40 
50 
60 
70 
80 
90 
100 
Time (Mins) 
%
 P
ro
gr
e
ss
iv
e
ly
 M
o
ti
le
 
Time (Mins) 
Manual Coverslips 
Fixed Coverslips 
4.2.1.2 Determination of slide type required for CASA assessment of motility 
Hamilton Thorne 2X-Cell chambered slides (manual coverslips) were compared to 
MicroCell fixed counting chamber slides. Prepared sperm (80% fraction) were 
subjected to capacitating conditions and motility parameters, (VCL, ALH, 
hyperactivation (appendix), total motile and progressive motility (figure 4-3 A&B)), 
subsequently measured using CASA. 800 cells were counted for both slide types. Data 
from repeat experiments (n=3) was pooled, and results statistically analysed using Mann 
Whitney and Kruskall Wallace tests. Progressive motility was significantly increased in 
samples on the MicroCell fixed counting chamber slides compared to the Hamilton 
Thorne manual slides at both 60 min (P≤0.05) and 120 min (P≤0.05) (figure 4-3 B).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-3. Variation in motility between two slide types (A) % total motile (B) % progressively 
motile. The result shown is the mean ± SE measured at defined time points up to 180 min N= 3 for both 
parameters, * indicates a significant increase between manual and fixed slides at independent time points. 
Significance was considered as P≤0.05  
A 
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4.2.1.3. Assessment of motility parameters in capacitating and non-capacitating 
media 
To determine optimal incubation times under capacitating and non-capacitating 
conditions, prior to acquiring CASA readings, motility parameters were measured over 
a period of 180 min in both NCM and CM. As expected, in the 40% fraction there was a 
highly significant (P≤0.01) increase across all motility parameters measured (VCL, 
ALH (appendix), total motile, progressively motile and hyperactivation (figures 4-4 
A,C,E)) for samples incubated in CM compared to NCM across all time points. 
Similarly, the 80% fraction showed highly significant increases in VCL (P≤0.001) and 
ALH (P≤0.05) in CM compared to NCM across all time points (appendix). 
Hyperactivation also showed highly significant increases (P≤0.001) at time 0, 60 and 
120 min, with a P≤0.005 at 180 min. There was no significant difference seen in total 
motility between the two media types with progressive motility only being significantly 
increased after 180 min (P≤0.005) (Figures 4-4 B, D, F). Kruskall-Wallace statistical 
analysis showed that there was no significant difference in any parameters measured 
when looking independently at samples in NCM or CM (40% and 80% fractions) across 
180 min time course.  
   0                  60                120               180 
64 
 
Figure 4-4. Expression of basal (control) motility values in non-capacitating (NCM) and 
capacitating media (CM) for 40% and 80% fractions. % total motile: (A) 40% (B) 80%, 
progressively motile: (C) 40% (D) 80% and hyperactivation: (E) 40% (F) 80%. The result shown is 
the mean ± SE for % total motile, % progressively motile and hyperactivation. In this study all motility 
parameters were measured over a period of 180 min under non-capacitating and capacitating 
conditions comparing the difference between the two media types. N= 6 for both parameters for the 
40% fraction and N= 5 for NCM and n= 9 for CM for the 80% fraction, ** indicates a significant 
increase (P≤0.01), *** indicates a significant increase (P≤0.005 or P≤0.001) between NCM and CM at 
independent time points (Mann Whitney test and Kruskal-Wallace test).  
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4.2.2 Development of methods for the assessment of motility for drug screening  
4.2.2.1. Inter-ejaculate and Intra-ejaculate variation with respect to motility 
parameters measured on CASA 
In order to examine the variability in motility between different ejaculates from the 
same man, the percentage of motile cells and progressively motile cells were examined 
from 5 donors on two separate occasions. When evaluating within donor variation 2/5 
donors showed similar motility in both ejaculates (no significant differences) 
(highlighted in figure 4-5A) however, 3/5 donors showed a significant increase 
(P≤0.05) in the percentage of motile cells in the 2nd sample compared to the 1st sample 
assessed (figure 4-5A). With regard to progressive motility 2/5 donors showed 
significant differences (P≤0.05) between the 2 samples produced with the remaining 3 
donors indicating no significant changes (figure 4-5B).   
 
As expected, the variation between donor samples was found to be greater than the 
within sample variation. The percentage of motile cells was found to be significantly 
different (P≤0.05) between every donor, with the exception of donor 1 (d1) in 
comparison to donor 2 (d2) and d2 in comparison to donor 5 (d5) (highlighted in figure 
4-5A), when comparing the 1
st
 sample from each donor.  However, when evaluating the 
difference between the 2
nd
 samples produced the only significant result was d1 which 
was significantly decreased (P≤0.05) compared to the other 4 donors.  In the case of 
progressively motile cells the 1
st
 samples were all significantly different (P≤0.05) to one 
another except in one instance, donor 4 (d4) compared to d5 (highlighted in figure 4-
5B). The variation in the 2
nd
 sample was not as great as the 1
st
 sample with donors 
showing similar (non-significant) results (d1 compared to d3, d1 compared to d4 & d2 
compared to d5). The remaining samples were significantly different to one another 
(figure 4-5B).  The results from this study highlight the variability in assessments, both, 
within the same donor’s ejaculate and between different donor samples.  
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Figure 4-5. Inter-ejaculate variation in 5 donors following two assessments (A) % basal total motility 
(B) % basal progressive motility. The result shown is the mean ± SD for % total motile and % 
progressively motile. In this study, motility was assessed twice in 5 donors over a 4 month ± 1 week 
period. When evaluating within donor variation, where there is NO significant differences between the 2 
assessments the result is highlighted with red boxes. When evaluating between donor samples ‘a’ denotes 
NO significant difference when comparing samples produced for the 1
st
 assessment, ‘b’ denotes NO 
significant difference between donor samples when comparing samples produced for the 2
nd
 assessment.  
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4.2.2.2.  Assessment of motility parameters in capacitating and non-capacitating 
media treated with 1% DMSO  
Compounds identified through HTS were prepared in solution with ≤1% DMSO. To 
determine if 1% DMSO is detrimental to motility parameters, a sample was treated 
under capacitating and non- capacitating conditions ± 1% DMSO for 180 min. This 
investigation enabled any adverse or influential reaction seen in sperm motility as a 
result of 1% DMSO treatment to be excluded. No significant difference was noted in 
any of the motility parameters measured (VCL, hyperactivation, total motile and 
progressively motile (figure 4-6 A-D and appendix)). The lack of significance, as 
analysed by Mann Whitney and Kruskall-Wallace tests, in both 40% (appendix) and 
80% fractions (figure 4-6 and appendix) , in all media types examined (CM and NCM ± 
1% DMSO), indicates that the addition of 1% DMSO to media does not impact on 
motility throughout 180 min incubation. 
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Figure 4-6. Expression of basal (control) motility values in non-capacitating (NCM) and capacitating 
(CM) media treated with 1% DMSO for 80% fraction (A) % total motile NCM, (B) % progressively 
motile NCM, (C) % total motile CM and (D) % progressively motile CM. The result shown is the mean ± 
SE for % total motile and % progressively motile. In this study all motility parameters were measured over 
a period of 180 min under non capacitating and capacitating conditions comparing the difference between 
treatment with 1% DMSO and non-treated media. N= 3 for NCM and NCM + 1% DMSO, N= 4 for CM 
and CM + 1% DMSO, no significant difference noted at any time point.  
  
no significant difference noted at any time point.  
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4.3 Discussion   
The aim of these experiments were to examine the potential variables in the protocol 
proposed for screening sperm samples from donors and sub-fertile patients in order to 
improve experimental efficiency and to standardise laboratory protocol.  
4.3.1 Repeatability and Reliability of system  
4.3.1.1 Number of aliquots from a single sample that need to be taken to assess 
motility parameters    
Sample variation within an individual occurs as a natural part of any semen sample 
(Fraser, 2001, Alvarez, 2003). The reasons behind this variation include period of 
sexual abstinence, transport of the sample to the laboratory, analytical and systematic 
errors (CASA) and inherent biological variation (Fraser, 2001, Alvarez, 2003). Sperm 
preparation methods are designed to isolate high grade spermatozoa from low grade 
spermatozoa and debris (Mortimer, 2000a, Mortimer and Mortimer, 2013a) and thus 
reduce sample variation within a single sample, although these methods do not 
completely eliminate it.  Individual samples contain inherent random fluctuations 
around a homeostatic set point which can be influenced by environmental and 
biological factors (Fraser, 2001), and not all ejaculates from the same individual or 
between different individuals will therefore be identical. This variation needs to be 
recognised and accounted for if comparisons within populations or between clinics are 
to be made (Fraser, 2001, Alvarez, 2003, Jørgensen et al., 2001, Castilla et al., 2006).  
 
Furthermore, the limitations of CASA technology must also be considered. Although 
CASA systems may be discredited as being poor determinates of semen concentration, 
they allow objective analysis of sperm motility kinematics as long as standard operating 
procedures are followed (Fraser, 2001, Mortimer and Mortimer, 2013a). The effect of 
sampling error on sperm concentration has previously been examined using motile 
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human sperm, analyzing a minimum of 200, 400, and 1,000 sperm (Tomlinson et al., 
2010).  Results were found to be similar regardless of the number of sperm assessed by 
this group (Tomlinson et al., 2010). To exclude variation as a result of the use of CASA 
this study followed expert recommendations on how to use CASA, limiting errors to a 
minimum (Fraser, 2001, Tomlinson et al., 2010, Mortimer and Mortimer, 2013a).  
 
The standard procedure, as defined by ESHRE, states that at least 200 motile 
spermatozoa should be analysed per sample/aliquot when determining sperm motility 
characteristics using CASA (Fraser and Group, 1998, Tomlinson et al., 2010). 
Inaccuracies can occur as a result of in homogeneity errors when using fixed chamber 
slides (Mahmoud et al., 1997) where the use of a smaller volume i.e. 6µl (2 aliquots) 
may not be as representative of a whole sample when compared to 12µl (4 aliquots) 
(Mahmoud et al., 1997, Tomlinson et al., 2001). This study has shown that if the sample 
is thoroughly mixed (flicking of the tube to re-suspend cells) before analysis, there is no 
significant difference in the variation in the sample whether you read 4 separate aliquots 
or 2 separate aliquots (figure 4-2).  Under capacitating conditions the range in variation 
of the results in the 80% fraction is considerably narrower than that seen in the 40% 
fraction in both systems. This is as expected, because the 80% fraction contains a high 
proportion of motile and progressively motile spermatozoa (Oaconnell, 2003, Mortimer 
and Mortimer, 2013c). Overall, the results of these experiments do not show any clear 
difference between the two approaches to CASA analysis when assessing cells under 
either capacitating or non-capacitating conditions (40% or 80% fractions), indicating 
that either approach could be used with minimal sampling error. As the more 
economical of the two systems it was decided to use the 2 replicate, 400 cells per 
replicate system in the final protocol.        
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4.3.1.2 Determination of slide type required for assessment of motility 
Variation in concentration between the two slide types was not measured in this study 
although it has previously been examined (Mahmoud et al., 1997, Tomlinson et al., 
2001). The reusable Hamilton Thorne slides have been shown to overestimate sample 
concentration as cells may not spread evenly across the chamber (Mahmoud et al., 1997, 
Hoogewijs et al., 2012). This could impact on cell motility by 1) increasing cell 
clumping and 2) increasing the chance of adherence of cell to slides, despite the 
presence of BSA in the media (Mortimer and Mortimer, 2013a). Hamilton Thorne slides 
may be treated with a nitrocellulose and polyvinyl coating to prevent sperm adhesion 
and to decrease effects on motility (Chapeau and Gagnon, 1987) although, it is not 
advisable to treat fixed chamber slides in the same manner. Another factor that may 
contribute to sticking when using Hamilton Thorne slides includes frequent washing, 
slides are washed using hot tap water and vigorous rubbing, they are then rinsed with 
deionised water and allowed to air dry in an upright position. This process can result in 
smears and scratches along with other superficial damage to the slides and/or coverslips 
which can alter motility itself and increase mistakes when analysing on CASA. Both 
slide types use a small volume (3μl or 4μl for disposable and reusable slides 
respectively) which could explain some of the variability seen in the results (figure 4-3 
A-B). However, samples were mixed before addition to slides to minimise variation. 
Variability (Mahmoud et al., 1997) seen on the reusable slides could be due to 
differences between chambers, presumably as a result of unequal pressure being 
asserted by the individual placement of coverslips. The two slide types used in this 
investigation are also loaded in different manners, the Hamilton Thorne 2xCell slides 
with separate glass coverslips are filled by ‘drop loading’ whereas the MicroCell 4 
chambered fixed coverslips are filled by capillary loading (Mahmoud et al., 1997, 
Mortimer and Mortimer, 2013a). Fixed chamber slides that are filled by capillary flow 
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are subject to the Segre Silberberg effect (Douglas‐Hamilton et al., 2005a, 
Douglas‐Hamilton et al., 2005b, Leja, 2005, Mortimer and Mortimer, 2013c). Although 
the Segre Silberberg effect has been proven to affect concentration readings it has very 
little bearing on motility and thus would have minimal effect in this study (Mortimer 
and Mortimer, 2013c). It is known that slide types with manual coverslips incur drift 
and should to be left to equilibrate for 60secs before recording results (Mortimer and 
Mortimer, 2013c). The MicroCell 4 fixed chambered slides incur no known drift and 
readings can be taken instantly after addition of sample.  
 
Disposable, single use, fixed chamber slides are becoming the preferred choice for 
many IVF laboratories (Tomlinson et al., 2001). They can be used to measure 
concentration and motility and have been shown to produce reproducible and 
consistently reliable counts when examined using latex beads and homogenised sperm 
samples (Mahmoud et al., 1997). There are clear advantages to using fixed chamber 
slides with consistent depths of 20µm for assessing sperm motility when compared to 
standard reusable glass slides with separate cover slips (Tomlinson et al., 2001) 
especially as sperm motion characteristics are heavily dependent on chamber material 
and depth (Le Lannou et al., 1992, Kraemer et al., 1998). In contradiction to this study, 
Tomlinson et al (2001) previously measured motility between reusable glass slides 
(Makler and Horwell) and fixed chambered slides (Cell Vu, MicroCell and Leja) with 
no significant differences noted in motility parameters. This conflict may be explained 
by methodological differences. As a result of this experiment, unless unavailable, the 
MicroCell 4 fixed chamber slides were used preferentially.              
4.3.1.3 Assessment of motility parameters in capacitating and non-capacitating media 
Following ejaculation, capacitation (a complex series of molecular events that sperm 
undergo) occurs allowing sperm to be able to fertilise oocytes (Visconti et al., 2002). 
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Importantly this process can be replicated in vitro in specialised culture media, the 
composition of which is based on electrolyte concentration of oviductal fluid (Visconti 
et al., 2002). To enable capacitation to occur, capacitating media contains energy 
substrates, such as pyruvate, lactate and glucose, a cholesterol acceptor (serum 
albumin), NaHCO3, Ca
2+
 , low K
+
 , and physiological Na
+
 concentrations (Visconti et 
al., 2002). The key component that differs between the two media types used in this 
study (NCM and CM) is the addition of HCO3
-
 to CM. HCO3
- 
is essential for the 
development of capacitation and sperm motility (Boatman and Robbins, 1991a, 
Visconti et al., 1995a). An increased intracellular HCO3
-
 and Ca
2+
 stimulate soluble 
adenylate cyclase activity in sperm which leads to an increase in tyrosine 
phosphorylation resulting in increased motility and hyperactivation (Visconti et al., 
2002, Visconti et al., 1995a, Battistone et al., 2013).   This explains the significant 
increase in all motility parameters measured (VAP, VSL, VCL, total motile, 
progressively motile and HA) in the 40% fraction across all time points and similarly 
(VCL, ALH, progressively motile (180 min) and hyperactivation) in the 80% fraction 
when samples are in CM compared to NCM (appendix).
  
 
Sperm velocity is highly temperature dependent and it is essential that experiments be 
carried out at 37
o
C to attempt to obtain as close to the physiological environment as 
possible (Appell and Evans, 1977, Mortimer and Mortimer, 2013c). The samples in 
NCM were incubated for 15 min after preparation (DGC) before readings were taken to 
allow the sample to return to 37
o
C before analysis. The cells in CM were incubated for 
2 hrs 30 min at 37
o
C with 5% CO2 to allow capacitation before analysis. Motility 
parameters remained stable for both fractions in either media, over the entire period of 
analysis (180 min). This indicates that the spermatozoa were stable in both media types 
over a period of 3 hrs at 37
o
C. As a result of capacitation, there was a difference in the 
incubation times between samples in NCM and CM before motility analysis, however 
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both media results show no significant deterioration over time suggesting that no 
significant difference in the results would be seen for NCM samples if they had been 
incubated for 2 hrs 30 min in advance of analysis.        
4.3.1.4 Determination of variability between ejaculates from the same donor and 
different donor samples 
Numerous studies have been published discussing the biological variation in semen 
parameters (Mallidis et al., 1991, Alvarez, 2003, Keel, 2006). The smallest between 
subject variability in this study was found for total motility which is in accordance with 
previous studies (Poland et al., 1985, Alvarez, 2003). The smallest within subject 
variability in this study was found for progressive motility which differs to previous 
studies (Poland et al., 1985, Alvarez, 2003) however, it has been previously reported 
that variations in semen parameters produce contradictory results between groups 
(Mallidis et al., 1991). The within subject variability in this study showed lower levels 
of variation than the between subjects variation which is in agreement with previous 
reports (Heuchel et al., 1983, Alvarez, 2003). The results from this study, although 
evaluating a limited number of donors, corroborates previous reports and reinforces the 
need to be aware of variation both within subjects and between donor samples when 
conducting experiments. Thus, in chapter 5, 6 and 7 where some donors were assessed 
on more than one occasion, each sample was treated independently.  
 4.3.1.5 Assessment of motility parameters in capacitating and non-capacitating 
media treated with 1% DMSO  
Dimethyl sulfoxide (DMSO) is a dipolar aprotic solvent (Rammler and Zaffaroni, 
1967). Many compounds, therapeutic and toxic, that are not soluble in water are often 
soluble in DMSO. The physiologic and pharmacologic properties of DMSO are not 
completely understood (Brayton, 1986). DMSO is utilised in many biological 
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applications because it has many properties that are important for use, including rapid 
and enhanced penetration of other substances across biologic membranes; free radical 
scavenging; effects on coagulation and anticholinesterase activity. The systemic toxicity 
of DMSO is considered to be low making it suitable for addition to biological 
compounds (Brayton, 1986). The majority of HTS in drug discovery programmes use 
DMSO stock solutions because compounds are both highly soluble in DMSO and 
conferred long-term stability by its presence. However, to avoid adverse solubility 
enhancement of compounds and to reduce potential co-solvent effects, it is generally 
recommended that DMSO concentrations be kept to a minimum of ≤1% (Alsenz and 
Kansy, 2007).  
 
It has been reported that media not exceeding 1% has no detrimental effect on sperm 
motility, capacitation or the acrosome reaction (de Lamirande and Gagnon, 2002).  
However, there is very little other information available describing the effect of DMSO 
alone on sperm, although in research it is readily used in combination with compounds 
added to sperm suspensions (de Lamirande and Gagnon, 2002, Lefievre et al., 2002, 
Marín-Briggiler et al., 2005, Agirregoitia et al., 2010b, Wang et al., 2013). The effect of 
DMSO on sperm motility was therefore examined, in order to account for any 
favourable or adverse reactions as a result of its presence if added whilst screening drug 
discovery compounds. No significant differences were seen in any of the motility 
parameters measured in any sample in either media with or without 1% DMSO over a 
180min time course.  This result corroborates previous studies, showing that presence of 
1% DMSO has no effect on human sperm motility.   
76 
 
 
 
 
 
CHAPTER 5 
Motility Analysis of Sperm treated with 
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5.1 Introduction 
Store operated Ca
2+
 channels at the neck/midpiece region of spermatozoa, through a 
CICR mechanism, have been identified as being regulators of sperm motility (Harper et 
al., 2004, Costello et al., 2009) along with the discovery of the sperm specific CatSper 
channel which is primarily associated with the development of hyperactivated motility 
triggered by depolarization- induced Ca
2+
 entry (Ren et al., 2001, Krasznai et al., 2006, 
Barratt, 2011). CatSper has enormous potential as a target for pharmaceutical 
manipulation due to its unique expression in sperm (Martins da Silva et al., 2012).  
Martins de Silva et al developed a high throughput screening assay that identified 
compounds that increase [Ca
2+
]i in human sperm (Martins da Silva et al., 2012). 
Compounds from this high throughput assay screen were identified, using Ca
2+
 as a 
surrogate for motility, as potentially being able to enhance motility in human 
spermatozoa.         
The Flexstation assay is a HTS assay developed using a Flexstation microplate reader to 
measure progesterone evoked increases in intracellular Ca
2+
 in motile human 
spermatozoa (Martins da Silva et al., 2012). Optimised conditions were then selected to 
successfully screen a Chemogenomics library from the UoD DDU, The Chemogenomic 
library examined Tocris compounds that were selected on the supposition they would be 
selective and potent ion channel compounds, based on evidence from literature. This 
library comprised of 246 compounds with progesterone being used as an internal 
control for the assay. This screen identified 27 active compounds that were capable of 
generating a peak Ca
2+
 response after exposure to prepared spermatozoa, including 
compounds which are known to modulate cellular Ca
2+
. 6 of these compounds were 
subjected to in-depth spermatozoa motility assessments to try and identify novel 
compounds that have the ability to enhance sperm motility in an in vitro environment 
(Table 5.1). 5 of these compounds will be discussed in detail in this chapter with the 6
th
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compound Trequinsin hydrochloride being discussed in chapter 6. The benefits of the 
Chemogenomics screen for a complex system such as sperm is that it allowed for the 
identification of a range of pharmacologically active compounds that have known 
specific molecular targets giving you an indication of which proteins, receptors or 
enzymes may be in that system. This helps to define potential targets that may be 
activated/ inhibited when analysing the effects of unknown compounds.  
Table 5.1 Summary of active compounds identified in screen of the Chemogenomics library 
examined for their effects on sperm motility (Biosciences, 2013a-e)   
Compound name Primary action Chemical structure 
Leelamine 
Hydrochloride  
CB1 agonist  
GP 1a Highly selective CB2 
agonist 
 
EO 1428 Selective inhibitor of 
p38α and p38β  
 
JX 401 Potent, reversible p38α 
inhibitor 
 
PHA 665752 Potent and selective 
MET inhibitor  
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5.1.1 Cannabinoid agonists  
Leelamine hydrochloride (Lylamine hydrochloride, (+)-Dehydroabietylamine) is a CB1 
receptor agonist (IC50 2.86µM) (Biosciences, 2013d) and GP1a is a CB2 receptor 
agonist (Biosciences, 2013b) (Table 5.1). There are two different types of cannabinoid 
receptors that have been identified and cloned, both of which are members of the super-
family of G-protein – coupled receptors (Howlett et al., 2002). CB1 and CB2 receptors 
are so called because they are the receptors that respond to cannabinoid drugs. The CB1 
cannabinoid receptor was first isolated in the brain and found mainly at the terminals of 
central and peripheral neurons but it has since been identified as being expressed in 
other tissues including spleen, peripheral leukocytes, uterus, testis, individual sperm 
cells, muscle cells and placenta (Howlett et al., 2002, Schuel et al., 2002, Rossato et al., 
2005). It has been cloned from rat, mouse and human tissues and exhibits 99% 
homology across species (Howlett et al., 2002). The CB2 receptor exhibits 48% 
homology with the CB1 receptor and is primarily located to immune cells within and 
outside the central nervous system and has also been identified in human sperm cells 
(Ashton and Glass, 2007, Agirregoitia et al., 2010a).  
Functional CB1 and CB2 receptors have been identified in mature human spermatozoa 
(Rossato et al., 2005, Agirregoitia et al., 2010a) along with mRNA and proteins for CB1 
and CB2 receptors (Agirregoitia et al., 2010a, Amoako et al., 2013a). CB1 has been 
shown to be localised to the plasma membrane of the acrosomal region, tail and 
midpiece of human sperm, whereas CB2 has been found to be mainly localised in the 
post-acrosomal region, midpiece and tail of sperm cells (Agirregoitia et al., 2010a, 
Amoako et al., 2013b) 
Compounds that act via the CB1 and CB2 receptors reproduce some of the biological 
actions of the cannabinoid drugs such as  9-tetrahydrocannabinol (THC) which is 
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derived from the natural Cannabis sativa (Howlett et al., 2002). Along with 
cannabinoids, a family of unsaturated fatty acid derivatives with actions similar to 
cannabinoids have been identified and are known as endocannabinoids. Cannabinoids 
and endocannabinoids exert their effects via activation of specific cannabinoid receptors 
(Rossato et al., 2005, Amoako et al., 2013b).  Previous studies suggest that sperm 
function is regulated by endocannabinoids through a dual stage-dependent effect 
involving both CB1 and CB2 receptors (Agirregoitia et al., 2010a, Maccarrone, 2008).  
CB1 and CB2 receptors have also been associated to transduction pathways coupled to 
pertussis toxin-sensitive Gi/Go proteins. Through this they negatively affect adenylate 
cyclase activity and production of cAMP (Howlett et al., 2002), inhibit L, N, P and Q 
type voltage- gated Ca
2+
 channels (Howlett et al., 2002, Howlett, 2005) and positively 
affect A-type and inwardly rectifying K
+
 channels, phospholipase C and mitogen-
activated protein kinase (Howlett, 2005, Pertwee, 1997). CB1 receptors are also capable 
of coupling to Gs proteins to activate soluble adenylate cyclase (Pertwee, 1997, Glass 
and Felder, 1997, Calandra et al., 1999). Additionally, there have been reports that CB1 
and CB2 receptors enhance [Ca
2+
]i concentrations (Sugiura and Waku, 2000, Sugiura et 
al., 1997, Pertwee, 2005). This outlines the diversity of compounds acting on these 
receptors and the potential for different functional events.  An understanding of this 
complex system is fundamental to male infertility and importantly has the possibility to 
provide potential targets for pharmacological intervention in male infertility (Amoako et 
al., 2013b).  
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5.1.2. Mitogen activated protein kinases 
Mitogen activated protein kinases (MAPKs) are key regulatory enzymes that participate 
in cell growth, differentiation, survival, stress, cell cycle progression and apoptosis 
(Almog et al., 2008). MAPK cascades consist of levels of protein kinases that 
sequentially activate each other through phosphorylation. There are four major MAPK 
cascades known for mammals: ERK1-2, JNK 1-3, p38 α-δ and ERK5 (figure 5-1) 
(Gutkind, 1998, Pearson et al., 2001).   
EO1428 is a selective inhibitor of p38α and P38β2 (IC50 0.039µM) (Biosciences, 
2013a) and JX401 is a potent reversible inhibitor of p38α (IC50 32nM) (Biosciences, 
2013c) (Table 5-1). p38 MAPK is now known to be a stress related activated kinase 
which is initiated by a stress stimuli (Almog et al., 2008). The p38 MAPK cascade 
consists of sequential activation of MAP3Ks, MKK3/4/6, p38 α-δ, and several mitogen 
activating protein kinase activating protein kinases (MAPKAPKs) (figure 5-1) (Pearson 
et al., 2001, Almog et al., 2008).  
Figure 5-1. Key signalling components of the four major MAPK pathways in mammals (Berwick and Harvey, 
2011) 
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During spermatogenesis MAPKs function to mediate cell division, differentiation, 
survival and death (Wong and Yan Cheng, 2005). The knowledge of the function of 
MAPK in motility, capacitation and the acrosome reaction in mature spermatozoan is 
limited and controversial (Weidinger et al., 2005). The role of p38 was unknown until 
Almog et al identified that p38 MAPK is not only expressed in mature spermatozoa but 
is primarily localised to the tail (Almog et al., 2008). Almog et al also discovered that 
ERK stimulated progressive and hyperactivated motility whereas p38 MAPK acted to 
inhibit motility (Almog et al., 2008) (figure 5-2). Both ERK 1/2 and p38 MAPK have 
also been identified, positively, in having a role in PKC-mediated acrosome reaction 
(Almog et al., 2008).     
 
 
 
 
 
 
 
p38 MAPK is encoded by four genes that express nine isoforms with the main isoform 
found to be expressed in mature ejaculated human spermatozoa being p38α (Pearson et 
al., 2001, Almog et al., 2008). As mentioned previously both JX401 and EO1428 are 
selective inhibitors for p38α suggesting that these compounds should act to inhibit the 
p38 inhibition on sperm motility leading to increased progressive and hyperactivated 
Figure 5-2 Proposed model for p38 and ERK1/2 signalling in human sperm. p38 MAPK and ERK1/2 have 
been identified in the tail of mature human sperm. ERK stimulates and p38 inhibits progressive and 
hyperactivated motility. Both p38MAPK and ERK1/2 are positively associated with the acrosome reaction. 
(Almog et al., 2008)   
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motility. p38 inhibitors have been used previously with positive effects on both 
progressive motility and hyperactivation (Almog et al., 2008).  
 
5.1.3 c-MET kinase inhibitor 
PHA665752 is a potent, selective 2
nd
 generation ATP-competitive inhibitor of c-MET 
kinase, a receptor tyrosine kinase (Table 5-1) (IC50 9nM) (Biosciences, 2013e).   
 
Tyrosine kinases are themselves receptors for some growth factors that regulate cell 
proliferation and differentiation (Ullrich and Schlessinger, 1990, Herness and Naz, 
1999). The c-met proto-oncogene encodes a transmembrane glycoprotein p190
MET
 
tyrosine kinase receptor (Herness and Naz, 1999). The ligand for the c-met receptor has 
been identified and assigned as a scatter factor/ hepatocyte growth factor (SF/HGF) 
(Bottaro et al., 1991). SF/HGF has been identified as having potent motogenic, 
mitogenic and morphogenetic actions on epithelial cells and proteins have been 
identified in human amniotic fluid, human placental tissue, stromal components of 
human testis and in the ovary (Strain, 1993, Herness and Naz, 1999, Naldini et al., 
1991, Lail-Trecker et al., 1998). Depuydt et al identified that the c-met receptor is 
localised in the human seminiferous epithelium and on mature spermatozoa (Depuydt et 
al., 1996). This same group have also shown that HGF is present in seminal plasma 
(Depuydt et al., 1997) and has identified relationships between the concentration of 
HGF in human seminal plasma and andrological diseases, including asthenozoospermia, 
suggesting a link between HGF and motility (Depuydt et al., 1998). SF/HGF has been 
found to be differentially expressed in segments of the male genital tract, highest at the 
cauda and distal corpus of the epididymis, in mice (Naz et al., 1994). Herness et al 
identified that the c-met receptor is present in human mature sperm cells predominantly 
in the acrosomal subcellular site (Herness and Naz, 1999). The c-met receptor is 
tyrosine phosphorylated/ autophosphorylated during capacitation through cross-talk 
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with other molecules (Naz, 1996) (figure 5-3). Protein tyrosine phosphorylation has a 
role in a variety of cellular functions including regulation of various receptors (Ullrich 
and Schlessinger, 1990). Tyrosine phosphorylation increases in human spermatozoa 
during capacitation and is an important regulatory pathway in events associated with 
capacitation. The signalling pathway of c-met kinases function on human sperm cells 
has not been elucidated but previous reports indicate that c-met and its ligand (SF/HGF) 
may have an important function in sperm motility owing to its motogenic properties 
(Naz et al., 1991, Naz, 1996, Herness and Naz, 1999, Naz and Rajesh, 2004). 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 5-3. Heuristic model by Naz et al showing tyrosine phosphorylation signalling pathways in 
human sperm cells involved in capacitation. There are three major pathways in the sperm cell; 
cAMP/PKA-dependent pathway (pathway I), receptor tyrosine kinase pathway (pathway II), and non-
receptor protein tyrosine kinase pathway (pathway III). The pathway by which c-met kinases function is 
pathway II. These cascades are not mutually exclusive and it is possible they include cross-talk amongst 
several molecules. Many key molecules and receptors still need to be elucidated to fully understand the 
molecular mechanism and signal transduction cascade involved in capacitation. (Naz and Rajesh, 2004) 
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5.2 Experimental Design 
Semen samples obtained from donors were prepared using DGC. Each sample was 
diluted in either NCM or CM as appropriate to a final concentration of 20 million/ml. 
Samples in NCM were placed in an incubator at 37
o
C for 15 min whereas samples in 
CM were placed in a 5% CO2
 
incubator at 37
o
C for 2 hrs 30 min. 99µl of semen sample 
was placed in a round bottom tube followed by the addition of 1µl of the appropriate 
compound. 1% DMSO was added to the control tube to act as a vehicle control. After 
re-suspending cells, 3µl of sperm suspension was loaded onto a preheated fixed 
chamber slide and CASA analysis conducted at 30 min intervals over a period of 3 hrs. I 
will only be discussing total motility, progressive motility and hyperactivation in detail. 
The results for VCL and ALH are available in the appendix. 
5.3 Results  
5.3.1 Motility assessment by CASA of five hit compounds  
5.3.1.1 Leelamine Hydrochloride 
When spermatozoa were treated with Leelamine Hydrochloride (40µM), there was a 
decrease in total motility, progressive motility and hyperactivation when both the 40% 
and 80% fraction were assessed under non-capacitating conditions (appendix). Treated 
cells, after capacitation, from the 40% fraction showed significant changes instantly in 
the percentage of motile cells (P≤0.05; figure 5-4A), whereas significant alterations in 
progressive motility were not observed until after 150 min (P≤0.05; figure 5-4B). 
Hyperactivation also decreased although this result was not significant (appendix). 
Results from the 80% fraction identified no significant differences between control and 
treated cells. However, a time- dependent decrease in hyperactivation was noted over 
the 3hr time course (figure 5-4C). The predominant effect exhibited by spermatozoa 
after prolonged exposure to this compound, in both the 40% and 80% fractions, under 
capacitating and non-capacitating conditions, was a decrease in all motility parameters 
assessed.  
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Figure 5-4. Expression of basal (control) motility values compared to Leelamine Hydrochloride 
treated samples capacitating conditions. (A) % total motile (40% fraction CM), (B) % 
progressively motile (40% fraction CM) and (C) % hyperactivation (80% fraction CM). The result 
shown is the mean ± SE. In this study all motility parameters were measured over a period of 180 
min capacitating conditions comparing the difference between the control and treated samples. N= 4 
for all parameters, * indicates a significant increase (P≤0.05) between control and treated samples at 
independent time points (Mann Whitney test and Kruskall-Wallace test).   
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5.3.1.2 GP1a 
After evaluating the effects of a CB1 agonist on sperm motility, GP1a, a CB2 agonist, 
was examined (40µM). The results from cells treated with GP1a were similar to that of 
Leelamine hydrochloride with the trend exhibiting decreased motility. Once again, cells 
under non-capacitating conditions treated with the agonist displayed less motile cells 
than control in both the 40% (appendix) and 80% fractions (P≤0.05 figure 5-5A). 
However, progressive motility and hyperactivation were not significantly changed from 
control (appendix). The most substantial changes were exhibited when the sperm cells 
had been exposed to GP1a after capacitation. In the 40% fraction total motile, 
progressively motile and hyperactivation, were all significantly decreased (figure 5-
5B,C&D). Cells from the 80% fraction revealed time-dependent decreases in 
hyperactivation (P≤0.05) after 30 min treatment (figure 5-5F). However, significant 
decreases in total motility were not observed until after 180 min treatment (figure 5-5E) 
with no changes in progressive motility observed (appendix).  
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Figure 5-5. Expression of basal (control) motility values compared to treated samples in non 
capacitating (NCM) and capacitating (CM) media, (A) % total motile (80% fraction NCM),  (B) % 
total motile (40% fraction CM), (C) % progressively motile (40% fraction CM), (D) % hyperactivation 
(40% fraction CM), (E) % total motile (80% fraction CM) and (F) % hyperactivation (80% fraction CM). 
The result shown is the mean ± SE for all parameters. In this study all motility parameters were measured 
over a period of 180 min under either non-capacitating or capacitating conditions comparing the 
difference between the control and treated samples. N= 3 for both parameters, * indicates a significant 
increase (P≤0.05) between control and treated samples at independent time points (Mann Whitney test 
and Kruskall-Wallace test).   
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5.3.1.3 EO1428 
CASA analysis of sperm treated with EO1428 (40µM) under non-capacitated conditions 
showed significant decreases in total motility and progressive motility (P≤0.05, 
appendix) for cells from the 40% fraction. Treated samples from the 80% fraction 
displayed significant decreases in total motility (P≤0.05, figure 5-6A). The percentage 
of progressively motile cells was observed to decrease significantly after 30 min 
treatment and this decrease was sustained for the remainder of the time-course (P≤0.05, 
figure 5-6B). However, no change was observed in hyperactivation compared to control 
(appendix). Cells treated with this agonist, similarly to GP1a, exhibited a higher 
proportion of significant decreases in sperm motility in capacitated cells compared to 
non-capacitated. The 40% fraction under these conditions showed significant decreases 
in total motility, progressive motility and hyperactivation (P≤0.05, figure 5-6 C, D and 
appendix). Spermatozoa from the 80% fraction displayed significant reductions 
(P≤0.05) in hyperactivation after 60 min an effect that was sustained over the remainder 
of the time-course (figure 5-6E). Kruskall Wallace statistical analysis indicated that 
hyperactivation was significantly lower in the treated spermatozoa (p=0.036) over the 
3hr time-course (figure 5-6E). Progressive motility appeared to increase compared to 
control after 60 and 90 min treatment however, this was not a significant increase and 
was not sustained (appendix). Total motility remained unchanged from control 
(appendix). 
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Figure 5-6. Expression of basal (control) motility values compared to EO1428 treated samples in 
non-capacitating (NCM) and capacitated (CM) media. (A) % total motile (80% fraction NCM), (B) % 
progressive motility (80% fraction NCM), (C) % total motile (40% fraction CM), (D) % progressive 
motility (40% fraction CM) and (D) % hyperactivation (80% fraction CM). The result shown is the mean 
± SE for all parameters. In this study all motility parameters were measured over a period of 180 min 
under non-capacitating or capacitating conditions comparing the difference between the control and 
treated samples. N= 4 for both parameters, * indicates a significant increase (P≤0.05) between control and 
treated samples at independent time points (Mann Whitney test and Kruskall-Wallace test).   
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5.3.1.4 JX401 
In motility parameters, under non-capacitating conditions, sperm progressive motility 
and hyperactivation were significantly decreased (P≤0.05) for the 40% fraction (figure 
5-7A & appendix respectively). No significant changes were observed in any other 
parameter over the time-course (appendix). For the 80% fraction both the percentage of 
total motile and progressively motile cells, treated with JX401 (40µM), showed 
significant decreases after 60 min (total motile) and 30 min (progressively motile) 
which is sustained for the 180min incubation (appendix and figure 5-7B). 
Hyperactivation was also found to be significantly lower after 30 min incubation 
(appendix). This compound differed to the others examined with the most significant 
results being produced under non-capacitating conditions instead of capacitating as 
shown previously.  Cells from the 40% fraction, exposed to capacitating conditions, 
following treatment with this compound, exhibited reduced progressive motility 
instantly and this effect was sustained after 30, 90 and 120 min (figure 5-7C). However, 
no significant differences were found for any other kinematic parameter (appendix). 
Treated sperm collected from the 80% fraction revealed significant decreases in total 
motility and hyperactivation when compared to control (appendix) however, 
progressive motility remained unchanged from control (appendix).   
 
 
 
 
 
 
92 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-7. Expression of basal (control) motility values compared to treated samples in non-
capacitating (NCM) and capacitating media. (A) % progressive motility (40% fraction, NCM), (B) % 
progressive motility (80% fraction, NCM) and (C) % progressively motile (40% fraction, CM).  The 
result shown is the mean ± SE for motility parameters measured. All motility parameters were measured 
over a period of 180 min under non-capacitating or capacitating conditions. N= 3 for all parameters, * 
indicates a significant increase (P≤0.05) between control and treated samples at independent time points 
(Mann Whitney test and Kruskall-Wallace test).   
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5.3.1.5 PHA665752 
PHA665752 (40µM) was the only compound that produced no significant changes from 
control when motility parameters were examined for the 40% fraction under non-
capacitating conditions (appendix). The 80% fraction under the same (non-capacitating) 
conditions exhibited significant decreases (P≤0.05) in the percentage of motile cells 
after 90 min but was not sustained (appendix). No other parameters where significantly 
changed from control under these conditions (appendix). Cells that had been capacitated 
prior to treatment, when assessing motility, exhibited significant decreases for the 
percentage of total motile (180 min) and progressively motile (120 min) cells when 
compared to control in the 40% fraction (appendix). Similarly to GP1a and EO1428 the 
most significant decreases in kinematic parameters were identified from the 80% 
fraction after capacitation. PHA665752 was causative of decreases in hyperactivation, 
along with, a time-dependent decrease in the percentage of total motile cells (P≤0.05, 
figures 5-8A&B). Progressive motility exhibited no significant changes from control 
(appendix). Kruskall Wallace statistical analysis identified time-dependent significant 
decreases in spermatozoa treated with PHA665752 for hyperactivation (figures 5-8B). 
 
 
 
 
 
 
 
Figure 5-8. Expression of basal (control) motility values compared to treated samples in capacitating 
(CM) media in 80% fraction for (A) % total motile and (B) hyperactivation. The result shown is the 
mean ± SE for motility parameters measured. In this study all motility parameters were measured over a 
period of 180 min under capacitating conditions comparing the difference between the control and treated 
samples. N= 3 for both parameters, * indicates a significant increase (P≤0.05) between control and treated 
samples at independent time points (Mann Whitney test and Kruskall-Wallace test).   
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5.4 Discussion 
The primary aim of this chapter was to examine the effects of compounds, identified 
from the Flexstation high-throughput screening assay, on motility parameters of human 
sperm from donors and sub fertile patients. However, the predominant effect seen as a 
result of addition of the 5 other agonists examined (Leelamine hydrochloride, GP1a, 
EO1428, JX402 and PHA665752) indicated significant decreases in all motility 
parameters.  
 
Cannabinoid receptor agonists increase [Ca
2+
]i but fail to enhance sperm motility  
The results of this chapter showed that motility parameters of human sperm, specifically 
the percentage of total motile cells, were decreased when exposed to both a CB1 agonist; 
Leelamine hydrochloride, and a CB2 agonist; GP1a. This result reflects previous studies 
examining the effects of cannabinoids on sperm function (Rossato et al., 2005). 
Endocannabinoids (a group of endogenous, lipid mediators) have been found to play a 
role in motility and negatively affect fertilising potential of human sperm (Francavilla et 
al., 2009). The two best characterised members of the endocannabinoid family are N-
arachidonoylethanolamine (anandamide, AEA) and 2-arachidonoylglycerol (2-AG, a 
monoacylglycerol) both of these endocannabinoids are capable of working at the type 1 
(CB1 receptor) and type 2 (CB2 receptor) cannabinoid receptors (Howlett et al., 2002, 
Francavilla et al., 2009). Increases in intracellular Ca
2+
, as a result of cannabinoid 
agonist addition (Howlett et al., 2002), induces production of AEA which in turn 
through a dual stage-dependent effect activates both CB1 and CB2 receptors (Marzo et 
al., 2005, Maccarrone, 2008, Agirregoitia et al., 2010a). The most well know 
endocannabinoid is N-arachidonoylethanolamine (anandamide, AEA) (Devane et al., 
1992). The biosynthesis of AEA is complex but most of the pathways involved in the 
synthesis of AEA are by a specific phospholipase (NAPE-PLD) with AEA being 
synthesised from the precursor N-acylphosphatidylethanolamine (NAPE) (Okamoto et 
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al., 2007). The effects of AEA are terminated when AEA is taken up through an AEA 
membrane transporter after which it is degraded to ethanolamine (EtNH2) and 
arachidonic acid (AA) by the fatty acid amide hydrolase (FAAH) (Cravatt and 
Lichtman, 2002, Amoako et al., 2013b).  
 
Significant levels of AEA have been found to be present in human seminal plasma, as 
sperm leave seminal plasma and approach the egg in the female reproductive tract; they 
are exposed to progressively decreasing AEA concentrations (Rossato et al., 2005, 
Amoako et al., 2010). It has been theorised that the high AEA concentrations observed 
in seminal plasma could act to maintain sperm in a quiescent metabolic state that can be 
activated within the female reproductive tract (Schuel et al., 2002). Once a threshold 
level of AEA is reached membrane hyperpolarization is triggered increasing the influx 
of Ca
2+
. This theory is supported by differential expression of NAPE-PLD and FAAH 
that finely control levels of AEA in mouse oviduct (Wang et al., 2006).  In this respect, 
decreasing AEA concentration in the female reproductive tract secretions could reduce 
its inhibitory effect on sperm, thus rendering them suitable for capacitation and gaining 
their fertilisation potential (Rossato et al., 2005). The existence of this AEA gradient 
suggests a modulatory role of the endocannabinoid system on human sperm function 
and could modulate sperm cell motility (Agirregoitia et al., 2010a, Amoako et al., 
2013b).   
 
Leelamine was found from the Flexstation screen to increase [Ca
2+
]i in human sperm 
cells which potentially increases production of AEA leading to increased levels of AEA 
and a decrease in sperm function, including sperm motility, by promoting inhibition 
through activation of the CB1 receptor (mechanisms described previously, figure 5-9). 
Similarly, the incubation of sperm cells with a selective CB2 receptor agonist GP1a, also 
exhibited significant decreases in motility parameters which corroborates a previous 
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study by Agirregoitia et al who identified a shift in the proportion of cells from A grade 
to B grade on addition of CB2 agonist (Agirregoitia et al., 2010a). These results suggest 
that cannabinoids do have a role in controlling sperm motility however it may be more 
beneficial for their potential therapeutic applications to further study their possible use 
as contraceptives rather than motility enhancers.  
 
 
       
 
 
 
 
 
Mitogen activated protein kinase inhibitors fail to enhance sperm motility 
Treatment with both JX401 and EO1428 was found to significantly decrease total 
motility, progressive motility and hyperactivation of treated cells under all conditions 
examined. Numerous groups have published information regarding MAPK cascades 
involvement in spermatogenesis and spermatozoa functions, however this data is 
controversial and information regarding the nature of endogenous and physiologically 
relevant sperm- ligands, that are capable of activating MAPK’s including p38, remain 
unknown (Weidinger et al., 2005, Wong and Yan Cheng, 2005, Almog and Naor, 
2008). However, previous groups making use of p38 inhibitors in assessing sperm 
motility noticed increases in sperm motility and hyperactivation (Almog et al., 2008) 
which contradicts the results of this study. As described previously p38α has been 
Figure 5-9. The endocannabinoid system and sperm function. Alterations in [Ca
2+
]i  prompt AEA 
production which binds to the extracellular site of CB1 (CB1R) leading to inhibition of sperm motility, 
acrosome reaction and capacitation. AEA is broken down via the synthesizing phospholipase NAPE-PLD 
and the AEA hydrolyzing FAAH which cleaves AEA into ethanolamine (EtNH2) and AA. Image from 
Wang et al. (Wang et al., 2006)  
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identified to be located at the sperm tail and has been proposed to negatively affect 
progressive motility and hyperactivation (figure 5-3) (Almog et al., 2008). This 
suggested that the use of specific p38α inhibitors would have the opposite effect 
allowing for improved motility and hyperactivation. As this was not seen to be the case 
in this study, but has been seen previously (Almog et al., 2008), it suggests the 
possibility that these compounds may be toxic to spermatozoa (Li et al., 2009). p38α is 
broadly expressed and is the most abundant p38 family member found to be present in 
most cell types (Porras et al., 2004). Due to the limited understanding of p38 signalling 
pathways in sperm it could be possible that inhibition of p38α could be detrimental not 
only to sperm motility but to other vital functions associated with cell survival.  Almog 
et al proposed that p38 works in association with ERK1/2 to regulate sperm motility 
with ERK1/2 promoting and p38 inhibiting motility (Almog et al., 2008) however, 
Weidinger et al published an opposite report that concluded that ERK1/2 inhibited 
sperm motility (Weidinger et al., 2005). In this instance, if p38 and ERK1/2 are 
regulating motility, and ERK1/2 is actually inhibiting motility, then it is possible that 
p38 might be promoting motility and addition of p38 inhibitors would surmise that you 
would see a decrease in sperm motility under these circumstances. An earlier study, on 
demembranated fowl sperm, had suggested that the MAPK pathway had a function in 
sperm motility after noticing inhibited flagella motility on addition of MAPK inhibitors 
(Ashizawa et al., 1997). p38 is known to play a vital role in germ cell development, 
specifically in spermatogenesis having a role in disturbing the blood testes barrier to 
allow preleptolene spermatocytes to migrate to the adluminal compartment (Almog and 
Naor, 2010). Previous studies on mice have also indicated the importance of p38 
through targeted inactivation of the p38α gene which resulted in embryonic death due to 
a placental defect (Adams et al., 2000). If p38α inhibitors were proposed for use 
clinically in increasing sperm motility the potential negative effects on the prospective 
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embryo (Adams et al., 2000) would need to be considered suggesting that p38α 
inhibitors may not be of use in pharmacological intervention without causing systemic 
toxicity and embryonic death (Adams et al., 2000, Li et al., 2009).   
 
C-met inhibitors decrease motility when spermatozoa are in a capacitated state 
The effect of c-met on human ejaculated spermatozoa is still not clear with published 
results being controversial (Wiltshire et al., 2000, Catizone et al., 2006). C-met receptor 
induces its biological activities through binding its ligand; HGF/SF which has potent 
mitogenic, motogenic and morphogenetic activities (Herness and Naz, 1999, Kitamura 
et al., 2000, Wiltshire et al., 2000). Transgenic studies have shown that in mice targeted 
HGF gene disruption is lethal in utero (Uehara et al., 1995) identifying the importance 
of action through this ligand and its associated c-met receptor. This study suggests that 
inhibiton of the c-met receptor would prevent HGF binding resulting in a similar effect 
to that seen in the knock out study. Naz et al have previously examined the relationship 
between HGF sperm motility in murine models and their results suggested HGF may be 
involved in the attainment of motility in mammalian sperm (Naz et al., 1994). HGF has 
also been reported to have a positive effect on epididymal sperm motility in rats 
(Catizone et al., 2006). This same group identified c-met receptors to be localized both 
on the head and the flagellum of isolated epididymal spermatozoa and suggested in rats 
that HGF/c-met are related to epididymal acquisition and maintenance of sperm motility 
(Catizone et al., 2006). This data contrasts with studies on human sperm where it has 
been reported that HGF does not significantly maintain or alter human sperm motility 
(Kitamura et al., 2000, Wiltshire et al., 2000). This conflicting data suggests that the 
effects of HGF/c-met function differently in rodents than in humans (Catizone et al., 
2006). The data available from studies on human ejaculated spermatozoa report that 
HGF has no active role in controlling sperm motility however both studies suggest the 
possibility of HGF playing a role in epididymal maturation and maintenance of motility 
99 
 
(Kitamura et al., 2000, Wiltshire et al., 2000). The results of this study corroborate that 
of Wiltshire et al and Kitamura et al suggesting that HGF/c-met do not appear to control 
ejaculated human sperm motility. Use of PHA665752 (c-met inhibitor) when in 
combination with spermatozoa under non-capacitating conditions exhibited no changes 
to motility parameters compared to control. This inhibition of c-met would have no 
effect on sperm motility if HGF/c-met are not associated with controlling motility.  
However, these results are not conclusive and under capacitating conditions the 
percentage of motile, progressively motile and hyperactivated cells displayed time-
dependent decreases which could support the role for c-met in maintaining motility with 
the use of inhibitors preventing this action. Further evidence supporting that HGF may 
have a supporting role in maintaining sperm motility is that the c-met receptor has been 
found to be tyrosine phosphorylated/ autophosphorylated during capacitation, an effect 
that is enhanced by HGF/SF (Herness and Naz, 1999). Tyrosine phosphorylation of 
sperm membrane proteins is vital in development of fertilising capacity, the c-met 
receptor may have involvement in this process through its ability to be phosyphorylated/ 
autophosphorylated at tyrosine residues (Herness and Naz, 1999). Inhibition of c-met 
would inhibit tyrosine kniase activity decreasing hyperactivation (Bajpai and Doncel, 
2003) a result which is corroborated by this study.  Tyrosine phosphorylation is a 
hallmark of capacitation in mammalian sperm (Visconti et al., 1995b, Signorelli et al., 
2012) and leads to increases [Ca
2+
]i and activation of Catsper channels (Wennemuth et 
al., 2003, Signorelli et al., 2012) suggesting that c-met could play a role in increasing 
sperm motility. Inhibition of c-met would therefore decrease motility in capacitated 
sperm as seen is this study.  The results of this study and previous publications suggest 
that C-met inhibitors would not be beneficial clinical treatments for sperm motility 
(Depuydt et al., 1998, Herness and Naz, 1999, Kitamura et al., 2000, Wiltshire et al., 
2000).  
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CHAPTER 6 
Motility Analysis of the PDE inhibitor 
Trequinsin Hydrochloride 
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6.1 Introduction 
6.1.1 Phosphodiesterase inhibitor  
Trequinsin hydrochloride is a potent phosphodiesterase inhibitor of cGMP-inhibited 
phosphodiesterase (PDE3) (Biosciences, 2013f) (IC50 250pM) (Table 6-1).  
Table 6.1 Summary on Trequinsin Hydrochloride identified from screen of the Chemogenomics 
library (Biosciences, 2013f)   
Cyclic adenosine monophospahate (cAMP) plays an important role in the signalling 
pathways that regulate sperm motility (Tash, 1990), capacitation and the acrosome 
reaction (Visconti et al., 1995c). Levels of cAMP are regulated by two key enzymatic 
reactions: (i) soluble adenylyl cyclase which produces cAMP from adenosine 
triphosphate (ATP) and (ii) cyclic nucleotide phosphodiesterases (PDEs). PDEs degrade 
cAMP to 5’AMP and are important in controlling cyclic nucleotide levels in 
spermatozoa (Lefievre et al., 2002). There are at least 11 identified families of 
phosphodiesterases, many with several different isoforms, which are classified 
according to kinetics, mechanism of regulation, affinity and substrate specificity 
(Beavo, 1995, Soderling and Beavo, 2000). PDEs are highly specific for hydroloyis of 
cAMP (PDE 4, 7 and 8),cyclic guanine monophosphate (cGMP) (PDE 5, 6 and 9) or 
they hydrolize both cAMP and cGMP (PDE 1, 2, 3, 10 and 11) (Lefievre et al., 2002). 
Lefievre et al  (2000) identified that the PDEs present in spermatozoa have a higher 
affinity for cAMP after observing that the rate of hydrolysis of cAMP in sperm by PDEs 
is 3 fold higher than that of cGMP (Lefievre et al., 2000). Currently PDE 1 (Vasta et al., 
2005), PDE 2, PDE 3, PDE 4 and PDE 5, PDE 8 (Richter et al., 1999) and PDE 11 
(Yuasa et al., 2001) have been identified in mammalian and human testis and 
spermatozoa along with mRNA transcripts being identified for six types of PDEs (Fisch 
Compound name Primary action Chemical structure 
Trequinsin 
Hydrochloride 
Selective inhibitor of 
PDE3 
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et al., 1998, Lefievre et al., 2000, Lefievre et al., 2002, Richter et al., 1999, Yan et al., 
2001, Fisher et al., 1998, Fawcett et al., 2000, Coskran et al., 2006).   
 
As mentioned, PDE3 has mixed specificities with cGMP acting to inhibit the hydrolysis 
of cAMP by PDE3 (Lefievre et al., 2002). The activity of PDE3 is regulated by 
feedback mechanisms involving cAMP dependent PKA phosphorylation (Visconti et 
al., 1997) (figure 6-1). 
   
 
 
 
 
 
 
cAMP is a key second messenger in protein tyrosine phosphorylation, motility and 
capacitation (Tash, 1990). Previous studies investigating the effects of PDE3 specific 
inhibitors have identified that they act by increasing the level of cAMP in sperm 
(Lefievre et al., 2002). This, combined with the discovery that Trequinsin hydrochloride 
increases levels of intracellular Ca
2+
,
 
led to the investigation of the effect of Trequinsin 
hydrochloride on sperm motility.  
Figure 6-1.Signaling pathways involved in sperm capacitation. Two pathways involved in human sperm 
capacitation, one corresponds to the activation of PKA by cAMP, and the other involves downregulation of 
Ser/Thr phosphatases by the Src family kinase (SFK). Both pathways lead to PKA substrate phosphorylation 
followed by tyrosine phosphorylation resulting in capacitation. PDEs play a role in the pathway by degrading 
cAMP to 5’AMP (red circle). (Battistone et al., 2013) 
 
103 
 
6.2 Experimental Procedure 
Experimental procedure for sperm preparation and CASA analysis is identical to that as 
described for compounds in chapter 5.  
 
Kremer mucus penetration tests were conducted using methylcellulose prepared in 
NCM. Capillary tubes were placed in the methylcellulose for 30 min at 37
o
C allowing 
the tubes to fill. One end was then sealed and the open end was placed in prepared 
sperm (donor and patient samples, see chapter 2 for details). Sperm preparations and 
capillary tubes were incubated in appropriate incubators (CO2 or normal) for 1 hr. The 
capillary tubes were then removed and the open ends sealed with plasticine. The tubes 
were marked at 1 cm and 2 cm points before being viewed on a microscope using a 20X 
objective. Results were normalised to parallel untreated 1% DMSO controls.  
 
Assessment of the acrosome reaction was conducted by staining with PSA labelled 
FITC. Sperm were prepared through DGC, capacitated for 2 hrs 30 min before 
treatment with the appropriate drug for 1hr. CM only was used as a negative control (1 
hr), 1% DMSO was used as a vehicle control (1 hr) and Ca
2+
 ionophore was used as a 
positive control (15 min). Sperm were washed twice and re-suspended in sodium 
chloride before being smeared on a microscope slide. After air drying the smear was 
fixed in 95% (v/v) ethanol before the addition of PSA labelled FITC. After 1 hr the 
slides were washed three times with PBS and mounted. Analysis was conducted using 
the fluorescence setting on an EVOS xl digital inverted microscope.    
 
The hypo-osmotic swelling test was used to examine sperm vitality after drug treatment. 
Sperm suspensions were further incubated with hypo-osmotic medium and sodium 
citrate dihydrate at 37
o
C in 5% CO2 for 30 min. Sperm with coiled tails were counted as 
viable.  
 
For further details refer to chapter 2.       
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6.3 Results 
6.3.1 CASA motility analysis of Trequinsin Hydrochloride 
It was clear that sperm samples under non-capacitating conditions that were then 
exposed to Trequinsin exhibited the most dramatic responses from both the 40% and 
80% fraction. Progressive motility was significantly increased instantaneously after 
treatment with the compound (P=0.002) and this increase was sustained for the entire 
time-course (P≤0.05) (figure 6-2A). The greatest increment in hyperactivation, when 
stimulated by Trequinsin, was found in the 40% fraction under non-capacitating 
conditions after 90 min (P≤0.05) which continued to be significantly increased for the 
remainder of the time-course (P˂0.005) (figure 6-2B). However, total motility remained 
unchanged from control (appendix).    
 
Spermatozoa from the 80% fraction (high quality sperm) exhibited a pronounced 
increase in progressive motility when treated with Trequinsin, after incubation at 37
o
C, 
in non-capacitating conditions. This statistical increase in progressive motility was 
sustained for the entirety of the 3 hr time-course (0-60 min, 150 & 180 min P≤0.05, 90 
& 120 min P˂0.005) (figure 6-2C). Similarly to the 40% fraction the percentage of 
hyperactivated cells in the 80% fraction was significantly higher than control after 90 
min incubation with the compound (P≤0.05, figure 6-2D). Furthermore, hyperactivated 
motility was increased after 150 min and 180 min treatment (P˂0.005 & P≤0.05 
respectively). This increase in progressive motility and hyperactivation supports the 
knowledge that PDE inhibitors increase cAMP leading to capacitation (Lefievre et al., 
2000, Lefievre et al., 2002). However, similarly to the 40% fraction there was no 
significant change in total motility for this parameter (appendix). When sperm cells 
were exposed to Trequinsin after capacitation the resulting effect on motility was the 
opposite of non- capacitating conditions. The 40% fraction exhibited significant 
decreases in motility after 180 min incubation with a steady decline evident over the 
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entire time-course for the percentage of total motile, progressively motile and 
hyperactivated cells (appendix). Similarly, to the 40% fraction, the 80% fraction 
demonstrated a noticeable decline in motility which was most evident and significant in 
the percentage of hyperactivated cells after 150 and 180 min treatment (P=0.041 & 
P=0.004 respectively) (appendix and figure 6-2E). No change was observed for both the 
40% and 80% fractions after capacitation for the percentage of total motile and 
progressively motile cells (appendix).          
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Figure 6-2. Expression of basal (control) motility values compared to treated samples in non-
capacitating (NCM) and capacitating (CM) media for (A) % progressively motile (40% fraction 
NCM), (B) hyperactivation (40% fraction NCM), (C) % progressively motile (80% fraction NCM), (D) 
hyperactivation (80% fraction NCM) and (E) hyperactivation (80% fraction CM). The result shown is the 
mean ± SE for motility parameters measured. In this study all motility parameters were measured over a 
period of 180 min under capacitating conditions comparing the difference between the control and treated 
samples. N= 6 for both parameters, * indicates a significant increase (P≤0.05), ** indicates P≤0.005 
between control and treated samples at independent time points (Mann Whitney test and Kruskall-
Wallace test).   
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The dramatic opposing effects seen in response to treatment with Trequinsin under non-
capacitating and capacitating conditions directed analysis to compare the Trequinsin 
stimulated increase, in both the 40% and 80% fraction, under non-capacitating 
conditions, to that of the controls after capacitation (figure 6-3). When comparing the 
motility parameters from sperm cells, in the 40% fraction, no significant difference was 
noted between capacitated control and the treated non-capacitated sperm cells 
suggesting that the treated non-capacitated sperm are now acting similarly to a 
capacitated sample (figure 6-3A&B). Treatment with Trequinsin increased progressive 
motility in the treated, non-capacitated cells to within the range of control capacitated 
cells on instant addition of the agonist. These parameters remained similar to the 
capacitated control throughout the time-course until it reached 180min incubation when 
it was found that all parameters assessed exhibited a significant decrease compared to 
capacitated control (P≤0.05, figure 6-3A&B and appendix). The percentages of total 
motile cells were also increased in the treated, non-capacitated sample to the same as 
the capacitated control instantaneously although, at the 90min and 180min time-points 
the percentage of total motile cells was significantly decreased in the treated samples 
(P≤0.05 and P≤0.005 figure 6.-3A).  This could indicate that the action of the 
compound may not last past the 3hr time course and would need testing for a longer 
period of time to examine any lasting motility alterations.  
 
The same comparison was run for the 80% capacitated control and the 80% non-
capacitated treated sample. The similarities in the 80% fractions were not as great as 
those noted for the 40% fraction. After 0 min the only parameter that was similar to the 
capacitated control was progressive motility. The percentage of total motile cells were 
similar to the capacitated control after 30 min incubation and remained this way until 
the 3 hr time point when it was found to have significantly decreased (P=0.41, figure 6-
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3C).  The percentage of progressively motile cells after 30 min treatment was observed 
to be similar to the capacitated control however; hyperactivation was significantly 
higher in the capacitated control at this point (P≤0.05, appendix). Hyperactivated 
motility displayed variable results that were only similar to the capacitated control after 
90, 150 and 180 min (appendix). The percentage of progressively motile cells, after 
treatment with Trequinsin, increased instantaneously, an effect that was sustained with 
the exception of 90 and 180 min incubations (figure 6-3D).     
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Figure 6-3. Comparing basal (control) motility values under capacitating conditions to Trequinsin 
treated non-capacitated samples. (A) % total motile (40% fraction), (B) % progressively motile (40% 
fraction), (C) % total motile (80% fraction) and (D) % progressively motile (80% fraction). The result 
shown is the mean ± SE for motility parameters measured. In this study all motility parameters were 
measured over a period of 180 min.  N= 6 for all parameters, * indicates a significant increase (P≤0.05), 
** indicates P≤0.005 between control and treated samples at independent time points (T-test, Mann 
Whitney test and Kruskall-Wallace test).  
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6.3.2 Examination of sperm motility through an artificial viscous medium: 
methylcellulose (Kremer mucus penetration test) 
To examine the ability of sperm treated with Trequinsin Hydrochloride to penetrate 
cervical mucus, a viscous medium methylcellulose, was used as a cervical mucus 
substitute in the Kremer mucus penetration assay. Previous studies have reported that 
sperm penetration into mucus correlates with their functional capacity and fertilisation 
rates both in vivo and in vitro (Aitken et al., 1992, Barratt et al., 1989, Eggert-Kruse et 
al., 1989).  Sperm cells were incubated with Trequinsin for 1hr before cell penetration 
was analysed.    
 
The initial Kremer penetration assay was conducted on capacitated sperm from the 80% 
fraction using progesterone as a positive control. Progesterone has previously been 
shown to increase sperm penetration under these conditions (Alasmari, 2013) and was 
used as a positive control in the Flexstation assay screen.  Capacitated cells from the 
80% fraction, incubated with Trequinsin, failed to increase penetration into the viscous 
medium. However, under the same conditions 3.6µM progesterone stimulated 
significant increases in cell penetration at both 1 cm and 2 cm (P≤0.005, figure 6-4A).  
 
CASA analysis identified significant increases in motility in the 40% fraction under 
non-capacitating conditions although, this was not reflected in 80% capacitated 
samples. To examine whether this effect was the same in this functional motility assay 
analysis was conducted on cells from the 40% fraction under non-capacitating 
conditions. Under these conditions Trequinsin treated cells significantly increased 
penetration at both distances (P≤0.005, figure 6-4B). This result corroborates the CASA 
analysis indicating that Trequinsin is capable of increasing motility in non-capacitated 
cells. Treatment with progesterone under these conditions did not significantly change 
the proportion of cells penetrating at 1 cm although, at 2 cm the proportion of cells was 
significantly increased (P≤0.005, figure 6-4B).    
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Figure 6-4. Trequinsin induced penetration of sperm cells into viscous medium. Cells from (A) 80% 
fraction under capacitating conditions and (B) 40% fraction under non-capacitating condition were 
evaluated for the number of sperm penetrating to 1 cm and 2 cm. The cells were counted and normalised 
to values in untreated controls (red dashed line). N= 5 for all experiments and all values are the mean ± 
SE. ***- indicates a significant difference from the control, considered to be P≤0.005 & P≤0.001 as 
assessed by non-parametric Mann Whitney U test.  
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6.3.3 Vitality analysis (HOS test) of treated sperm cells  
This study utilised the hypo-osmotic swelling test in an attempt to analyse the effect 
seen in capacitated sperm after 3 hrs incubation with Trequinsin. Both the CASA 
analysis and Kremer mucus penetration test identified a decrease in sperm motility in 
the 80% fraction under capacitating conditions. To ensure that addition of this 
compound to human sperm is not toxic over long periods of time a vitality assessment 
was conducted.  
Donor spermatozoa were capacitated for 2 hrs 30 min before being incubated with 
Trequinsin for a period of 3 hrs. Following incubation the vitality of the sperm cells was 
assessed. The result identified a mean of 92.5% of living cells with the results ranging 
from 88% - 99% from the 3 donor samples assessed (figure 6-5). This result was not 
significantly different from control suggesting that this compound is not killing the 
cells.   
 
 
 
 
 
 
Figure 6-5. Vitality analysis after incubation with Trequinsin. Trequinsin Hydrochloride (red bar) was 
assessed for its effects on sperm vitality after incubation with sperm cells for a period of 3 hrs. All values 
are the mean ± SE, n=3 for each experiment.  No statistical difference was noted from control (grey bars). 
Analysis was conducted using Pearson’s Chi squared test and significance was assessed as P≤0.05.   
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6.3.4 Response of patient samples to incubation with Trequinsin Hydrochloride 
To evaluate what effect Trequinsin may have in a clinical setting the same analysis were 
performed on treated patient samples.     
 
6.3.4.1 CASA Motility analysis of patient samples pre-treated with Trequinsin 
Patient samples provided by the ACU, after capacitation, were treated with Trequinsin. 
All samples examined were from patients attending the ACU for IVF and motility 
analysis was conducted over a period of 2 hrs using CASA (see chapter 2 for detailed 
methods). Results for each patient were analysed independently (Table 6.2). Treated 
patient samples exhibited significant increases in VCL (8/9) and ALH (9/9) resulting in 
significant increases in hyperactivated motility (Table 6-2). Following an increase in 
ALH, LIN was significantly decreased in 8/9 patients along with progressive motility. 
However, one patient did show significant increases (P8) in progressive motility but this 
result was highly variable for this patient across the time-course (Table 6-2). The results 
for all samples, regarding total motility, were variable however the predominant 
response showed no change in the percentage of motile cells (Table 6-2). Significant 
increases were observed from this CASA analysis for hyperactivation but only 2/9 
patients exhibited significant increases in all the four time points, with 1 patient 
exhibiting significant increases after 60 min. 3/9 patients displayed no change in 
hyperactivation with the remaining 3 patients exhibiting variable results (Table 6-2).  
 
Overall the result of treatment on patients with Trequinsin hydrochloride was better 
than that of the donor response under the same conditions (80% fraction, capacitated). 
Donors exhibited significant increases in VCL and hyperactivation which is opposite to 
results obtained for the patient samples under the same parameters (Table 6-2). There 
also were no significant differences noted in ALH for treated donors where there were 
clear increases in ALH in patient samples.    
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Trequinsin Hydrochloride 
  VCL LIN ALH 
Patient No. 0 30 60 120 0 30 60 120 0 30 60 120 
P1       
P2 – –   – – – –  
P3 –   –    –  
P4 – – – –     
P5       
P6  –  –  –  –  – 
P7 – –  –  –   – –  
P8  – – –     – 
P9  – – – – –   – –  
  Total Motile 
Progressively 
Motile Hyperactivation 
Patient No. 0 30 60 120 0 30 60 120 0 30 60 120 
P1 – –       
P2  –  –  –  – – –  
P3  – –  – – –  – –  – 
P4 –       – – – – 
P5  – – –  –  –  
P6 – – – – –  – – – –  – 
P7 –  – –  – – – – –  – 
P8 –  –  –    – – – – 
P9 –    – –   – – – – 
 
Table 6.2 Identification of motility kinematics analysed by CASA, from patient samples, after 
incubation with Trequinsin Hydrochloride. Motility parameters after stimulation with Trequinsin 
Hydrochloride were evaluated from 9 patients undergoing IVF at Ninewells ACU. The table identifies the 
6 motility parameters evaluated for each patient over a period of 2 hrs. Statistical significance (see key) 
was determined from comparison with control ± SD. If the agonist response was greater than or less than 
control it was considered as a significant result.  
 
 
 
 
 
  
Key 
=Increase
 = Decrease
–   = No change 
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6.3.4.2 Kremer mucus penetration assay to assess functional motility of patient sperm 
treated with Trequinsin Hydrochloride 
Donor samples exhibited significant increases in sperm penetrating ability when under 
non-capacitating conditions. When evaluating capacitated cells an increase compared to 
control was observed however it was not significant. The patient samples available for 
analysis were all IVF so had been capacitated for treatment. Although, we have 
previously shown that Trequinsin does not seem to influence capacitated cells as much 
as non-capacitated it was necessary to use these patient samples. The result from this 
assay confirmed the results observed from donor samples with no change compared to 
control at the 1 cm distance and a slight increase at the 2 cm distance (figure 6-6). 
However, this increase similarly to donors did not reach a significant level. 
Progesterone once again was used as a positive control. In this assay progesterone did 
not significantly increase penetrating ability at 1 cm in contrast to the donors but it did 
significantly increase the proportion of cells penetrating at 2 cm the same as donors 
(figure 6-6). 
 
 
 
 
   
 
Figure 6-6. Agonist induced sperm penetration into viscous medium. Sperm penetration into viscous 
medium upon application of 40µM Trequinsin Hydrochloride or 3.6µM progesterone as measured by 
counting cells at 1 cm and 2 cm. The number of sperm penetrating to 1 cm and 2 cm was assessed and 
normalised to values in untreated controls (red dashed line). All values are the mean ± SE (n=9 
experiments performed with 9 different patient samples). *- indicates a significant difference (P≤0.05), 
***- indicates a significant difference (P≤0.005) from the control, as assessed by non-parametric analysis 
Mann Whitney U test. 
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6.3 Discussion 
Trequinsin hydrochloride enhances motility, assessed by CASA, and increases 
penetration into a cervical mucus substitute  
A variety of cellular functions are regulated by cyclic guanine monophosphate (cGMP) 
or cyclic adenosine monophosphate (cAMP) levels (Richter et al., 1999). Cyclic 
nucleotide functions are dependent on a dynamic intracellular equilibrium between 
synthesis and degradation (Rossi et al., 1985). The use of nonselective PDE inhibitors 
have been shown to affect capacitation (Visconti et al., 1995c, deLamirande et al., 
1997), sperm motility (Tesariki et al., 1992, Jaiswal and Majumder, 1996) and acrosome 
reaction (Tesarik et al., 1992).  
  
Trequinsin hydrochloride is a selective potent inhibitor of cGMP-inhibited 
phosphodiesterase (PDE3). In this study it significantly increased progressive motility 
and hyperactivation in non-capacitated samples. Lefievre et al (2002) identified PDE3A 
isoforms in ejaculated human spermatozoa however, immunocytochemistry 
experiments indicated it to be localised to the postacrosomal segment of the sperm head 
(Lefievre et al., 2002). This same group tested the involvement of PDE3 in sperm 
function using Milrinone (a selective PDE3 inhibitor) which increased cAMP levels in 
sperm but not to the extent to induce capacitation or have any effect on motility or 
tyrosine phosphorylation (Lefievre et al., 2002). However, the data presented in this 
study contradicts these results with dramatic increases in motility and hyperactivation as 
a result of treatment with Trequinsin. The positioning of PDE3 at the postacrosomal 
region of the sperm head does not suggest a role in sperm motility and from the work of 
Lefievre et al (2002) it is reported that the use of PDE3i alone does not increase cAMP 
levels enough to induce capacitation or alterations in sperm motility (Lefievre et al., 
2002). The results from the Flexstation identified Trequinsin as being a compound that 
increased [Ca
2+
]i levels of sperm to an equivalent concentration of that seen after 
treatment with progesterone suggesting that capacitation may have been triggered in 
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these sperm cells (Baldi et al., 1991). Elevation of [Ca
2+
]i is essential for changes in 
flagella function as a manifestation of capacitation (Lishko et al., 2012b). This 
knowledge led to the possibility that Trequinsin was functioning not only through PDE3 
but through another signalling pathway. This theory was tested through the use of the 
patch clamp technique (performed by Steven Mansell) and identified Trequinsin as 
having activation kinetics almost identical to progesterone (data not shown) suggesting 
that Trequinsin may act via the CatSper cation channel. Activation of CatSper, by 
Trequinsin, would lead to an elevation in [Ca
2+
]i and promote hyperactivated motility 
(Mannowetz et al., 2013), both of which are reported in this study. However, cells that 
had previously been capacitated before exposure to Trequinsin exhibited a time 
dependent decrease in motility especially in the percentage of hyperactivated cells.  
Human sperm flagella are long and thin (40µM and ˂2µM respectively) and because 
diffusion is inversely proportional to the area through which a substance diffuses it 
takes molecules many seconds to traverse through the flagellum from the mid-piece to 
the end-piece (Lishko et al., 2012b). Thus, ATP produced in the mitochondria of the 
midpiece, which is needed for sperm motility, especially hyperactivation, takes a long 
time to reach the end of the flagellum (Lishko et al., 2012b). To be able to compensate 
for this delay, flagella movement especially at the tip of the sperm tail is generated 
through glycolysis (Miki et al., 2004, Mukai and Okuno, 2004, Williams and Ford, 
2001). Glucose is required to sustain an optimal ATP concentration in human sperm 
motility and is essential in supporting hyperactivated motility (Williams and Ford, 
2001). Human sperm obtain a high proportion of their energy from glycolysis of 
glucose to lactate and a marked decline in vigorous motility was identified when sperm 
cells were incubated over long periods of time (Williams and Ford, 2001, Chulavatnatol 
and Haesungcharern, 1977). This decrease in motility was attributed to the stress of 
prolonged incubation which resulted in a decreased concentration of ATP and ADP. 
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The use of Trequinsin under capacitating conditions would have required an 
instantaneous release of ATP to increase and sustain hyperactivation of cells that had 
previously been capacitated. Williams and Ford (2001) accounted for leakage of 
adenine nucleotides from dead/dying cells concluding that the loss of ATP/ADP wasn’t 
owing to cell death (Williams and Ford, 2001). Results from this study also showed that 
Trequinsin did not alter sperm vitality suggesting that the decrease in motility observed 
under capacitating conditions was not because the compound is detrimental to sperm 
survival. This same effect had previously been observed with use of caffeine to 
artificially stimulate motility resulting in an increased demand for energy 
(Chulavatnatol and Haesungcharern, 1977). If the glycolysis of endogenous substrate is 
not fast enough the result is a depletion in ATP level detrimental to motility 
(Chulavatnatol and Haesungcharern, 1977), an effect that was noted in both donor and 
patient samples which had been capacitated before treatment. However, 
supplementation of glucose after incubation in all studies mentioned re-stored motility 
to normal levels suggesting this detriment is not permanent (Miki et al., 2004, Mukai 
and Okuno, 2004, Williams and Ford, 2001, Chulavatnatol and Haesungcharern, 1977).                
 
Similarly to progesterone (Alasmari et al., 2013b), Trequinsin initiated an increase in 
penetrating ability of sperm through a cervical mucus substitute, when under non-
capacitating conditions. This result supports the determination of Trequinsin 
hydrochloride functioning via the CatSper channel. This compound has the potential of 
being beneficial therapeutically in increasing sperm motility however, further research 
needs to be conducted to confirm the motility effects observed under capacitating 
conditions are not irreversible and to see whether further supplementation with glucose 
prevents this effect.      
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CHAPTER 7 
Investigating the effects of novel ion 
channel compounds on sperm motility 
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7.1 Introduction 
Discovery of new drugs targeting sperm motility to facilitate conception is particularly 
challenging. Two commonly used methods in drug discovery are computational 
chemistry and molecular modelling, however HTS has broadened these approaches to 
allow for identification of hits through screening extensive chemical or focused libraries 
(Miller, 2006). 
 
Sperm are highly complex systems that rely on post- translational modifications as their 
primary signalling mechanism. Ionic gradients and ion channels are fundamental 
resources allowing changes in electrical potential and the concentration of second 
messengers (Visconti et al., 2011). They regulate intracellular signalling pathways and 
control physiological changes within the cell (Darszon et al., 2011). Ca
2+
 plays a pivotal 
role in fertilisation and plays crucial roles in maturation, motility and the acrosome 
reaction in invertebrate and vertebrate spermatozoa (Yanagimachi, 1994). Over the past 
10 years the fundamental role of ion channels and particularly Ca
2+
 to sperm physiology 
has been consolidated (Kirichok et al., 2006, Darszon et al., 2008). Intracellular Ca
2+
 in 
sperm appears to be regulated by at least two processes; mobilisation of stored Ca
2+
 in 
the neck/midpiece region and/or through Ca
2+
 permeable ion channels and transporters 
(Ho and Suarez, 2001, Ren et al., 2001, Costello et al., 2009).         
 
Ion channels are integral proteins on the membrane of the cell that regulate ion 
transmission across the cell (Mok and Brenk, 2011). Ion channel targets remain 
unexploited in drug development with only 10% of drugs currently on the market 
known to bind to ion channels (Terstappen et al., 2010). Two sperm specific ion 
channels, CatSper and KSper (Slo3/Slo1) have been identified as the primary 
spermatozoal ion channels (Ren et al., 2001, Mannowetz et al., 2013, Santi et al., 2010, 
Schreiber et al., 1998). CatSper is a pH-regulated Ca
2+
 channel that is present on the 
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flagella of human sperm. Recently, Ca
2+ 
induced entry by progesterone has been 
identified as being via CatSper channels (Lishko et al., 2011, Strunker et al., 2011). 
CatSper are crucial to sperm motility and are fundamental to male fertility (Ren et al., 
2001).   
  
The knowledge of the importance of ion channels and in particular Ca
2+
 in sperm 
function led to the development of an ion channel assay based on a HTS approach. The 
HTS assay used was similar to that described for screening the chemogenomics library 
(chapter 5) however, this assay utilised an in-house ion channel focussed library 
assembled by the UoD DDU. This library of putative ion channel ligands was 
assembled from the ChEMBL database and from this library 3312 compounds were 
screened (Mok and Brenk, 2011). The HTS assay using a Flexstation microplate reader 
measured the agonist responses of the screened compounds compared to progesterone 
as a putative control. 70 of the compounds from the primary screen were examined 
further for ˃90% purity as demonstrated by chromatography- mass spectrometry 
(LCMS), reducing the number of compounds to 48 that evoked a concentration 
dependent increase in [Ca
2+
]i. The molecular and chemical structures of these 
compounds were further examined and 14 ion channel compounds were selected to 
undergo in-depth spermatozoa motility assessments.  
 
The 14 compounds will be identified as A1- H1 and A2- F2. Of the 14 compounds 
subjected to motility analysis the 5 most promising compounds (A1-E1) will be 
discussed in detail in this chapter with motility data for the remaining 9 (F1-H1 & A2- 
F2) being accessible in the appendix.   
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7.2 Experimental Procedure 
Motility analysis was conducted on spermatozoa from the 40% fraction, under non-
capacitating conditions, after DGC, from donor spermatozoa. This fraction was used as 
a surrogate for a patient sample (chapter 3). The 80% fraction, from a donor sample, 
under capacitating conditions, was evaluated to see if the compounds were capable of 
increasing motility in the high-density portion of strongly motile sperm (Oaconnell, 
2003).  Non-capacitated samples were left in the incubator at 37
o
C for 15 min before 
treatment with the compounds whereas capacitated samples were left in the 5% CO2 
incubator for 2.5 hrs before treatment with the compounds (for further details see 
chapter 2). Analysis was conducted at 30 minute intervals for a period of 3 hrs. We will 
only be discussing total motility, progressive motility in detail in this chapter. The 
results for VCL, ALH and hyperactivation are available in the appendix. 
 
 
Kremer mucus penetration tests, acrosome reaction analysis and vitality tests were 
conducted in an identical manner to that described in chapter 6.    
 
7.2 Results 
7.2.1 Motility assessment by CASA of five hit compounds  
7.2.1.1 Effect of 5 compounds on motility of 40% fraction in non-capacitating buffer 
A1 exhibited no significant differences to control in any of the motility parameters 
evaluated by CASA when the spermatozoa from the 40% fraction were evaluated under 
non-capacitating conditions (appendix). Total motility and progressive motility were 
unaffected by the compound at any of the time points analysed (figure 7-1 A&B).  
   
Spermatozoa incubated with B1 had a similar response to A1 with total motility and 
progressive motility exhibiting very little change in flagella motility between the treated 
sample and control (figure 7-1 A&B). The effects of C1, D1 and E1 on motility were 
very similar to that of A1 and B1with no significant changes seen in treated cells (figure 
7-1 A&B).  
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Figure 7-1. Expression of basal (control) motility values compared to treated samples in non-
capacitating (NCM) media, 40% fraction (A) % total motile and (B) % progressive motility. The result 
shown is the mean ± SE. In this study all motility parameters were measured over a period of 180 min 
under non-capacitating conditions comparing the difference between the control and treated samples. N= 
3 for all compounds, * indicates a significant increase (P≤0.05) between control and treated samples at 
independent time points (Mann Whitney test and Kruskall-Wallace test).   
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7.2.1.2 Motility resulting from exposure to 5 novel compounds in the 80% fraction 
after capacitation 
Exposure of spermatozoa from the 80% fraction, which had been capacitated before 
treatment, exhibited no significant changes from control for either total motile or 
progressive motility after treatment with A1, B1, C1 or D1 (appendix, figure 7-2). 
However, sperm incubated for 60 min with E1 were found to be significantly more 
progressively motile than control cells (P≤0.05) (figure 7-2) although, this was the only 
time point to exhibit significant increases. Examination of motility by use of CASA did 
not highlight any compounds that had a sustained, positive, significant effect on motility 
however; none of the compounds appear to be having a negative effect as was seen from 
compounds identified from the Chemogenomics screen (chapter 5).    
 
Figure 7-2. Expression of basal (control) motility values compared to treated samples in capacitating 
media (CM), 80% fraction for % progressive motility. The result shown is the mean ± SE. In this 
study all motility parameters were measured over a period of 180 min under capacitating conditions 
comparing the difference between the control and treated samples. N= 3 for all compounds, * indicates a 
significant increase (P≤0.05) between control and treated samples at independent time points (Mann 
Whitney test and Kruskall-Wallace test).   
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7.2.2 Evaluation of sperm motility into artificial viscous medium (Kremer test) 
To further evaluate sperm motility a functional assay that measures penetrating ability 
of cells into a viscous substrate (methylcellulose – alternative to cervical mucus) was 
conducted (Kremer, 1965, Ivic, 2002). To determine whether the motility response 
following the addition of agonists leads to impaired or improved penetration into 
viscous medium, donor samples were incubated with agonists for 1hr before cell 
penetration was analysed.   
The initial analysis was conducted on the 80% fraction following capacitation. Once 
again progesterone was used as a positive control alongside the treated compounds (see 
chapter 6.3.2). Exposure of cells prepared in CM to C1, D1 and E1 failed to increase 
cell penetration into methylcellulose. Stimulation with B1 and 3.6μM progesterone 
significantly enhanced penetration into viscous medium at distances of both 1 cm and 2 
cm (B1 P≤0.005, progesterone P 0.001; figure 7-3 A&B). A1 significantly decreased 
penetration at 1 cm (P≤0.05) however; it appeared to increase penetration at 2 cm 
although this did not reach statistical significance (figure 7-3 A&B).  
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Figure 7-3. Agonist induced penetration of cells into viscous medium. Cells from the 80% fraction 
under capacitating conditions were evaluated for the number of sperm penetrating to 1 cm (A) and 2 cm 
(B). The cells were counted and normalised to values in untreated controls (red dashed line). Agonists 
include: A1, B1 (n=5 experiments with 5 different donors), C1, D1 (n=3 experiments with 3 different 
donors), E1 (n=5 experiments with 5 different donors) and progesterone (n=11 experiments with 6 
different donors). All values are the mean ± SE. *- indicates a significant difference from the control, 
considered to be P≤0.05, ***- indicates significance of P≤0.005 & P≤0.001 as assessed by non-
parametric Mann Whitney U test.  
 
 
 
A 
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Sperm motility, when measured by CASA, was not found to increase as a result of 
agonist exposure (figure 7-1& 7-2) however, the penetration assay found B1 and 
progesterone significantly enhanced penetrating ability of sperm cells when under 
capacitating conditions (figure 7-3 A&B). To examine whether this effect was the same 
in our surrogate patient sample (40% fraction under non-capacitating conditions) the 
penetration assay was conducted on A1, B1, E1 and progesterone. It was decided to 
examine A1 under these conditions due to the increase in penetration seen at the 2 cm 
position under capacitating conditions (figure 7-3B) and E1 was selected following a 
significant increase in progressive motility being exhibited through CASA analysis 
(figure 7-2). Sperm cells exposed to C1 and D1 were not found to enhance motility or 
penetrating ability through CASA analysis or the Kremer assay and for this reason were 
not evaluated under these conditions. Sperm cells exposed to A1 and E1 showed no 
significant changes in penetrating ability compared to control at either distance. B1 and 
progesterone were both found to enhance penetrating ability at 1 cm however; this was 
not a significant result (figure 7-4A). At the 2 cm position B1 increased sperm cell 
penetration however; the results between donors were highly variable and did not 
produce a significant result. Progesterone produced a significant increase in the number 
of sperm cells able to penetrate the viscous medium at the 2 cm position under these 
conditions (P≤0.05; figure 7-4B).      
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Figure 7-4. Agonist induced penetration of cells into viscous medium. Cells from 40% fraction under 
non-capacitating conditions were evaluated for the number of sperm penetrating to 1cm (A) and 2cm (B). 
The cells were counted and normalised to values in untreated controls (red dashed line). Agonists include: 
A1 (n=4 experiments with 4 different donors), B1 (n=5 experiments with 5 different donors), E1 (n=4 
experiments with 4 different donors) and progesterone (n=18 experiments with 5 different donors). All 
values are the mean ± SE. *- indicates a significant difference from the control, considered to be P≤0.05 
as assessed by non-parametric Mann Whitney U test.  
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7.2.3 Evaluating acrosome reaction in response to agonist stimulation 
The Flexstation assay highlighted C1 and D1 as increasing intracellular Ca
2+
 however, 
this increase in Ca
2+
 is does not appear to affect motility measured, by CASA or the 
Kremer mucus penetration test. This raises the question as to what this increase in 
[Ca
2+
]i can be attributed to.  The knowledge of a Ca
2+
 store in the acrosomal region  
(Walensky and Snyder, 1995) led to the examination of the acrosome of cells after 
exposure to the aforementioned compounds.  
The mean percentage of sperm with reacted acrosomes was significantly increased 
compared to control when cells were exposed to 1% DMSO (P≤0.05; figure 7-5 A&B). 
The response to 1% DMSO was analysed due to these DDU compounds being in 
combination with DMSO. C1 induced the acrosome reaction in 42% of sperm cells 
which was a significantly higher percentage of cells compared to control, however, this 
result was not significantly different to the DMSO induced reaction indicating that this 
significant increase was most likely not a response solely of the agonist in question 
(figure 7-5A). D1 provoked the acrosome reaction in 59% of sperm cells which was a 
significantly higher proportion of cells than both the control and DMSO treated 
(P≤0.05; figure 7-5B). This result suggests that D1 could potentially be inducing a 
premature acrosome reaction which would be detrimental to the fertilising potential of 
spermatozoa exposed to this compound.   To ensure that the experiment was running 
successfully the effect of Ca
2+
 ionophore (A23187), a known inducer of the acrosome 
reaction (Aitken et al., 1993), was conducted in parallel to agonists. In both sets of 
experiments Ca
2+
 ionophore significantly enhanced the percentage of acrosome reacted 
cells when compared to control (P≤0.05; figure 7-5A, P≤0.001; figure 7-5B), DMSO 
(P≤0.05; figure 7-5A, P≤0.001; figure 7-5B), C1 (P≤0.05) and D1 (P≤0.05) 
independently (figure 7-5 A&B).        
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Figure 7-5. Agonist induced acrosome reaction. Staining with PSA-FITC allowed for evaluation of the 
percentage of sperm cells that become acrosome reacted in response to C1 (A) and D1 (B). All values are 
the mean ± SE, n=5 for all experiments. Significance was considered as P≤0.05 indicated by a 
(significantly different from control), b (significantly different form DMSO) and c (significantly different 
to agonist C1 or D1). Statistical significance evaluated by T-test or non-parametric Mann Whitney U test.  
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7.2.4 Vitality assessment of sperm cells exposed to agonists 
To further identify where this increase in [Ca
2+
]i measured by the Flexstation assay may 
have come from or could be attributed to the Hypo-osmotic swelling test (HOS) was 
conducted to test vitality after exposure to the agonists. It is known that as cells die they 
tend to show an increase in [Ca
2+
]i as a result. To be able to assess whether this increase 
seen in the Flexstation was a result of the cells dying the HOS test was conducted on 
cells stimulated by both C1 and D1. Capacitated sperm cells were exposed to either C1 
or D1 for a period of 3 hrs, equivalent to the amount of exposure assessed in the CASA 
motility assay, and the number of living cells assessed.  
 
The HOS test identified that neither C1 nor D1 appeared to have a detrimental effect on 
sperm vitality. The result for C1 indicated a mean of 93.5% of living cells with the 
results ranging from 85% - 99% from the 3 donor samples assessed (figure 7-6). Sperm 
cells exposed to D1 showed similar results to C1 with a mean of 95% living cells and a 
range of 90% - 98% from the 3 samples assessed (figure 7-6). Neither C1 nor D1 were 
significantly different from control (figure 7-6) suggesting that neither of the 
compounds were toxic to sperm cells.  
 
 
 
 
Figure 7-6. Vitality analysis after agonist exposure.  C1 (black bar) and D1 (green bar) were assessed 
for their effects on sperm vitality after incubation with sperm cells for a period of 3 hrs. All values are the 
mean ± SE, n=3 for each experiment.  Neither C1 nor D1 were statistically different from control (grey 
bars). Analysis was conducted using Pearson’s Chi squared test and significance was assessed as P≤0.05.   
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7.2.5 Effect of ion channel agonists on patient samples 
Analysis of ion channel compounds on motility of donors conducted through CASA 
analysis did not highlight any compounds that consistently increased any of the motility 
parameters evaluated (section 7.2.1). However, the Kremer penetration assay identified 
B1 along with progesterone as significantly stimulating penetration through the cervical 
mucus substitute methylcellulose (section 7.2.2). To determine whether this was a true 
agonist response CASA motility analysis and the Kremer penetration assay were 
conducted on patient samples after exposure to B1.        
 
7.2.5.1 CASA motility analysis of patient samples 
Patient samples provided by the ACU were incubated with B1 and motility kinematics 
measured by CASA over a period of 2 hrs. All samples examined were from patients 
undergoing IVF at the ACU and the results from each sample will be assessed 
independently (table 7.1).    
 
Incubation with B1, when compared with control, resulted in a huge variation in 
responses, in all parameters, between the 9 patients analysed. Significant increases were 
found at points in every parameter evaluated but none of these significant increases 
were consistent between samples (table 7.1). The only parameter that contained a 
sustained statistical increase over the 2 hr time course was found for the percentage of 
total motile cells, however, this was limited to only one sample (P8, table 7.1). P1 and 
P6 showed significant decreases in VCL compared to control that were sustained for the 
2 hrs evaluated. The predominant result after stimulation with B1 in all parameters was 
no significant change from control which corroborates the data from the donor analysis 
with this compound. 
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Table 7.1 Identification of motility kinematics, measured by CASA, from patient samples after 
exposure to B1. Motility parameters after stimulation with the agonist B1were evaluated from 9 patients 
undergoing IVF at Ninewells ACU. The table identifies the 6 motility parameters evaluated for each 
patient over a period of 2 hrs. Statistical significance (see key) was determined from comparison with 
control ± SD. If the agonist response was greater than or less than control it was considered as a 
significant result.  
 
 
 
 
 
 
B1 
  VCL LIN ALH 
Patient No. 0 30 60 120 0 30 60 120 0 30 60 120 
P1     –  – – –   – 
P2 –   – – –   – – – 
P3 – – – – –  –  –   
P4  – – – –  – –  – – – 
P5 – – – – – – – – – – – – 
P6 –    – – – – – – – – 
P7 – – – – – – – – – – – – 
P8 – – –  – – –  –  – – 
P9 – – – – – – – – – – – – 
  
Total Motile 
 
Progressive 
Motility 
Hyperactivation 
 
Patient No. 0 30 60 120 0 30 60 120 0 30 60 120 
P1 –  – – – –  –  – – 
P2 – – –  – –   – –  – 
P3 –   – –   – – – – – 
P4 – – – – – – – – – – – – 
P5 – – – – – – – – – – – – 
P6 – – –  – –   – – – – 
P7 – – – – – – – – – – – – 
P8 –   – – –  – – – 
P9 – – –  – – – – – – – – 
Key 
=Increase
 = Decrease
–   = No change 
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7.2.5.2 Assessing functional motility of patient samples stimulated by B1 
Section 7.2 identified that treatment with B1 and progesterone significantly enhances 
penetration of donor cells into methylcellulose (B1 P≤.0.005, Progesterone P≤0.001, 
n=5 figure 7-3 A&B). To ensure this result was not only valid in WHO normal donor 
samples the same assay was conducted on patient samples. The patients were all 
undergoing IVF at the ACU at Ninewells hospital. The results from this assay were 
consistent with the donor assay with cells exhibiting significantly increased penetrating 
ability after incubation with B1 and progesterone (P≤0.05 at 1 cm, P≤0.005 at 2 cm; 
figure 7-7). However, B1 was only found to show a significant increase in the number 
of cells penetrating to the 2 cm position (P≤0.05; figure 7-7) instead of at both positions 
as seen with donor samples (figure 7-3).  
 
When the behaviour of sperm swimming within viscous medium was investigated using 
CASA, neither B1 nor progesterone produced significant alterations in the speed of 
progression through the viscous medium (appendix). This observation is consistent with 
the effects of B1 seen in standard medium (figure 7-1 & 7-2).   
 
 
 
 
 
 
 
 
Figure 7-7. Agonist induced sperm penetration into viscous medium. Sperm penetration into viscous 
medium upon application of 10µM B1 or 3.6µM progesterone measured by counting cells at 1 cm and 2 
cm. The number of sperm penetrating to 1 cm and 2 cm was assessed and normalised to values in 
untreated controls (red dashed line). All values are the mean ± SE (n=9 experiments performed with 9 
different patient samples). *- indicates a significant difference (P≤0.05), ***- indicates a significant 
difference (P≤0.005) from the control, as assessed by non-parametric analysis Mann Whitney U test.  
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7.3 Discussion 
The aims of this study were: 1) to examine whether the ion channel compounds 
increased sperm motility when evaluated by CASA analysis, 2) analyse whether agonist 
treated sperm were capable of penetrating viscous medium more effectively than 
untreated controls, 3) to establish the effects of agonists on sperm vitality and the ability 
to undergo the acrosome reaction and 4) after identifying promising compounds, to 
examine the robustness of the results by applying agonists to patient samples.     
 
B1 activation promotes sperm penetration into viscous medium but does not 
influence motility kinematics specifically 
The results from this chapter did not identify any ion channel compounds that 
consistently increased motility parameters, of donor or patient sperm, over a 3hr time-
course when analysed by CASA. This prompted examination of these agonists using an 
alternative motility assay, the Kremer mucus penetration test. Interestingly, the results 
from this assay identified that B1 and progesterone significantly enhanced penetrating 
abilities of sperm through a cervical mucus surrogate (methylcellulose) although, it did 
not significantly change any motility kinematic parameters.  
 
A previous study has described that direct activation of CatSper channels by 
progesterone has insignificant effects on hyperactivation when assessed by CASA 
analysis, however, progesterone was found to strongly enhance sperm penetrating 
abilities into methylcellulose (Alasmari et al., 2013b). This effect is similar to this study 
with the ion channel compound B1 showing insignificant effects on motility and 
hyperactivation when evaluating cells under both non-capacitating and capacitating 
conditions. However, this same compound significantly enhances spermatozoa’s 
penetrating ability into viscous medium under both conditions. The Flexstation assay 
identified B1 as increasing [Ca
2+
]i in sperm cells similarly to progesterone. These 
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findings could indicate that B1 may be acting via the sperm specific, Ca
2+
 permeable, 
CatSper cation channel in a similar manner to progesterone, although, further motility 
analysis needs to be conducted making use of CatSper ion channel blockers to confirm 
this theory. Stimulation of human sperm with progesterone has been shown to activate 
CatSper situated in the flagellum (Strunker et al., 2011, Lishko et al., 2011). The 
associated increase in [Ca
2+
]i is amplified and propagated forward by CICR at the sperm 
neck (Costello et al., 2009, Olson et al., 2010, Lefievre et al., 2012). Previous studies on 
animals and human have reported active Ca
2+
 propagation from the tail to the midpiece 
and head in response to varying stimuli (Xia et al., 2007, Suarez et al., 1993). This Ca
2+
 
propagation has an active role in the regulation of sperm behaviour. The theory behind 
B1 possibly acting via CatSper instead of acting via activation of Ca
2+
 stores results 
from previous work identifying that agonists that actively induce Ca
2+
 increase only 
from Ca
2+
 stores leads to a visible increase in hyperactivation as measured by CASA, 
whereas, the use of CatSper blockers on the same compounds resulted in no visible 
alteration in hyperactivation when measured by CASA (Alasmari, 2013). This 
information leads us to surmise that if B1 solely activated release of Ca
2+
 from internal 
stores you would have seen an increase in hyperactivation using CASA, which is not the 
case in this study. This suggests to me that it is more likely that B1 may act on CatSper 
with motility findings reported in this chapter being similar to that of this previous study 
with regard to compounds such as progesterone. Progesterone was found to regulate 
CatSper without showing an increase in hyperactivation that was measurable by CASA, 
similarly to B1. However, treated cells did exhibit significant increases when it came to 
the ability of spermatozoa to penetrate through methylcellulose (Alasmari, 2013, 
Alasmari et al., 2013b) which is a similar trait to that observed when spermatozoa are 
treated with B1. To be able to confirm this theory the next step for B1 would be to 
attempt to make use of known CatSper blockers on treated cells and measure [Ca
2+
]i 
137 
 
alterations and motility through both CASA and the Kremer mucus penetration test see 
if you still see the increase in penetrating ability.   
 
It has been reported that for sperm to be effective at penetrating through mucus they 
require the amplitude of lateral head movements to be ≥2.5μM but ˂7.0μM (Bjorndahl 
et al., 2010) . Similarly Tesarik et al described that for human sperm to be capable of 
penetrating the cumulus matrix they required small amplitudes of lateral head 
displacement with a predominantly linear movement but an increased beat cross 
frequency (Tesařík et al., 1990). Alasmari et al describe the main functional effect of 
activating CatSper is an enhanced penetration into viscous medium (Alasmari et al., 
2013b) which is an effect exhibited by B1 treated sperm. This enhanced penetration into 
viscous medium without enhanced motility kinematics, when measured by CASA, may 
result from the limitations of the CASA system which only measures movement of the 
sperm head and would be unable to distinguish subtle alterations in flagella beat that 
would enhance entry into viscous medium (Alasmari et al., 2013b). A group had 
previously investigated the effects of a caged progesterone analog (a known CatSper 
activator) on flagella bending of human sperm and they identified that after the 
progesterone activated CatSper it induced changes in curvature at the distal flagellum 
(Servin-Vences et al., 2012), these changes would not have been recognised by CASA 
owing to its inability to measure anything but alterations in movement at the sperm 
head. This would explain why no visible changes were noticed in motility when 
measured by CASA alone.     
 
This compound has the potential to be beneficial in a clinical setting acting to increase 
penetrating ability of spermatozoa with no detrimental effects on motility. This could be 
beneficial in treatments such as IUI in aiding the sperm to swim through and penetrate 
the zona pellucida and oocyte vestments to bind to the oocyte.  
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CHAPTER 8 
Investigating the incidence of sub-fertile 
patients, from andrology clinics, who 
could benefit clinically from sperm 
stimulants  
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8.1 Introduction 
Standard semen analysis is a subjective technique and has been found to be associated 
with large inter-laboratory variation making it difficult to predict accurate values 
(Larsen et al., 2000, Hargreave and Elton, 1983). Previously there had been controversy 
over the use of WHO reference values for diagnosis of infertility owing to the 
population they were created from being a ‘normal population’ of healthy men, rather 
than from men with proven fertility, raising concerns about the possibility of men 
conceiving who have semen analysis values below the WHO cut-off values (Lewis, 
2007, Jedrzejczak et al., 2008, Ombelet et al., 1997). The current WHO 2010 reference 
values have now corrected for this and the reference values generated are from healthy 
donors with known fertility (time to pregnancy ≤12 months) (Cooper et al., 2010).  The 
lower reference limits (LRL) outlined by WHO 2010, especially where motility is 
concerned (total motility; LRL 40% and progressive motility; LRL 32%), are similar to 
those proposed by John MacLeod and Ruth Gold in 1951 (Macleod and Gold, 1951b) 
suggesting that these new values are more robust than previous editions (Publicover and 
Barratt, 2011).  
 
Sperm motility is one of the fundamental requirements for sperm to be capable of 
successful fertilisation in vivo and in vitro (Donnelly et al., 1998). MacLeod and Gold 
(Macleod and Gold, 1951b) identified that there are clear differences in sperm motility 
between sub- fertile and fertile men which has since been corroborated by numerous 
groups (Barratt et al., 2011). For this reason it is one of the key characteristics that is 
measured through semen analysis to provide diagnostic and prognostic information for 
natural conception and ART (Publicover and Barratt, 2011). Along with motility, sperm 
morphology and concentration are also important factors affecting fertility that are 
measured during a routine semen analysis (Guzick et al., 2001). Proposed treatment 
plans for male factor infertility are dependent on the results from two independent 
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semen analyses (two samples produced on separate occasions with a minimum of 2 days 
and maximum of 7 days abstinence) with IUI being the initial treatment option used in 
an attempt to alleviate mild male factor infertility (Tournaye, 2012). To be eligible for 
IUI treatment the female partner has to have a normal fertility status and the 
unprocessed semen sample must contain a total motile count (TMC) of at least 1x10
6
-
3x10
6
 which corresponds to mild oligoasthenozoospermia and a minimum of 0.8x10
6
 
progressively motile cells must be recovered after sperm preparation (Tournaye and 
Cohlen, 2012, Tournaye, 2012, van Weert et al., 2004). Conception rates through IUI 
are very poor which reduces its use as the first-line treatment (van Weert et al., 2004, 
Campana et al., 1996) however, compared with IVF there is good evidence to suggest 
that IUI is a cost-effective treatment that should be initiated before more invasive and 
expensive treatments are considered (Goverde et al., 2000, Karande et al., 1999).  
 
 The range and distribution of semen profiles of men attending different infertility 
clinics is considerable. It is difficult, and maybe impossible, to identify a standard 
patient profile from semen analysis data owing to patients representing different clinical 
populations i.e. patients are a mixture of primary and tertiary referrals, NHS or private.  
Although this is the case, using semen analysis data from the two centres as a guide, it is 
possible to predict the percentage of patients who may benefit from in vitro drug 
stimulation to increase the concentration of motile cells.  Publicover and Barratt (2011) 
constructed a graph using data adapted from Hargreave and Elton (1983) to predict 
conception according to the concentration of motile cells (figure 8-1) (Publicover and 
Barratt, 2011, Hargreave and Elton, 1983).  This graph identifies reduced conception 
rates below 2 million motile cells/ml before a plateau occurs where the numbers of 
motile cells do not have an effect on conception. The area that is important for targeting 
for novel drug stimulation, according to this graph, would be patients who have less 
than 2 million motile cells/ml.     
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Using the data from Publicover and Barratt (2011) and the knowledge that an 
unprocessed semen sample must contain a TMC between 1x10
6
- 3x10
6
 to qualify for 
IUI (Tournaye and Cohlen, 2012), as a first-line treatment, this study aims to identify 
the benefits of a specific treatment i.e. novel drug therapies that can be used to increase 
sperm motility.  The clinical use of sperm stimulants may be enough to increase the 
TMC of some patients, who previously were not illegible for IUI owing to a low TMC, 
to allow them to use less invasive treatments as a first treatment option.   
 
 
 
 
 
 
 
  
Figure 8-1 Figure courtesy of Publicover and Barratt denoting likelihood of conception 
with regard to the concentration of motile cells. Data adapted from Hargreave and Elton 
(1983) depicting a plateau in conception rates with higher concentrations of motile cells. 
Reduced conception rates are noted below 2 million motile cells/ml (blue bar) this is the target 
area where improving motility by use of motility enhancing drugs would have most effect on 
improving fertility (Publicover and Barratt, 2011).   
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8.2 Experimental design 
The analysis evaluated the semen characteristics of 3239 patients from clinic A and 552 
patients from clinic B. Patients where all the data was missing were excluded from the 
study (31 patients’ clinic A, 0 patients’ clinic B). Patients were divided into categories 
according to the WHO 2010 reference parameters for semen analysis with patients 
being classed as oligozoospermic (concentration of ˂15 million/ml), asthenozoospermic 
(total motility ˂40% and/or progressive motility ˂32%), teratozoospermic (normal 
forms ˂4%) or a combination of two or three of these factors, cryptozoospermic (˂1 
million/ml), normozoospermic (concentration ˃15 million/ml, total motility ˃40%, 
progressive motility ˃32% and ˃4% normal forms) and finally azoospermic. 
For statistical analysis all parameters were analysed, utilizing frequency distributions 
and P-P plots (probability plots for assessing how closely two data sets agree), for 
normality. Semen analysis data from both of the clinics was not found to be normally 
distributed and after transformation the data remained non-normal. For the purposes of 
correlation/regression data is not required to be normally distributed, however, 
assumptions are made about “error” which is the difference between the observed and 
predicted values (also called residuals). Scatter plots and correlation analysis was 
conducted on three pairs of variables; 1) % motile with % normal forms, 2) % motile 
with concentration and 3) % normal forms with concentration. Linear regression 
analysis was then conducted on these same variables and the “error” was analysed for 
normality by use of histograms.   
        
Cumulative frequency distributions depicting the concentration of motile cells were 
generated for the two datasets. Azoospermic patients were excluded from the dataset. 
To focus the dataset only patients with a concentration of 6 million motile cells per ml 
(calculated from WHO 2010 lower reference limits: concentration ˂15 million/ml, total 
motility ˂40%) were included in the analysis (clinic A n= 687, clinic B n=175).      
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8.3 Results 
According to the WHO 2010 reference parameters for semen analysis, for clinic A,  
56% of the patients were identified to be normozoospermic with 6% exhibiting solely 
motility dysfunction (asthenozoospermia) and a further 10% showing poor motility 
combined with either poor sperm morphology, low concentration or a combination of 
all three factors (teratozoosprmia, oligozoospermia or oligoasthenoteratozoospermia) 
(figure 8-2).  This differed to the data collected from clinic B with only 24% of patients 
being considered normal and 4% exhibiting isolated asthenozoospermia with a further 
25% exhibiting poor motility in combination with other factors (figure 8-3). With the 
exception of the patients characterised has being normal the highest percentage of 
patients in both clinics were identified as being teratozoospermic 10% and 22%, clinic 
A and B respectively (figure 8-2 and 8-3).  When the three single parameters 
(oligozoospermia, teratozoospermia and asthenozoospermia) were compared with one 
another the correlation between the parameters was found to be highly significant 
(P≤0.000) for both clinic A and B although, after visually comparing the parameters in a 
scatter plot you would not expect this to be a highly significant result (figure 8-4 A-C 
and 8-5 A-C). Correlation can be statistically significant simply because of the large 
number of cases, not because there is a meaningful bivariate relationship which appears 
to be the case for these datasets. Baring this in mind, when looking at the correlations, 
the linear regression model identifies the percentage of variance explained by the 
model, which for clinic A is 11%, suggesting that both morphology and sperm 
concentration influence progressive motility and vice versa. Similarly for the dataset for 
clinic B linear regression analysis identified that both independent variables (sperm 
concentration and morphology) contribute to the model of motility 16% of the time. 
These percentages suggest there is a correlation between the three factors although it is 
minimal.    
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Figure 8-2 Classification of patients according to WHO reference parameters (WHO, 2010e) for 
semen analysis for patients attending clinic A (2002-2003) . 
 
 
 
 
 
 
 
 
 
 
 
Figure 8-3. Classification of patients according to WHO reference parameters (WHO, 2010e) for 
semen analysis for patients attending clinic B (2011) 
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Figure 8-4 Scatter plots identifying correlations for Clinic A. 2-D plots looking at correlations 
between motility and morphology (A), motility and concentration (B) and morphology and concentration 
(C). N= 3239   
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Figure 8-5 Scatter plots identifying correlations for Clinic B. 2-D plots looking at correlations 
between motility and morphology (A), motility and concentration (B) and morphology and concentration 
(C). N= 552   
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In an attempt to corroborate this, data from both clinics was further separated into two 
groups with a lower limit and upper limit: 1) semen with a concentration of less than, 
and including, 15 million/ml (WHO 2010 criteria) and 2) semen with a concentration of 
less than, and including, 100 million/ml. The same analysis as before was then 
conducted on the same pairs of variables within these two groups. When these same 
parameters (oligozoospermia, teratozoospermia and asthenozoospermia) were compared 
within their segregated groups the lower limit (less than 15 million/ml) once again 
identified a highly significant correlation (P≤0.000) for both clinic A and clinic B 
although, after visually comparing the parameters the scatter plots do not show a 
meaningful linear relationship (appendix). Linear regression analysis identifies that the 
total variance explained by the model is 12.2% with regards to clinic A and only 6% 
with regard to clinic B once again confirming a small correlation between the three 
parameters.    
 
For the high concentration group, once again the correlations for both clinics are highly 
significant (clinic A; p≤0.000 - all parameters, clinic B; p≤0.01 - sperm concentration 
and motility, p≤0.000 motility and morphology and concentration and morphology). 
Linear regression analysis identified 6.5% variance is due to the model for clinic A and 
11.4% for clinic B. This data highlights the variability between patients with the total 
percentage of variance explained by the model being greatest in the low concentration 
group for clinic A (12.2% vs 6% clinic B) whereas, the greatest variance explained by 
the model is greater in the high concentration group for clinic B (11.4% vs 6.5% clinic 
A). This data suggests that although a correlation does appear to exist between the three 
parameters it is only minimal identifying that each factor can be assessed independently 
and is not reliant on the other two parameters. This data suggests therapeutic 
advancements in motility are not restrained by the concentration and quantity of 
morphologically normal sperm.    
148 
 
As mentioned previously Publicover and Barratt (2011) identified that to increase the 
likelihood of a successful conception the ideal concentration of motile cells is ≥2 
million/ml (Publicover and Barratt, 2011). Below this value small changes in the 
concentration of motile cells can have a noticeable effect on the chance of conception 
making it an ideal target area for motility enhancers. Using the data collected from the 
two centres it was possible to identify patients who, according to the graph from 
Publicover and Barratt (2011) (figure 8-1), would be suitable for and may benefit from 
in vitro drug treatment to increase motility. Data from clinic A highlighted 13% of 
patients (n=3015, azoospermic patients excluded) having a concentration of motile cells 
≤2 million per ml with clinic B exhibiting 22% of patients (n=494, azoospermic patients 
excluded), under the same category, with the potential of benefiting from motility 
stimulants. 
 
Data collected previously in this study (chapter 6) identified a potential therapeutic drug 
treatment (Trequinsin Hydrochloride) that can increase motility in vitro. This compound 
was capable of increasing total motility and specifically progressive motility by 
approximately 20%. Given this knowledge it is possible to predict that in patients with 
poor/low motility you would also see a 20% increase in motility of cells treated with 
this compound. Using guidelines from Ninewells Assisted Conception Unit it is 
possible to calculate the percentage of patients from both clinics who, after treatment 
with motility enhancing drugs, could be eligible for less invasive treatment options than 
currently used. Patients with concentrations of motile cells ≤1 million/ml would 
normally be treated with ICSI. The data for clinic A identified 1% (n=3015) whereas 
clinic B identified 3% (n=494) of patients after treatment with motility enhancing drugs, 
that could be eligible for IVF before the more invasive treatment of ICSI. To be eligible 
for IUI patients need to have a concentration of motile cells ≥5 million/ml, using this 
value as a guideline; it was possible to calculate that 3% of patients from clinic A 
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(n=3015) and 19% of patients from clinic B (n=494), after treatment, would be eligible 
for IUI instead of IVF.   
 
Looking at sub-fertile patients (below WHO normal semen parameters) it was possible 
to generate a cumulative frequency curve identifying the percentage of patients from 
both clinic A and clinic B independently that have the potential of benefiting from 
treatment with motility stimulants (figure 8-6A). Looking at the curves from both 
clinics it is clear to see that they both follow a similar pattern indicating that the sub-
fertile patients have similar profiles regardless of the spatio-temporal differences in data 
collection (figure 8-6A). Because the patient profiles follow a similar trend the data 
from the two clinics was combined to produce a single curve (figure 8-6B). In this 
analysis we are looking specifically at the potential of improving motility of patients 
who have a concentration of ≤2 million/ml motile cells and using the single curve it is 
possible to identify that approximately 60% of the sub-fertile patients from the two 
clinics combined fit this profile (figure 8-6B indicated by red line).  
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Figure 8-6 Cumulative frequency graph depicting the percentage of sub-fertile patients 
from clinic A and B independently (azoospermic patients included) (A) and combined 
(azoospermic patients excluded) (B). These graphs highlight the percentage of patients with 
below WHO normal values for concentration of motile cells. Using the graphs it is possible to 
determine the percentage of patients who could benefit from motility enhancing stimulants (red 
line).      
A 
B 
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8.4 Discussion 
Motility dysfunction is major problem with regard to male infertility (Hull et al., 1985) 
with previous studies identifying isolated asthenozoospermia as the most frequent 
semen abnormality (Milardi et al., 2012). Similarly to Curi et al (2003) these dataset 
identified a higher percentage of patients with motility dysfunction in combination with 
factors such as poor morphology and/or low concentration than patients presenting with 
solely poor motility highlighting that novel treatments to improve motility could have a 
beneficial effect not only for couples with isolated motility problems but also with 
combined factors (Curi et al. 2003). This is further supported by this dataset and the 
findings of Macleod and Gold (1951) that sperm concentration contributes to sperm 
motility and this study further identifies sperm morphology as a  contributing factor 
(Macleod and Gold, 1951b).  The main aim of this study was to identify the sub-set of 
patients who would benefit clinically from treatments that specifically enhance motility. 
Combining the data from the two clinics 15% (n=3509) of patients could benefit from 
motility stimulants, according to the graph by Publicover and Barratt (2011) (Publicover 
and Barratt, 2011). By looking specifically at the sub-fertile patients (Below WHO 
normal concentrations of motile cells) it is possible to identify that almost 55% of these 
patients would be eligible for treatment with motility stimulants (excluding the 
azoospermic patients). This highlights the potential clinical benefits of successful 
treatment with motility enhancing stimulants.  
 
The ability to increase success rates after IUI and make IUI more accessible to more 
patients through the use of motility stimulants would decrease the financial (Van 
Voorhis et al., 2001) and emotional burden on patients and healthcare providers. The 
proposed motility stimulants could  significantly increase the number of progressively 
motile cells produced meaning that men who previously had below the threshold 
number of motile cells for IUI (between 1x10
6
-3x10
6
 unprocessed sample)  could now 
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be eligible for treatment (Tournaye and Cohlen, 2012, Tournaye, 2012, Van Voorhis et 
al., 2001).  However, this data is based on semen analysis meaning it is not possible to 
guarantee that these samples would produce a minimum of 0.8x10
6
 total motile cells 
post preparation as required for IUI (Tournaye, 2012). Combining data from both Clinic 
A (1.8%) and Clinic B (1.2%) it has been possible to predict that 1.3% of patients, after 
treatment with motility enhancing drugs, could be eligible for IVF before the more 
invasive treatment of ICSI. Similarly it is possible to predict that a combined total of 
5% (n=3509) of patients could now be considered for IUI as a first line treatment 
instead of IVF (Clinic A 2.6% n=3015, Clinic B 19.2% n=494). From this study it is 
only possible to predict the percentage of patients who previously were not eligible for 
IUI but after treatment with motility stimulants could become eligible. It is not possible 
to predict the potential beneficial effects motility stimulants could have on conception 
rates after treatment through IUI. However, there is good evidence that IUI is a cost 
effective treatment option that is less invasive than IVF and ICSI (Tournaye, 2012, Van 
Voorhis et al., 2001, Comhaire et al., 1995). With the discovery of novel compounds 
that enhance motility the success rates for fertilisation through IUI should increase 
making it a more viable option for more couples as an initial therapy for couples with 
male factor infertility. 
There are a number of assumptions made from this data to be able to come to the 
conclusions drawn in this study. It is important to remember that even through 
improvement of motility you may not improve conception rates. There are a number of 
factors that contribute to a successful fertilisation that are not accounted for in this study 
including DNA abnormalities, inability to capacitate at the correct time, premature 
acrosome reaction and problems with phospholipase C Zeta activation to name but a 
few (Amdani et al., 2013, Donnelly, 2000).      
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CHAPTER 9 
Conclusion and Future work 
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The primary aims of this thesis were to: (1) identify a sub-group of spermatozoa from 
donor samples that can be used, in research, as a representative sample for patient 
samples, (2) develop, and (3) implement a protocol for screening compounds, identified 
from a Flexstation screen, that have the possibility of enhancing motility through 
increasing [Ca
2+
]i in sperm and finally, (4) establish the incidence of asthenozoospermia 
in patients who have previously undergone fertility treatment to identify patients who 
would benefit from therapeutic advancements in this area.  
 
Key findings and future work 
By establishing the optimum conditions in vitro (chapter 4) it was possible to develop a 
robust system for screening of motility enhancing compounds. Six compounds 
identified from the Chemogenomics library and fourteen compounds from the UoD 
DDU ion channel library were then tested using the standard operating procedure 
developed in chapter 4. The majority of these compounds were found to have no 
beneficial effects on sperm motility posing questions as to why these compounds 
increase [Ca
2+
]i  in sperm. To be able to further examine the effects of these compounds 
studies need to be conducted examining vitality and presence of the acrosome. With 
respect to chapter 5, the data highlights the importance of one compound identified 
from the Chemogenomics library; Trequinsin Hydrochloride. This data identified that 
Trequinsin increases [Ca
2+
]i resulting in a significant increase in motility when 
measured by CASA and Kremer mucus penetration assays under non-capacitating 
conditions. This study, through the use of patch clamping, identifies CatSper activation 
by this PDEi suggesting that CatSper is an unidentified target of PDEi’s in human 
sperm cells.   
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Trequinsin hydrochloride, after patch clamping, identified changes in human sperm 
potassium currents (hKSper). hKSper have been shown to originate in the sperm 
flagellum and have been found to support CatSper activity (Mannowetz et al., 2013). 
The human sperm principle potassium channel has been identified as Slo1 and is 
dependent on intracellular Ca
2+
 concentrations (Mannowetz et al., 2013). Lishko et al 
and Strunker et al independently discovered that CatSper is activated by progesterone 
by shifting Catsper activation to more hyperpolarised membrane potentials, increasing 
intracellular Ca
2+ 
 resulting in hyperactivated motility (Lishko et al., 2011, Strunker et 
al., 2011, Lishko et al., 2012a). Activation of CatSper is vital for fertilisation and since 
potassium channels are well known to regulate membrane potentials Lishko et al 
proposed their role in capacitation and specifically supporting CatSper induced 
hyperactivation (Navarro et al., 2007, Mannowetz et al., 2013). Slo1 has been found to 
be inhibited in a dose dependent manner by micromolar concentrations of progesterone 
which in an in vivo environment suggests that once the spermatozoa get in close 
proximity to the oocyte the hKSper channel will become blocked by increasing 
concentrations of progesterone, leading to membrane depolarization. This shift in 
membrane potential activates CatSper channels allowing for an influx of Ca
2+
 which in 
turn
 
elevates [Ca
2+
]i. This triggers Ca
2+
 dependent processes such as hyperactivated 
motility enabling spermatozoa to become capable of fertilisation (Mannowetz et al., 
2013). This study proposes Trequinsin Hydrochloride functions in a similar manner to 
progesterone acting to inhibit Slo1 triggering membrane depolarisation thereby 
supporting full activation of CatSper. These events trigger hyperactivation allowing for 
penetration of the oocyte vestements and successful fertilisation. 
 
The improvement in sperm motility attributed to treatment with B1 (chapter 7) were less 
pronounced than those seen in response to Trequinsin (chapter 6) with significant 
increases only visible when analysed by the Kremer mucus penetration assay. This 
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suggests that although it is possible B1 is activating CatSper it may not be an effective 
activator of sperm motility. B1 may only function via the CatSper channel which would 
allow for changes in flagella pattern to strongly enhance sperm penetration through 
viscous media but may not be capable of triggering Ca
2+
 release from internal stores 
preventing inducement of hyperactivation (Alasmari et al., 2013b). Thus it could be 
speculated that addition of this compound to spermatozoa from a therapeutic view point 
would not be wholly beneficial. If this compound were to be used in IUI procedures it 
appears it would be successful in aiding sperm penetration through cervical mucus but 
would not affect the sperms ability to, on reaching the oocyte, successfully penetrate the 
oocyte vestements to complete fertilisation.  
 
One key issue that has been highlighted in this study is that use of 1% DMSO induces a 
premature acrosome reaction in cells treated with this compound for a long period of 
time (chapter 7). This is a similar problem to that found with use of pentoxifylline 
treatment previously (Tardif et al., 2014). One solution to this problem could be to 
examine the effects on motility of sperm preparations with a limited incubation with the 
motility enhancing compound which is then washed off. The motility of these sperm 
can then be examined after the wash to see if the motility enhancement is sustained 
reducing the risk of a premature acrosome reaction.  
   
Whilst the work in this study has highlighted two potential compounds that successfully 
increase sperm motility; 1) Trequinsin hydrochloride (commercially available) and 2) 
B1 (previously unknown compound) these compounds have only been examined a 
limited number of times on both donor and patient samples. To categorically confirm 
their potential for increasing motility further studies are required. Furthermore, this 
work would need to be expanded on in order to confirm the proposed models in this 
study. Through the use of activators, inhibitors and/ or patch clamp studies experiments 
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need to be conducted to confirm that Trequinsin and B1 activate CatSper specifically 
and to investigate their effects on the human sperm potassium channel Slo1. These 
compounds also warrant closer examination to evaluate any unwanted effects such as; 
premature acrosome reaction or adverse effects caused by long incubations with the 
compounds. These compounds were identified as increasing [Ca
2+
]i through a 
Flexstation Assay Screen to ensure this response is genuinely repeatable it would be 
beneficial to conduct fluorimetric population measurements on treated samples in 
parallel with motility analysis. To further clarify whether these compounds are 
activating CatSper alone or have any currently unidentified effects on Ca
2+
 stores the 
use of single cell imaging of samples would enable identification of Ca
2+
 store 
mobilisation as a result of treatment with these compounds. It would also be beneficial 
to conduct single cell Ca
2+
 imaging on sperm treated by each of the compounds to allow 
for exact identification of the increase in [Ca
2+
]i seen as a result of drug stimulation.     
This study has helped to develop a standard operating procedure for efficiently and 
reliably analysing the motility effects of sperm treated with compounds identified from 
the Flexstation screen. The results identified that in the future it would be beneficial to 
only analyse the effects of potential compounds on capacitated sperm. However, it is 
beneficial to analyse the effects on both the 40% fraction and 80% fraction from donor 
sperm. To ensure that the positive or negative effects on sperm are a true result of 
treatment with the compounds, in the future, the effect of leukocytes especially in the 
40% fraction needs to be accounted for.         
 
Male factor infertility is the cause of sub-fertility in 50% of cases with sperm 
dysfunction being the single most common factor responsible for male infertility (Hull 
et al., 1985, Thonneau et al., 1991). ART is currently the main way of treating male 
factor infertility but it is expensive and invasive (Comhaire et al., 1995, Van Voorhis et 
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al., 2001). The ability to treat more patients with IUI as a first line treatment for male 
factor infertility, through the use of motility stimulants, would make fertility treatment 
more accessible to couples worldwide who are not eligible for state funded treatments. 
This study identifies for the first time that through the use of motility enhancers it may 
be possible to treat a further 5% (chapter 8) of patients attending two independent 
fertility clinics with IUI before the more invasive procedure of IVF. It is also 
conceivable that these stimulants could not only increase the access to IUI (through 
making more patients eligible for treatment) but could potentially improve pregnancy 
rates within this treatment. This would make IUI a cost-effective, sustainable treatment 
option. This study has highlighted the percentage of sub-fertile patients from two 
independent fertility clinics. Through the use of a cumulus frequency curve it is possible 
to identify the percentage of patients, according to their concentration of motile cells, 
which could benefit from potential novel treatments. The similarity in the trend 
exhibited by the sub-fertile patients from the two independent clinics (chapter 8) 
suggests that this graph could be used in the future as a guideline for identifying target 
groups of patients for future studies.                                   
    
 
     
 
 
 
 
  
159 
 
References  
ABU-HEIJA, A. T., FLEMING, R., JAMIESON, M. E., YATES, R. W. S. & COUTTS, J. R. T. 1996. The 
Effect of Sperm-Mucus Interaction Test on the Outcome of in vitro Fertilization and 
Ovulation Induction Combined with Intrauterin Insemination. Journal of Obstetrics and 
Gynaecology Research, 22, 229-233. 
ADAMS, R. H., PORRAS, A., ALONSO, G., JONES, M., VINTERSTEN, K., PANELLI, S., VALLADARES, 
A., PEREZ, L., KLEIN, R. & NEBREDA, A. R. 2000. Essential Role of p38± MAP Kinase in 
Placental but Not Embryonic Cardiovascular Development. Molecular cell, 6, 109-116. 
AGARWAL, A. & SAID, T. 2011. Interpretation of Basic Semen Analysis and Advanced Semen 
Testing. In: SABANEGH, E. S. (ed.) Male Infertility. Humana Press. 
AGIRREGOITIA, E., CARRACEDO, A., SUBIRÁN, N., VALDIVIA, A., AGIRREGOITIA, N., PERALTA, L., 
VELASCO, G. & IRAZUSTA, J. 2010a. The CB2 cannabinoid receptor regulates human 
sperm cell motility. Fertility and sterility, 93, 1378-1387. 
AGIRREGOITIA, E., CARRACEDO, A., SUBIRÁN, N., VALDIVIA, A., AGIRREGOITIA, N., PERALTA, L., 
VELASCO, G. & IRAZUSTA, J. 2010b. The CB(2) cannabinoid receptor regulates human 
sperm cell motility. Fertility and sterility, 93, 1378-87. 
AITKEN, R. J. 2006. Sperm function tests and fertility. International Journal of Andrology, 29, 
69-75. 
AITKEN, R. J., BOWIE, H., BUCKINGHAM, D., HARKISS, D., RICHARDSON, D. W. & WEST, K. M. 
1992. Sperm Penetration into a Hyaluronic Acid Polymer as a Means of Monitoring 
Functional Competence. Journal of Andrology, 13, 44-54. 
AITKEN, R. J., BUCKINGHAM, D. W. & FANG, H. G. 1993. Analysis of the Responses of Human 
Spermatozoa to A23187 Employing a Novel Technique for Assessing the Acrosome 
Reaction. Journal of Andrology, 14, 132-141. 
ALASMARI, W. 2013. Regulation of calcium signalling for flagellar activity in human sperm and 
its significance in male fertility. phD, University of Dundee. 
ALASMARI, W., BARRATT, C. L. R., PUBLICOVER, S. J., WHALLEY, K. M., FOSTER, E., KAY, V., 
MARTINS DA SILVA, S. & OXENHAM, S. K. 2013a. The clinical significance of calcium-
signalling pathways mediating human sperm hyperactivation. Human reproduction 
(Oxford, England), 28, 866-876. 
ALASMARI, W., COSTELLO, S., CORREIA, J., OXENHAM, S. K., MORRIS, J., FERNANDES, L., 
RAMALHO-SANTOS, J., KIRKMAN-BROWN, J., MICHELANGELI, F., PUBLICOVER, S. & 
BARRATT, C. L. R. 2013b. Ca2+ Signals Generated by CatSper and Ca2+ Stores Regulate 
Different Behaviors in Human Sperm. Journal of Biological Chemistry, 288, 6248-6258. 
ALMOG, T., LAZAR, S., REISS, N., ETKOVITZ, N., MILCH, E., RAHAMIM, N., DOBKIN-BEKMAN, M., 
ROTEM, R., KALINA, M., RAMON, J., RAZIEL, A., BRIETBART, H., SEGER, R. & NAOR, Z. 
2008. Identification of Extracellular Signal-regulated Kinase 1/2 and p38 MAPK as 
Regulators of Human Sperm Motility and Acrosome Reaction and as Predictors of Poor 
Spermatozoan Quality. Journal of Biological Chemistry, 283, 14479-14489. 
ALMOG, T. & NAOR, Z. 2008. Mitogen activated protein kinases (MAPKs) as regulators of 
spermatogenesis and spermatozoa functions. Molecular and Cellular Endocrinology, 
282, 39-44. 
ALMOG, T. & NAOR, Z. 2010. The role of Mitogen activated protein kinase (MAPK) in sperm 
functions. Molecular and Cellular Endocrinology, 314, 239-243. 
ALSENZ, J. & KANSY, M. 2007. High throughput solubility measurement in drug discovery and 
development. Advanced drug delivery reviews, 59, 546-67. 
ALVAREZ, C. 2003. Biological variation of seminal parameters in healthy subjects. Human 
Reproduction, 18, 2082-2088. 
AMOAKO, A. A., GEBEH, A. K., MARCZYLO, E. L., WILLETS, J. M., ELSON, J., MARCZYLO, T. H. & 
KONJE, J. C. 2013a. Impact of reference gene selection for type 2 cannabinoid receptor 
gene expression studies in human spermatozoa. Andrologia, 45, 278-284. 
AMOAKO, A. A., MARCZYLO, T. H., LAM, P. M. W., WILLETS, J. M., DERRY, A., ELSON, J. & 
KONJE, J. C. 2010. Quantitative analysis of anandamide and related acylethanolamides 
160 
 
in human seminal plasma by ultra performance liquid chromatography tandem mass 
spectrometry. Journal of Chromatography B, 878, 3231-3237. 
AMOAKO, A. A., MARCZYLO, T. H., MARCZYLO, E. L., ELSON, J., WILLETS, J. M., TAYLOR, A. H. & 
KONJE, J. C. 2013b. Anandamide modulates human sperm motility: implications for 
men with asthenozoospermia and oligoasthenoteratozoospermia. Human 
Reproduction, 28, 2058-2066. 
ANDERSON, J. E., FARR, S. L., JAMIESON, D. J., WARNER, L. & MACALUSO, M. 2009. Infertility 
services reported by men in the United States: national survey data. Fertility and 
Sterility, 91, 2466-2470. 
APPELL, R. A. & EVANS, P. R. 1977. The effect of temperature on sperm motility and viability. 
Fertility and sterility, 28, 1329-32. 
ASHIZAWA, K., HASHIMOTO, K., HIGASHIO, M. & TSUZUKI, Y. 1997. The Addition of Mitogen-
Activated Protein Kinase and p34cdc2Kinase Substrate Peptides Inhibits the Flagellar 
Motility of Demembranated Fowl Spermatozoa. Biochemical and Biophysical Research 
Communications, 240, 116-121. 
ASHTON, J. C. & GLASS, M. 2007. The Cannabinoid CB2 Receptor as a Target for Inflammation-
Dependent Neurodegeneration. Curr Neuropharmacol, 5, 73-80. 
AUSTIN, C. R. 1951. Observations on the penetration of the sperm in the mammalian egg. 
Australian journal of scientific research. Ser. B: Biological sciences, 4, 581-96. 
AVIDAN, N., TAMARY, H., DGANY, O., CATTAN, D., PARIENTE, A., THULLIEZ, M., BOROT, N., 
MOATI, L., BARTHELME, A., SHALMON, L., KRASNOV, T., ASHER, E. B., OLENDER, T., 
KHEN, M., YANIV, I., ZAIZOV, R., SHALEV, H., DELAUNAY, J., FELLOUS, M., LANCET, D. & 
BECKMANN, J. S. 2003. CATSPER2, a human autosomal nonsyndromic male infertility 
gene. European Journal of Human Genetics, 11, 497-502. 
BAJPAI, M. & DONCEL, G. F. 2003. Involvement of tyrosine kinase and cAMP-dependent kinase 
cross-talk in the regulation of human sperm motility. Reproduction, 126, 183-195. 
BALDI, E., CASANO, R., FALSETTI, C., KRAUSZ, C., MAGGI, M. & FORTI, G. 1991. INTRACELLULAR 
CALCIUM ACCUMULATION AND RESPONSIVENESS TO PROGESTERONE IN 
CAPACITATING HUMAN SPERMATOZOA. Journal of Andrology, 12, 323-330. 
BALDI, E., LUCONI, M., BONACCORSI, L. & FORTI, G. 1998. Nongenomic effects of progesterone 
on spermatozoa: Mechanisms of signal transduction and clinical implications. Frontiers 
in Bioscience, 3. 
BARRATT, C. L. R. 2011. The mystery is solved-CatSper is the principal calcium channel 
activated by progesterone in human spermatozoa. Asian Journal of Andrology, 13, 
351-352. 
BARRATT, C. L. R., MANSELL, S., BEATON, C., TARDIF, S. & OXENHAM, S. K. 2011. Diagnostic 
tools in male infertility-the question of sperm dysfunction. Asian Journal of Andrology, 
13, 53-58. 
BARRATT, C. L. R., OSBORN, J. C., HARRISON, P. E., MONKS, N., DUNPHY, B. C., LENTON, E. A. & 
COOKE, I. D. 1989. THE HYPO-OSMOTIC SWELLING TEST AND THE SPERM MUCUS 
PENETRATION TEST IN DETERMINING FERTILIZATION OF THE HUMAN OOCYTE. Human 
Reproduction, 4, 430-434. 
BARRATT, C. L. R. & PUBLICOVER, S. J. 2012. Sperm are promiscuous and CatSper is to blame. 
Embo Journal, 31. 
BATTISTONE, M. A., DA ROS, V. G., SALICIONI, A. M., NAVARRETE, F. A., KRAPF, D., VISCONTI, P. 
E. & CUASNICÚ, P. S. 2013. Functional human sperm capacitation requires both 
bicarbonate-dependent PKA activation and down-regulation of Ser/Thr phosphatases 
by Src family kinases. Molecular human reproduction, gat033--gat033-. 
BAVISTER, B. D. 2002. Early history of in vitro fertilization. Reproduction, 124, 181-196. 
BEAVO, J. A. 1995. CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES - FUNCTIONAL IMPLICATIONS 
OF MULTIPLE ISOFORMS. Physiological Reviews, 75, 725-748. 
BERGER, T., MARRS, R. P. & MOYER, D. L. 1985. COMPARISON OF TECHNIQUES FOR SELECTION 
OF MOTILE SPERMATOZOA. Fertility and Sterility, 43, 268-273. 
161 
 
BERWICK, D. C. & HARVEY, K. 2011. LRRK2 signaling pathways: the key to unlocking 
neurodegeneration? Trends in Cell Biology, 21, 257-265. 
BIOSCIENCES, T. 2013a. EO 1428 Supplier | CAS 321351-00-2 | Tocris Bioscience | EO1428 
[Online]. Available: http://www.tocris.com/dispprod.php?ItemId=5402 [Accessed 12th 
August 2013]. 
BIOSCIENCES, T. 2013b. GP 1a Supplier | Tocris Bioscience | GP1a [Online]. Available: 
http://www.tocris.com/dispprod.php?ItemId=5469 [Accessed 12th August 2013]. 
BIOSCIENCES, T. 2013c. JX 401 Supplier | CAS 349087-34-9 | Tocris Bioscience | JX401 [Online]. 
Available: http://www.tocris.com/dispprod.php?ItemId=5188 [Accessed 12th August 
2013]. 
BIOSCIENCES, T. 2013d. Leelamine Supplier | CAS 1446-61-3 | Tocris Bioscience | 
Dehydroabietylamine | Lylamine hydrochloride [Online]. Available: 
http://www.tocris.com/dispprod.php?ItemId=109462 [Accessed 5th March 2013]. 
BIOSCIENCES, T. 2013e. PHA 665752 Supplier | CAS 477575-56-7 | Tocris Bioscience | 
PHA665752 [Online]. Available: http://www.tocris.com/dispprod.php?ItemId=88278 
[Accessed 13th August 2013]. 
BIOSCIENCES, T. 2013f. Trequinsin Supplier | CAS 78416-81-6 | Tocris Bioscience | HL-725 
[Online]. Available: http://www.tocris.com/dispprod.php?ItemId=142512 [Accessed 
13th August 2013]. 
BJORNDAHL, L., MORTIMER, D., BARRATT, C. L. R., CASTILLA, J. A., MENKVELD, R., KVIST, U., 
ALVAREZ, J. G. & HAUGEN, T. B. 2010. A Practical Guide to Basic Laboratory Andrology, 
United Kingdom, Cambridge University Press. 
BOATMAN, E. & ROBBINS, R. S. 1991a. Bicarbonate : Carbon-dioxide regulation of sperm 
capacitation, hyperactivated motility, and acrosome reactions. Biology of reproduction, 
44, 806-813. 
BOATMAN, E. & ROBBINS, R. S. 1991b. Bicarbonate : Regulation and of Sperm Hyperactivated 
Acrosome. Biology of reproduction, 44, 806-813. 
BOIVIN, J., BUNTING, L., COLLINS, J. A. & NYGREN, K. G. 2007. International estimates of 
infertility prevalence and treatment-seeking: potential need and demand for infertility 
medical care. Human Reproduction, 22, 1506-1512. 
BOTTARO, D. P., RUBIN, J. S., FALETTO, D. L., CHAN, A. M. L., KMIECIK, T. E., VANDEWOUDE, G. 
F. & AARONSON, S. A. 1991. IDENTIFICATION OF THE HEPATOCYTE GROWTH-FACTOR 
RECEPTOR AS THE C-MET PROTOONCOGENE PRODUCT. Science, 251, 802-804. 
BRAYTON, C. F. 1986. Dimethyl sulfoxide (DMSO): a review. The Cornell veterinarian, 76, 61-90. 
BREITBART, H. 2002. Intracellular calcium regulation in sperm capacitation and acrosomal 
reaction. Molecular and Cellular Endocrinology, 187, 139-144. 
BRENKER, C., GOODWIN, N., WEYAND, I., KASHIKAR, N. D., NARUSE, M., KRAHLING, M., 
MULLER, A., KAUPP, U. B. & STRUNKER, T. 2012. The CatSper channel: a polymodal 
chemosensor in human sperm. Embo Journal, 31, 1654-1665. 
BREWIS, I. A., MORTON, I. E., MOHAMMAD, S. N., BROWES, C. E. & MOORE, H. D. M. 2000. 
Measurement of intracellular calcium concentration and plasma membrane potential 
in human spermatozoa using flow cytometry. Journal of Andrology, 21, 238-249. 
BURKMAN, L. J. 1991. DISCRIMINATION BETWEEN NONHYPERACTIVATED AND CLASSICAL 
HYPERACTIVATED MOTILITY PATTERNS IN HUMAN SPERMATOZOA USING 
COMPUTERIZED ANALYSIS. Fertility and Sterility, 55, 363-371. 
BUZADZIC, B., VUCETIC, M., JANKOVIC, A., STANCIC, A., KORAC, A., KORAC, B. & OTASEVIC, V. 
2014. New insights into male (in)fertility: The importance of NO. British Journal of 
Pharmacology, n/a-n/a. 
CALANDRA, B., PORTIER, M., KERNÉIS, A., DELPECH, M., CARILLON, C., LE FUR, G., FERRARA, P. 
& SHIRE, D. 1999. Dual intracellular signaling pathways mediated by the human 
cannabinoid CB1 receptor. European Journal of Pharmacology, 374, 445-455. 
CAMPANA, A., SAKKAS, D., STALBERG, A., BIANCHI, P. G., COMTE, I., PACHE, T. & WALKER, D. 
1996. Intrauterine insemination: evaluation of the results according to the woman's 
162 
 
age, sperm quality, total sperm count per insemination and life table analysis. Human 
Reproduction, 11, 732-736. 
CARLSON, A. E., BURNETT, L. A., DEL CAMINO, D., QUILL, T. A., HILLE, B., CHONG, J. A., MORAN, 
M. M. & BABCOCK, D. F. 2009. Pharmacological Targeting of Native CatSper Channels 
Reveals a Required Role in Maintenance of Sperm Hyperactivation. PLoS ONE, 4, 
e6844. 
CARRERA, A., MOOS, J., NING, X. P., GERTON, G. L., TESARIK, J., KOPF, G. S. & MOSS, S. B. 1996. 
Regulation of protein tyrosine phosphorylation in human sperm by a 
calcium/calmodulin-dependent mechanism: Identification of a kinase anchor proteins 
as major substrates for tyrosine phosphorylation. Developmental Biology, 180, 284-
296. 
CASTILLA, J. A., ALVAREZ, C., AGUILAR, J., GONZÁLEZ-VAREA, C., GONZALVO, M. C. & 
MARTÍNEZ, L. 2006. Influence of analytical and biological variation on the clinical 
interpretation of seminal parameters. Human reproduction (Oxford, England), 21, 847-
51. 
CATIZONE, A., RICCI, G., DEL BRAVO, J. & GALDIERI, M. 2006. Hepatocyte growth factor 
modulates in vitro survival and proliferation of germ cells during postnatal testis 
development. Journal of Endocrinology, 189, 137-146. 
CATTERALL, W. A. 2000. STRUCTURE AND REGULATION OF VOLTAGE-GATED Ca2+ CHANNELS. 
Annual Review of Cell and Developmental Biology, 16, 521-555. 
CATTERALL, W. A. & FEW, A. P. 2008. Calcium Channel Regulation and Presynaptic Plasticity. 
Neuron, 59, 882-901. 
CHANG, M. C. 1951. Fertilizing capacity of spermatozoa deposited into the fallopian tubes. 
Nature, 168, 697-8. 
CHAPEAU, C. & GAGNON, D. C. 1987. Nitrocellulose and Polyvinyl Coatings Prevent Sperm 
Adhesion to Glass Without Affecting the Motility of Intact and Demembranated 
Human Spermatozoa. Journal of Andrology, 8, 34-40. 
CHEMES, H. E., BRUGO OLMEDO, S., CARRERE, C., OSES, R., CARIZZA, C., LEISNER, M. & 
BLAQUIER, J. 1998. Ultrastructural pathology of the sperm flagellum: association 
between flagellar pathology and fertility prognosis in severely asthenozoospermic 
men. Human Reproduction, 13, 2521-2526. 
CHEN, Y. Q., CANN, M. J., LITVIN, T. N., IOURGENKO, V., SINCLAIR, M. L., LEVIN, L. R. & BUCK, J. 
2000. Soluble adenylyl cyclase as an evolutionarily conserved bicarbonate sensor. 
Science, 289, 625-628. 
CHULAVATNATOL, M. & HAESUNGCHARERN, A. 1977. Stabilization of adenylate energy charge 
and its relation to human sperm motility. Journal of Biological Chemistry, 252, 8088-
8091. 
COMHAIRE, F., MILINGOS, S., LIAPI, A., GORDTS, S., CAMPO, R., DEPYPERE, H., DHONT, M. & 
SCHOONJANS, F. 1995. The effective cumulative pregnancy rate of different modes of 
treatment of male infertility. Andrologia, 27, 217-221. 
COOPER, T. G., NOONAN, E., VON ECKARDSTEIN, S., AUGER, J., BAKER, H. W. G., BEHRE, H. M., 
HAUGEN, T. B., KRUGER, T., WANG, C., MBIZVO, M. T. & VOGELSONG, K. M. 2010. 
World Health Organization reference values for human semen characteristics. Human 
Reproduction Update, 16, 231-245. 
COSKRAN, T. M., MORTON, D., MENNITI, F. S., ADAMOWICZ, W. O., KLEIMAN, R. J., RYAN, A. 
M., STRICK, C. A., SCHMIDT, C. J. & STEPHENSON, D. T. 2006. Immunohistochemical 
Localization of Phosphodiesterase 10A in Multiple Mammalian Species. Journal of 
Histochemistry & Cytochemistry, 54, 1205-1213. 
COSTELLO, S., MICHELANGELI, F., NASH, K., LEFIEVRE, L., MORRIS, J., MACHADO-OLIVEIRA, G., 
BARRATT, C., KIRKMAN-BROWN, J. & PUBLICOVER, S. 2009. Ca2+-stores in sperm: their 
identities and functions. Reproduction, 138, 425-437. 
CRAVATT, B. F. & LICHTMAN, A. H. 2002. The enzymatic inactivation of the fatty acid amide 
class of signaling lipids. Chemistry and Physics of Lipids, 121, 135-148. 
163 
 
CURI, S. M., ARIAGNO, J. I., CHENLO, P. H., MENDELUK, G. R., PUGLIESE, M. N., SARDI SEGOVIA, 
L. M., REPETTO, H. E. H. & BLANCO, A. M. 2003. Asthenozoospermia: analysis of a large 
population. Archives of andrology, 49, 343-9. 
DAI, S., HALL, D. D. & HELL, J. W. 2009. Supramolecular Assemblies and Localized Regulation of 
Voltage-Gated Ion Channels. Physiological Reviews, 89, 411-452. 
DARSZON, A., ACEVEDO, J. J., GALINDO, B. E., HERNÁNDEZ-GONZÁLEZ, E. O., NISHIGAKI, T., 
TREVIÑO, C. L., WOOD, C. & BELTRÁN, C. 2006. Sperm channel diversity and functional 
multiplicity. Reproduction, 131, 977-988. 
DARSZON, A., GUERRERO, A., GALINDO, B. E., NISHIGAKI, T. & WOOD, C. D. 2008. Sperm-
activating peptides in the regulation of ion fluxes, signal transduction and motility. 
International Journal of Developmental Biology, 52, 595-606. 
DARSZON, A., NISHIGAKI, T., BELTRAN, C. & TREVIÑO, C. L. 2011. Calcium channels in the 
development, maturation, and function of spermatozoa. Physiological reviews, 91, 
1305-55. 
DASCAL, N. 2001. Ion-channel regulated by G proteins. TRENDS in Edocrinology & Metabolism, 
12, 391-398. 
DAVID, G., SERRES, C. & JOUANNET, P. 1981. Kinematics of human spermatozoa. Gamete 
Research, 4, 83-95. 
DE JONGE, C. 2005. Biological basis for human capacitation. Human Reproduction Update, 11, 
205-214. 
DE LAMIRANDE, E. & GAGNON, C. 2002. The extracellular signal-regulated kinase (ERK) 
pathway is involved in human sperm function and modulated by the superoxide anion. 
Molecular human reproduction, 8, 124-35. 
DE LAMIRANDE, E. & O’FLAHERTY, C. 2008. Sperm activation: Role of reactive oxygen species 
and kinases. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 1784, 106-
115. 
DELAMIRANDE, E., LECLERC, P. & GAGNON, C. 1997. Capacitation as a regulatory event that 
primes spermatozoa for the acrosome reaction and fertilization. Molecular Human 
Reproduction, 3, 175-194. 
DEMOTT, R. P. & SUAREZ, S. S. 1992. Hyperactivated sperm progress in the mouse oviduct. 
Biology of Reproduction, 46, 779-785. 
DEPUYDT, C. E., DE POTTER, C. R., ZALATA, A., BAEKELANDT, E., BOSMANS, E. & COMHAIRE, F. 
H. 1998. Levels of Hepatocyte Growth Factor/Scatter Factor (HGF/SF) in Seminal 
Plasma of Patients With Andrological Diseases. Journal of Andrology, 19, 175-182. 
DEPUYDT, C. E., ZALATA, A., DE POTTER, C. R., VAN EMMELO, J. & COMHAIRE, F. H. 1996. 
Genetic regulation of gametogensis: The receptor encoded by the human C-MET 
oncogene is expressed in testicular tissue and on human spermatozoa. Molecular 
Human Reproduction, 2, 2-8. 
DEPUYDT, C. E., ZALATA, A., FALMAGNE, J. B., BOSMANS, E. & COMHAIRE, F. H. 1997. 
Purification and characterization of hepatocyte growth factor (HGF) from human 
seminal plasma. International Journal of Andrology, 20, 306-314. 
DEVANE, W. A., HANUS, L., BREUER, A., PERTWEE, R. G., STEVENSON, L. A., GRIFFIN, G., 
GIBSON, D., MANDELBAUM, A., ETINGER, A. & MECHOULAM, R. 1992. ISOLATION AND 
STRUCTURE OF A BRAIN CONSTITUENT THAT BINDS TO THE CANNABINOID RECEPTOR. 
Science, 258, 1946-1949. 
DONNELLY, E. T., LEWIS, S. E., MCNALLY, J. A. & THOMPSON, W. 1998. In vitro fertilization and 
pregnancy rates: the influence of sperm motility and morphology on IVF outcome. 
Fertility and sterility, 70, 305-14. 
DOUGLAS‐HAMILTON, D. H., SMITH, N. G., KUSTER, C. E., VERMEIDEN, J. P. W. & ALTHOUSE, G. 
C. 2005a. Capillary‐Loaded Particle Fluid Dynamics: Effect on Estimation of Sperm 
Concentration. Journal of Andrology, 26, 115-122. 
164 
 
DOUGLAS‐HAMILTON, D. H., SMITH, N. G., KUSTER, C. E., VERMEIDEN, J. P. W. & ALTHOUSE, G. 
C. 2005b. Particle Distribution in Low‐Volume Capillary‐Loaded Chambers. Journal of 
Andrology, 26, 107-114. 
EGGERT-KRUSE, W., GERHARD, I., TILGEN, W. & RUNNEBAUM, B. 1989. CLINICAL-
SIGNIFICANCE OF CROSSED INVITRO SPERM-CERVICAL MUCUS PENETRATION TEST IN 
INFERTILITY INVESTIGATION. Fertility and Sterility, 52, 1032-1040. 
ESCOFFIER, J., BOISSEAU, S., SERRES, C., CHEN, C.-C., KIM, D., STAMBOULIAN, S., SHIN, H.-S., 
CAMPBELL, K. P., DE WAARD, M. & ARNOULT, C. 2007. Expression, localization and 
functions in acrosome reaction and sperm motility of CaV3.1 and CaV3.2 channels in 
sperm cells: An evaluation from CaV3.1 and CaV3.2 deficient mice. Journal of Cellular 
Physiology, 212, 753-763. 
ESFANDIARI, N., SALEH, R. A., BLAUT, A. P., SHARMA, R. K., NELSON, D. R., THOMAS, A. J., 
FALCONE, T. & AGARWAL, A. 2002. Effects of temperature on sperm motion 
characteristics and reactive oxygen species. International journal of fertility and 
women's medicine, 47, 227-33. 
ESHRE, E. S. O. H. R. A. E. 2012. The world's number of IVF and ICSI babies has now reached a 
calculated total of 5 million. 
ESPOSITO, G., JAISWAL, B. S., XIE, F., KRAJNC-FRANKEN, M. A. M., ROBBEN, T., STRIK, A. M., 
KUIL, C., PHILIPSEN, R. L. A., VAN DUIN, M., CONTI, M. & GOSSEN, J. A. 2004. Mice 
deficient for soluble adenylyl cyclase are infertile because of a severe sperm-motility 
defect. Proceedings of the National Academy of Sciences of the United States of 
America, 101, 2993-2998. 
FAWCETT, L., BAXENDALE, R., STACEY, P., MCGROUTHER, C., HARROW, I., SODERLING, S., 
HETMAN, J., BEAVO, J. A. & PHILLIPS, S. C. 2000. Molecular cloning and 
characterization of a distinct human phosphodiesterase gene family: PDE11A. 
Proceedings of the National Academy of Sciences, 97, 3702-3707. 
FISCH, J. D., BEHR, B. & CONTI, M. 1998. Enhancement of motility and acrosome reaction in 
human spermatozoa: differential activation by type-specific phosphodiesterase 
inhibitors. Human Reproduction, 13, 1248-1254. 
FISHER, D. A., SMITH, J. F., PILLAR, J. S., ST. DENIS, S. H. & CHENG, J. B. 1998. Isolation and 
Characterization of PDE8A, a Novel Human cAMP-Specific Phosphodiesterase. 
Biochemical and Biophysical Research Communications, 246, 570-577. 
FORD, W. C. L., REES, J. M., MCLAUGHLIN, E. A., LING, L. & HULL, M. G. R. 1994. Pentoxifylline 
acts synergistically with A23187 to increase the penetration of zona-free hamster 
oocytes by cryopreserved human spermatozoa. International Journal of Andrology, 17, 
199-204. 
FORSTER, M. S., SMITH, W. D., LEE, W. I., BERGER, R. E., KARP, L. E. & STENCHEVER, M. A. 1983. 
SELECTION OF HUMAN-SPERMATOZOA ACCORDING TO THEIR RELATIVE MOTILITY 
AND THEIR INTERACTION WITH ZONA-FREE HAMSTER EGGS. Fertility and Sterility, 40, 
655-660. 
FRANCAVILLA, F., BATTISTA, N., BARBONETTI, A., VASSALLO, M. R. C., RAPINO, C., 
ANTONANGELO, C., PASQUARIELLO, N., CATANZARO, G., BARBONI, B. & 
MACCARRONE, M. 2009. Characterization of the Endocannabinoid System in Human 
Spermatozoa and Involvement of Transient Receptor Potential Vanilloid 1 Receptor in 
Their Fertilizing Ability. Endocrinology, 150, 4692-4700. 
FRASER, C. G. 2001. Biological variation: from principles to practice, Amer. Assoc. for Clinical 
Chemistry. 
FRASER, L., BARRATT, C. L., CANALE, D., COOPER, T., DEJONGE, C., IRVINE, S., MORTIMER, D., 
OEHNINGER, S. & TESARIK, J. 1997. Consensus workshop on advanced diagnostic 
andrology techniques. ESHRE Andrology Special Interest Group. Human Reproduction, 
12, 873-873. 
FRASER, L. & GROUP, S. I. 1998. Guidelines on the application of CASA technology in the 
analysis of spermatozoa. 13, 142-145. 
165 
 
FRASER, L. R. 1977. Motility patterns in mouse spermatozoa before and after capacitation. J 
Exp Zool, 202, 439-44. 
FRASER, L. R. 1998. Sperm capacitation and the acrosome reaction. Human Reproduction, 13. 
GADELLA, B. M. & VISCONTI, P. E. 2006. Regulation of capacitation. In: BARRATT, C. L. R. & DE 
JONGE, C. J. (eds.). Cambridge: Cambridge University Press. 
GARNIER-LHOMME, M., BYRNE, R. D., HOBDAY, T. M. C., GSCHMEISSNER, S., WOSCHOLSKI, R., 
POCCIA, D. L., DUFOURC, E. J. & LARIJANI, B. 2009. Nuclear Envelope Remnants: Fluid 
Membranes Enriched in STEROLS and Polyphosphoinositides. Plos One, 4. 
GARRETT, C., LIU, D. Y., CLARKE, G. N., RUSHFORD, D. D. & BAKER, H. W. G. 2003. Automated 
semen analysis: ‘zona pellucida preferred’ sperm morphometry and straight‐line 
velocity are related to pregnancy rate in subfertile couples. Human Reproduction, 18, 
1643-1649. 
GHALENO, L. R., VALOJERDI, M. R., CHEHRAZI, M. & SHARBATOGHLI, M. 2013. Evaluation of 
conventional semen parameters, intracellular reactive oxygen species, DNA 
fragmentation and dysfunction of mitochondrial membrane potential after semen 
preparation techniques: a flow cytometric study. Archives of Gynecology and 
Obstetrics, 1-8. 
GLASS, M. & FELDER, C. C. 1997. Concurrent Stimulation of Cannabinoid CB1 and Dopamine D2 
Receptors Augments cAMP Accumulation in Striatal Neurons: Evidence for a Gs 
Linkage to the CB1 Receptor. The Journal of Neuroscience, 17, 5327-5333. 
GOODWIN, L. O., KARABINUS, D. S., PERGOLIZZI, R. G. & BENOFF, S. 2000. L-type voltage-
dependent calcium channel α-1C subunit mRNA is present in ejaculated human 
spermatozoa. Molecular Human Reproduction, 6, 127-136. 
GOVERDE, A. J., MCDONNELL, J., VERMEIDEN, J. P. W., SCHATS, R., RUTTEN, F. F. H. & 
SCHOEMAKER, J. 2000. Intrauterine insemination or in-vitro fertilisation in idiopathic 
subfertility and male subfertility: a randomised trial and cost-effectiveness analysis. 
The Lancet, 355, 13-18. 
GUERIN, J. F., MATHIEU, C., LORNAGE, J., PINATEL, M. C. & BOULIEU, D. 1989. IMPROVEMENT 
OF SURVIVAL AND FERTILIZING-CAPACITY OF HUMAN-SPERMATOZOA IN AN IVF 
PROGRAM BY SELECTION ON DISCONTINUOUS PERCOLL GRADIENTS. Human 
Reproduction, 4, 798-804. 
GUTKIND, J. S. 1998. The Pathways Connecting G Protein-coupled Receptors to the Nucleus 
through Divergent Mitogen-activated Protein Kinase Cascades. Journal of Biological 
Chemistry, 273, 1839-1842. 
GUZICK, D. S., OVERSTREET, J. W., FACTOR -L ITVAK, P. A. M., BRAZIL, C. K., NAKAJIMA, S. T., 
COUTIFARIS, C., CARSON, S. A., CISNEROS, P., STEINKAMPF, M. P., HILL, J. A., XU, D. & 
VOGEL, D. L. 2001. Sperm morphology, Motility, and Concentration in Fertile and 
Infertile Men. The New England journal of Medicine, 345, 1388-1393. 
HAMAMAH, S., MAGNOUX, E., ROYERE, D., BARTHELEMY, C., DACHEUX, J. L. & GATTI, J. L. 
1996. Internal pH of human spermatozoa: effect of ions, human follicular fluid and 
progesterone. Molecular human reproduction, 2, 219-24. 
HARGREAVE, T. B. & ELTON, R. A. 1983. Is conventional sperm analysis of any use? British 
journal of urology, 55, 774-9. 
HARPER, C. V., BARRATT, C. L. R. & PUBLICOVER, S. J. 2004. Stimulation of Human Spermatozoa 
with Progesterone Gradients to Simulate Approach to the Oocyte: INDUCTION OF 
[Ca2+]i OSCILLATIONS AND CYCLICAL TRANSITIONS IN FLAGELLAR BEATING. Journal of 
Biological Chemistry, 279, 46315-46325. 
HERNESS, E. A. & NAZ, R. K. 1999. Presence and Tyrosine Phosphorylation of c-met Receptor in 
Human Sperm. Journal of Andrology, 20, 640-647. 
HESS, R. A. & RENATO DE FRANCA, L. 2008. Spermatogenesis and cycle of the seminiferous 
epithelium. Advances in experimental medicine and biology, 636, 1-15. 
166 
 
HEUCHEL, V., SCHWARTZ, D. & CZYGLIK, F. 1983. BETWEEN AND WITHIN SUBJECT 
CORRELATIONS AND VARIANCES FOR CERTAIN SEMEN CHARACTERISTICS IN FERTILE 
MEN. Andrologia, 15, 171-176. 
HILDEBRAND, M. S., AVENARIUS, M. R., FELLOUS, M., ZHANG, Y., MEYER, N. C., AUER, J., 
SERRES, C., KAHRIZI, K., NAJMABADI, H., BECKMANN, J. S. & SMITH, R. J. H. 2010. 
Genetic male infertility and mutation of CATSPER ion channels. European Journal of 
Human Genetics, 18. 
HO, H. 2001. Hyperactivation of mammalian spermatozoa: function and regulation. 
Reproduction, 122, 519-526. 
HO, H.-C. & SUAREZ, S. S. 2001. An Inositol 1,4,5-Trisphosphate Receptor-Gated Intracellular 
Ca2+ Store Is Involved in Regulating Sperm Hyperactivated Motility. Biology of 
Reproduction, 65, 1606-1615. 
HOOGEWIJS, M. K., DE VLIEGHER, S. P., GOVAERE, J. L., DE SCHAUWER, C., DE KRUIF, A. & VAN 
SOOM, A. 2012. Influence of counting chamber type on CASA outcomes of equine 
semen analysis. Equine veterinary journal, 44, 542-9. 
HOWLETT, A. C. 2005. Cannabinoids. In: PERTWEE, R. (ed.) Handbook of Experimental 
Pharmacology. Heidelberg, Germany: Springer-Verlag. 
HOWLETT, A. C., BARTH, F., BONNER, T. I., CABRAL, G., CASELLAS, P., DEVANE, W. A., FELDER, 
C. C., HERKENHAM, M., MACKIE, K., MARTIN, B. R., MECHOULAM, R. & PERTWEE, R. G. 
2002. International Union of Pharmacology. XXVII. Classification of Cannabinoid 
Receptors. Pharmacological Reviews, 54, 161-202. 
HULL, M. G. R., GLAZENER, C. M. A., KELLY, N. J., CONWAY, D. I., FOSTER, P. A., HINTON, R. A., 
COULSON, C., LAMBERT, P. A., WATT, E. M. & DESAI, K. M. 1985. Population study of 
causes, treatment, and outcome of infertility. British Medical Journal, 291, 1693-1697. 
IKAWA, M., INOUE, N., BENHAM, A. M. & OKABE, M. 2010. Fertilization: a sperm's journey to 
and interaction with the oocyte. Journal of Clinical Investigation, 120, 984-994. 
IMAI, H., SUZUKI, K., ISHIZAKA, K., ICHINOSE, S., OSHIMA, H., OKAYASU, I., EMOTO, K., UMEDA, 
M. & NAKAGAWA, Y. 2001. Failure of the Expression of Phospholipid Hydroperoxide 
Glutathione Peroxidase in the Spermatozoa of Human Infertile Males. Biology of 
Reproduction, 64, 674-683. 
IRVINE, D. S. 1998. Epidemiology and aetiology of male infertility. Human Reproduction, 13, 33-
44. 
IVIC, A. 2002. Critical evaluation of methylcellulose as an alternative medium in sperm 
migration tests. Human Reproduction, 17, 143-149. 
JAISWAL, B. S. & MAJUMDER, G. C. 1996. Cyclic AMP phosphodiesterase: A regulator of 
forward motility initiation during epididymal sperm maturation. Biochemistry and Cell 
Biology-Biochimie Et Biologie Cellulaire, 74, 669-674. 
JEDRZEJCZAK, P., TASZAREK-HAUKE, G., HAUKE, J., PAWELCZYK, L. & DULEBA, A. J. 2008. 
Prediction of spontaneous conception based on semen parameters. International 
Journal of Andrology, 31, 499-507. 
JEYENDRAN, R. S., VAN DER VEN, H. H., PEREZ-PELAEZ, M., CRABO, B. G. & ZANEVELD, L. J. D. 
1984. Development of an assay to assess the functional integrity of the human sperm 
membrane and its relationship to other semen characteristics. Journal of Reproduction 
and Fertility, 70, 219-228. 
JOHNSON, L. L., KATZ, D. F. & OVERSTREET, J. W. 1981. The movement characteristics of rabbit 
spermatozoa before and after activation. Gamete Research, 4, 275-282. 
JONES, E. L., MUDRAK, O. & ANDREI, O. 2010. Kinetics of human male pronuclear development 
in a heterologous ICSI model. Journal of Assisted Reproduction and Genetics,27, 277-
283. 
JØRGENSEN, N., ANDERSEN, A. G., EUSTACHE, F., IRVINE, D. S., SUOMINEN, J., PETERSEN, J. H., 
ANDERSEN, A. N., AUGER, J., CAWOOD, E. H., HORTE, A., JENSEN, T. K., JOUANNET, P., 
KEIDING, N., VIERULA, M., TOPPARI, J. & SKAKKEBAEK, N. E. 2001. Regional differences 
in semen quality in Europe. Human reproduction (Oxford, England), 16, 1012-9. 
167 
 
KARANDE, V. C., KORN, A., MORRIS, R., RAO, R., BALIN, M., RINEHART, J., DOHN, K. & 
GLEICHER, N. 1999. Prospective randomized trial comparing the outcome and cost of 
in vitro fertilization with that of a traditional treatment algorithm as first-line therapy 
for couples with infertility. Fertility and Sterility, 71, 468-475. 
KATZ, D., OVERSTREET, J. & HANSON, F. 1980. A new quantitative test for sperm penetration 
into cervical mucus. Fertility and Sterility, 33, 179-186. 
KAY, V. J., COUTTS, J. R. T. & ROBERTSON, L. 1993. PENTOXIFYLLINE STIMULATES 
HYPERACTIVATION IN HUMAN SPERMATOZOA. Human Reproduction, 8, 727-731. 
KEEL, B. A. 2006. Within- and between-subject variation in semen parameters in infertile men 
and normal semen donors. Fertility and Sterility, 85, 128-134. 
KIRICHOK, Y. & LISHKO, P. V. 2011. Rediscovering sperm ion channels with the patch-clamp 
technique. Molecular Human Reproduction, 17, 478-499. 
KIRICHOK, Y., NAVARRO, B. & CLAPHAM, D. E. 2006. Whole-cell patch-clamp measurements of 
spermatozoa reveal an alkaline-activated Ca2+ channel. Nature, 439, 737-740. 
KITAMURA, M., MATSUMIYA, K., NISHIMURA, K., YAMANAKA, M., MATSUMOTO, K. & 
OKUYAMA, A. 2000. Effect of hepatocyte growth factor on sperm motility. American 
Journal of Reproductive Immunology, 44, 193-196. 
KRAEMER, M., FILLION, C., MARTIN-PONT, B. & AUGER, J. 1998. Factors influencing human 
sperm kinematic measurements by the Celltrak computer-assisted sperm analysis 
system. Human reproduction (Oxford, England), 13, 611-9. 
KRASZNAI, Z., KRASZNAI, Z. T., MORISAWA, M., BAZSÁNÉ, Z. K., HERNÁDI, Z., FAZEKAS, Z., 
TRÓN, L., GODA, K. & MÁRIÁN, T. 2006. Role of the Na+/Ca2+ exchanger in calcium 
homeostasis and human sperm motility regulation. Cell motility and the cytoskeleton, 
63, 66-76. 
KRAUSZ, C., BONACCORSI, L., MAGGIO, P., LUCONI, M., CRISCUOLI, L., FUZZI, B., PELLEGRINI, S., 
FORTI, G. & BALDI, E. 1996. Two functional assays of sperm responsiveness to 
progesterone and their predictive values in in-vitro fertilization. Human reproduction 
(Oxford, England), 11, 1661-7. 
KREMER, J. 1965. A SIMPLE SPERM PENETRATION TEST. International Journal of Fertility, 10, 
209-&. 
LAIL-TRECKER, M., GULATI, R. & PELUSO, J. J. 1998. A role for hepatocyte growth factor scatter 
factor in regulating normal and neoplastic cells of reproductive tissues. Journal of the 
Society for Gynecologic Investigation, 5, 114-121. 
LARSEN, L., SCHEIKE, T., JENSEN, T. K. & BONDE, J. P. 2000. Computer-assisted semen analysis 
parameters as predictors for fertility of men from the general population. Human …, 
15, 1562-1567. 
LE LANNOU, D., GRIVEAU, J. F., LE PICHON, J. P. & QUERO, J. C. 1992. Effects of chamber depth 
on the motion pattern of human spermatozoa in semen or in capacitating medium. 
Human reproduction (Oxford, England), 7, 1417-21. 
LEE, M. A. & STOREY, B. T. 1986. BICARBONATE IS ESSENTIAL FOR FERTILIZATION OF MOUSE 
EGGS - MOUSE SPERM REQUIRE IT TO UNDERGO THE ACROSOME REACTION. Biology 
of Reproduction, 34, 349-356. 
LEFIEVRE, L., BEDU-ADDO, K., CONNER, S. J., MACHADO-OLIVEIRA, G. S. M., CHEN, Y., 
KIRKMAN-BROWN, J. C., AFNAN, M. A., PUBLICOVER, S. J., FORD, W. C. L. & BARRATT, 
C. L. R. 2007. Counting sperm does not add up any more: time for a new equation? 
Reproduction, 133, 675-684. 
LEFIEVRE, L., DE LAMIRANDE, E. & GAGNON, C. 2002. Presence of cyclic nucleotide 
phosphodiesterases PDE1, existing as a stable complex with calmodulin, and PDE3A in 
human spermatozoa. Biology of Reproduction, 67, 423-430. 
LEFIEVRE, L., DE LAMIRANDE, E. V. E. & GAGNON, C. 2000. The Cyclic GMP-Specific 
Phosphodiesterase Inhibitor, Sildenafil, Stimulates Human Sperm Motility and 
Capacitation but Not Acrosome Reaction. Journal of Andrology, 21, 929-937. 
168 
 
LEFIEVRE, L., NASH, K., MANSELL, S., COSTELLO, S., PUNT, E., CORREIA, J., MORRIS, J., 
KIRKMAN-BROWN, J., WILSON, S., BARRATT, C. & PUBLICOVER, S. 2012. 2-APB-
potentiated channels amplify CatSper-induced Ca2+ signals in human sperm. 
Biochemical Journal, 448, 189-200. 
LEJA 2005. The Segre Silberberg effect. 
LEWIS, S. E. M. 2007. Is sperm evaluation useful in predicting human fertility? Reproduction, 
134, 31-40. 
LI, M. W. M., MRUK, D. D. & CHENG, C. Y. 2009. Mitogen-activated protein kinases in male 
reproductive function. Trends in Molecular Medicine, 15, 159-168. 
LINDEMANN, C. B. & KANOUS, K. S. 1989. REGULATION OF MAMMALIAN SPERM MOTILITY. 
Archives of Andrology, 23, 1-22. 
LISHKO, P. V., BOTCHKINA, I. L., FEDORENKO, A. & KIRICHOK, Y. 2010. Acid Extrusion from 
Human Spermatozoa Is Mediated by Flagellar Voltage-Gated Proton Channel. Cell, 140, 
327-337. 
LISHKO, P. V., BOTCHKINA, I. L. & KIRICHOK, Y. 2011. Progesterone activates the principal Ca2+ 
channel of human sperm. Nature, 471, 387-391. 
LISHKO, P. V. & KIRICHOK, Y. 2010. The role of Hv1 and CatSper channels in sperm activation. 
The Journal of Physiology, 588, 4667-4672. 
LISHKO, P. V., KIRICHOK, Y., REN, D., NAVARRO, B., CHUNG, J.-J. & CLAPHAM, D. E. 2012a. The 
Control of Male Fertility by Spermatozoan Ion Channels. Annual Review of Physiology, 
74, 453-475. 
LISHKO, P. V., KIRICHOK, Y., REN, D. J., NAVARRO, B., CHUNG, J. J. & CLAPHAM, D. E. 2012b. 
The Control of Male Fertility by Spermatozoan Ion Channels. In: JULIUS, D. & 
CLAPHAM, D. E. (eds.) Annual Review of Physiology, Vol 74. Palo Alto: Annual Reviews. 
LIU, D. Y. & BAKER, H. W. G. 1988. THE PROPORTION OF HUMAN-SPERM WITH POOR 
MORPHOLOGY BUT NORMAL INTACT ACROSOMES DETECTED WITH PISUM-SATIVUM 
AGGLUTININ CORRELATES WITH FERTILIZATION INVITRO. Fertility and Sterility, 50, 
288-293. 
LIU, D. Y., LIU, M. L., CLARKE, G. N. & BAKER, H. W. G. 2007. Hyperactivation of capacitated 
human sperm correlates with the zona pellucida-induced acrosome reaction of zona 
pellucida-bound sperm. Human Reproduction, 22, 2632-2638. 
LIÉVANO, A., SANTI, C. M., SERRANO, C. J., TREVIÑO, C. L., BELLVÉ, A. R., HERNÁNDEZ-CRUZ, A. 
& DARSZON, A. 1996. T-type Ca2+ channels and α1E expression in spermatogenic cells, 
and their possible relevance to the sperm acrosome reaction. FEBS Letters, 388, 150-
154. 
LOPEZ-GONZALEZ, I., DE LA VEGA-BELTRAN, J. L., SANTI, C. M., FLORMAN, H. M., FELIX, R. & 
DARSZON, A. 2001. Calmodulin antagonists inhibit T-type Ca2+ currents in mouse 
spermatogenic cells and the zona pellucida-induced sperm acrosome reaction. 
Developmental Biology, 236, 210-219. 
LU, Q. & AN, W. F. 2008. Impact of novel screening technologies on ion channel drug discovery. 
Combinatorial Chemistry & High Throughput Screening, 11, 185-194. 
MACCARRONE, M. 2008. CB2 receptors in reproduction. British Journal of Pharmacology, 153, 
189-198. 
MACLEOD, J. & GOLD, R. Z. 1951a. The Male Factor in Fertility and Infertility. II. Spermatozoon 
Counts in 1000 Men of Known Fertility and in 1000 Cases of Infertile Marriage. The 
Journal of urology, 66, 436-49. 
MACLEOD, J. & GOLD, R. Z. 1951b. The Male Factor in Fertility and Infertility. III. An Analysis of 
Motile Activity in the Spermatozoa of 1000 Fertile Men and 1000 Men in Infertile 
Marriage. Fertility and sterility, 2, 187-204. 
MAHI, C. A. & YANAGIMACHI, R. 1978. Capacitation, acrosome reaction, and egg penetration 
by canine spermatozoa in a simple defined medium. Gamete Research, 1, 101-109. 
169 
 
MAHMOUD, A. M., DEPOORTER, B., PIENS, N. & COMHAIRE, F. H. 1997. The performance of 10 
different methods for the estimation of sperm concentration. Fertility and sterility, 68, 
340-5. 
MAKLER, A., MAKLER, E., ITZKOVITZ, J. & BRANDES, J. M. 1980. Factors affecting sperm 
motility. IV. Incubation of human semen with caffeine, kallikrein, and other 
metabolically active compounds. Fertility and sterility, 33, 624-30. 
MALLIDIS, C., HOWARD, E. J. & BAKER, H. W. G. 1991. VARIATION OF SEMEN QUALITY IN 
NORMAL MEN. International Journal of Andrology, 14, 99-107. 
MANNOWETZ, N., NAIDOO, N. M., CHOO, S.-A. S., SMITH, J. F., LISHKO, P. V. & ALDRICH, R. 
2013. Slo1 is the principal potassium channel of human spermatozoa. eLife, 2. 
MANSELL, S. A., PUBLICOVER, S. J., BARRATT, C. L. R. & WILSON, S. M. 2014. Patch clamp 
studies of human sperm under physiological ionic conditions reveal three functionally 
and pharmacologically distinct cation channels. Molecular Human Reproduction. 
MARTINS DA SILVA, S. J., HOPE, A. G., GRAY, D. W. & BARRATT, C. L. R. 2012. Validation of a 
novel high throughput screening assay to assess calcium responses in human sperm. 
Fertility and Sterility, 98, S84-S85. 
MARZO, V. D., PETROCELLIS, L. D. & BISOGNO, T. 2005. The Biosynthesis, Fate and 
Pharmacological Properties of Endocannabinoids. In: PERTWEE, R. (ed.) Cannabinoids: 
Handbook of Experimental Pharmacology. Germany: Springer- Verlag. 
MARÍN-BRIGGILER, C. I., JHA, K. N., CHERTIHIN, O., BUFFONE, M. G., HERR, J. C., VAZQUEZ-
LEVIN, M. H. & VISCONTI, P. E. 2005. Evidence of the presence of calcium/calmodulin-
dependent protein kinase IV in human sperm and its involvement in motility 
regulation. Journal of Cell Science, 118, 2013-2022. 
MATSON, P. & TARDIF, S. 2012. A preliminary search for alternatives to albumin as a medium 
supplement for the culture of human sperm. Reproductive Biology, 12, 329-331. 
MAYR, L. M. & BOJANIC, D. 2009. Novel trends in high-throughput screening. Current Opinion 
in Pharmacology, 9, 580-588. 
MCLESKEY, S. B., DOWDS, C., CARBALLADA, R., WHITE, R. R. & SALING, P. M. 1998. Molecules 
involved in mammalian sperm-egg interaction. International Review of Cytology - a 
Survey of Cell Biology, Vol 177, 177. 
MIKI, K., QU, W., GOULDING, E. H., WILLIS, W. D., BUNCH, D. O., STRADER, L. F., PERREAULT, S. 
D., EDDY, E. M. & O'BRIEN, D. A. 2004. Glyceraldehyde 3-phosphate dehydrogenase-S, 
a sperm-specific glycolytic enzyme, is required for sperm motility and male fertility. 
Proceedings of the National Academy of Sciences of the United States of America, 101, 
16501-16506. 
MILARDI, D., GRANDE, G., SACCHINI, D., ASTORRI, A. L., POMPA, G., GIAMPIETRO, A., DE 
MARINIS, L., PONTECORVI, A., SPAGNOLO, A. G. & MARANA, R. 2012. Male fertility and 
reduction in semen parameters: a single tertiary-care center experience. International 
journal of endocrinology, 2012, 649149-649149. 
MILLER, J. L. 2006. Recent developments in focused library design: Targeting gene-families. 
Current Topics in Medicinal Chemistry, 6, 19-29. 
MOK, N. Y. & BRENK, R. 2011. Mining the ChEMBL Database: An Efficient Chemoinformatics 
Workflow for Assembling an Ion Channel-Focused Screening Library. Journal of 
Chemical Information and Modeling, 51, 2449-2454. 
MOOHAN, J. M. & LINDSAY, K. S. 1995. SPERMATOZOA SELECTED BY A DISCONTINUOUS 
PERCOLL DENSITY GRADIENT EXHIBIT BETTER MOTION CHARACTERISTICS, MORE 
HYPERACTIVATION, AND LONGER SURVIVAL THAN DIRECT SWIM-UP. Fertility and 
Sterility, 64, 160-165. 
MORISAWA, M. 1994. CELL SIGNALING MECHANISMS FOR SPERM MOTILITY. Zoological 
Science, 11, 647-662. 
MORTIMER, D. 2000a. Sperm Preparation Methods. Journal of Andrology, 21, 357-366. 
MORTIMER, D., AITKEN, R. J., MORTIMER, S. T. & PACEY, A. A. 1995. Workshop report: clinical 
CASA--the quest for consensus. Reproduction, Fertility and Development, 7, 951-951. 
170 
 
MORTIMER, D., COURTOT, A. M., GIOVANGRANDI, Y., JEULIN, C. & DAVID, G. 1984. Human 
sperm motility after migration into, and incubation in, synthetic media. Gamete 
Research, 9, 131-144. 
MORTIMER, D. & MORTIMER, S. T. 2013a. Computer-Aided Sperm Analysis (CASA) of Sperm 
Motility and Hyperactivation. In: CARRELL, D. T. & ASTON, K. I. (eds.). Totowa, NJ: 
Humana Press. 
MORTIMER, D. & MORTIMER, S. T. 2013b. Maunal Methods for Sperm Motility Assessment. In: 
CARRELL, D. T. & ASTON, K. I. (eds.). Totowa, NJ: Humana Press. 
MORTIMER, D. & MORTIMER, S. T. 2013c. Spermatogenesis. In: CARRELL, D. T. & ASTON, K. I. 
(eds.). Totowa, NJ: Humana Press. 
MORTIMER, S. T. 1997. A critical review of the physiological importance and analysis of sperm 
movement in mammals. Human Reproduction Update, 3, 403-439. 
MORTIMER, S. T. 2000b. CASA — Practical Aspects Andrology Lab Corner. 
MORTIMER, S. T. & MORTIMER, D. 1990. Kinematics of Human Spermatozoa Incubated Under 
Capacitating Conditions. Journal of Andrology, 11, 195-203. 
MORTIMER, S. T., SCHOEVAERT, D., SWAN, M. A. & MORTIMER, D. 1997. Quantitative 
observations of flagellar motility of capacitating human spermatozoa. Human 
Reproduction, 12, 1006-1012. 
MORTIMER, S. T. & SWAN, M. A. 1995. Variable kinematics of capacitating human 
spermatozoa. Human Reproduction, 10, 3178-3182. 
MORTIMER, S. T. & SWAN, M. A. 1999. Effect of image sampling frequency on established and 
smoothing-independent kinematic values of capacitating human spermatozoa. Human 
Reproduction, 14, 997-1004. 
MORTIMER, S. T., SWAN, M. A. & MORTIMER, D. 1998. Effect of seminal plasma on 
capacitation and hyperactivation in human spermatozoa. Human Reproduction, 13, 
2139-2146. 
MUKAI, C. & OKUNO, M. 2004. Glycolysis Plays a Major Role for Adenosine Triphosphate 
Supplementation in Mouse Sperm Flagellar Movement. Biology of Reproduction, 71, 
540-547. 
NALDINI, L., WEIDNER, K. M., VIGNA, E., GAUDINO, G., BARDELLI, A., PONZETTO, C., 
NARSIMHAN, R. P., HARTMANN, G., ZARNEGAR, R., MICHALOPOULOS, G. K., 
BIRCHMEIER, W. & COMOGLIO, P. M. 1991. SCATTER FACTOR AND HEPATOCYTE 
GROWTH-FACTOR ARE INDISTINGUISHABLE LIGANDS FOR THE MET RECEPTOR. Embo 
Journal, 10, 2867-2878. 
NAVARRO, B., KIRICHOK, Y. & CLAPHAM, D. E. 2007. KSper, a pH-sensitive K+ current that 
controls sperm membrane potential. Proceedings of the National Academy of Sciences, 
104, 7688-7692. 
NAZ, R. K. 1996. Protein tyrosine phosphorylation and signal transduction during capacitation-
acrosome reaction and zona pellucida binding in human sperm. Archives of Andrology, 
37, 47-55. 
NAZ, R. K., AHMAD, K. & KUMAR, R. 1991. ROLE OF MEMBRANE PHOSPHOTYROSINE PROTEINS 
IN HUMAN SPERMATOZOAL FUNCTION. Journal of Cell Science, 99, 157-165. 
NAZ, R. K., JOSEPH, A., LEE, Y., AHMAD, K. & BHARGAVA, M. M. 1994. Expression of scatter 
factor/hepatocyte growth factor is regionally correlated with the initiation of sperm 
motility in murine male genital tract: Is scatter factor/hepatocyte growth factor 
involved in initiation of sperm motility? Molecular Reproduction and Development, 38, 
431-439. 
NAZ, R. K. & RAJESH, P. B. 2004. Role of tyrosine phosphorylation in sperm capacitation / 
acrosome reaction. Reproductive biology and endocrinology : RB&E, 2, 75. 
NICE, N. I. F. H. A. C. E. 2013. Fertility:assessment and treatment for people with fertility 
problems. 2nd edition ed. London: National Collaborating Centre for Women’s and 
Children’s Health. 
171 
 
O'FLAHERTY, C., DE LAMIRANDE, E. & GAGNON, C. 2006. Positive role of reactive oxygen 
species in mammalian sperm capacitation: triggering and modulation of 
phosphorylation events. Free Radical Biology and Medicine, 41, 528-540. 
OACONNELL, M. 2003. Differences in mitochondrial and nuclear DNA status of high-density 
and low-density sperm fractions after density centrifugation preparation*1. Fertility 
and Sterility, 79, 754-762. 
OKAMOTO, Y., WANG, J., MORISHITA, J. & UEDA, N. 2007. Biosynthetic pathways of the 
endocannabinoid anandamide. Chemistry & Biodiversity, 4, 1842-1857. 
OLSON, S., SUAREZ, S. & FAUCI, L. 2010. A Model of CatSper Channel Mediated Calcium 
Dynamics in Mammalian Spermatozoa. Bulletin of Mathematical Biology, 72, 1925-
1946. 
OLSON, S. D., FAUCI, L. J. & SUAREZ, S. S. 2011. Mathematical modeling of calcium signaling 
during sperm hyperactivation. Molecular Human Reproduction, 17, 500-510. 
OMBELET, W., BOSMANS, E., JANSSEN, M., COX, A., VLASSELAER, J., GYSELAERS, W., 
VANDEPUT, H., GIELEN, J., POLLET, H., MAES, M., STEENO, O. & KRUGER, T. 1997. 
Semen parameters in a fertile versus subfertile population: A need for change in the 
interpretation of semen testing. Human Reproduction, 12, 987-993. 
PACEY, A. A., DAVIES, N., WARREN, M. A., BARRATT, C. L. R. & COOKE, L. D. 1995. 
Hyperactivation may assist human spermatozoa to detach from intimate association 
with the endosalpinx. Human Reproduction, 10, 2603-2609. 
PARK, J.-Y., AHN, H.-J., GU, J.-G., LEE, K.-H., KIM, J.-S., KANG, H.-W. & LEE, J.-H. 2003. Molecular 
identification of Ca(2+)channels in human sperm. Exp Mol Med, 35, 285-292. 
PEARSON, G., ROBINSON, F., BEERS GIBSON, T., XU, B.-E., KARANDIKAR, M., BERMAN, K. & 
COBB, M. H. 2001. Mitogen-Activated Protein (MAP) Kinase Pathways: Regulation and 
Physiological Functions. Endocrine Reviews, 22, 153-183. 
PERTWEE, R. G. 1997. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacology & 
Therapeutics, 74, 129-180. 
PERTWEE, R. G. 2005. Pharmacological Actions of Cannabinoids. In: PERTWEE, R. (ed.) 
Cannabinoids. Springer Berlin Heidelberg. 
POLAND, M. L., MOGHISSI, K. S., GIBLIN, P. T., AGER, J. W. & OLSON, J. M. 1985. VARIATION OF 
SEMEN MEASURES WITHIN NORMAL MEN. Fertility and Sterility, 44, 396-400. 
PORRAS, A., ZULUAGA, S., BLACK, E., VALLADARES, A., ALVAREZ, A. M., AMBROSINO, C., 
BENITO, M. & NEBREDA, A. R. 2004. p38α Mitogen-activated Protein Kinase Sensitizes 
Cells to Apoptosis Induced by Different Stimuli. Molecular Biology of the Cell, 15, 922-
933. 
PUBLICOVER, S., HARPER, C. V. & BARRATT, C. 2007. [Ca2+]i signalling in sperm-making the 
most of what you've got. Nature Cell Biology, 9, 235-42. 
PUBLICOVER, S. J. & BARRATT, C. L. R. 2011. Sperm motility: things are moving in the lab! 
Molecular Human Reproduction, 17, 453-456. 
QI, H., MORAN, M. M., NAVARRO, B., CHONG, J. A., KRAPIVINSKY, G., KRAPIVINSKY, L., 
KIRICHOK, Y., RAMSEY, I. S., QUILL, T. A. & CLAPHAM, D. E. 2007. All four CatSper ion 
channel proteins are required for male fertility and sperm cell hyperactivated motility. 
Proceedings of the National Academy of Sciences, 104, 1219-1223. 
RAMMLER, D. H. & ZAFFARONI, A. 1967. BIOLOGICAL IMPLICATIONS OF DMSO BASED ON A 
REVIEW OF ITS CHEMICAL PROPERTIES. Annals of the New York Academy of Sciences, 
141, 13-23. 
RAUPRICH, O., BERNS, E. & VOLLMANN, J. 2010. Who should pay for assisted reproductive 
techniques? Answers from patients, professionals and the general public in Germany. 
Human reproduction (Oxford, England), 25, 1225-33. 
REN, D. & XIA, J. 2010. Calcium Signaling Through CatSper Channels in Mammalian 
Fertilization. Physiology, 25, 165-175. 
172 
 
REN, D. J., NAVARRO, B., PEREZ, G., JACKSON, A. C., HSU, S. F., SHI, Q., TILLY, J. L. & CLAPHAM, 
D. E. 2001. A sperm ion channel required for sperm motility and male fertility. Nature, 
413, 603-609. 
RICHTER, W., DETTMER, D. & GLANDER, H. J. 1999. Detection of mRNA transcripts of cyclic 
nucleotide phosphodiesterase subtypes in ejaculated human spermatozoa. Molecular 
Human Reproduction, 5, 732-736. 
ROSSATO, M., ION POPA, F., FERIGO, M., CLARI, G. & FORESTA, C. 2005. Human Sperm Express 
Cannabinoid Receptor Cb1, the Activation of Which Inhibits Motility, Acrosome 
Reaction, and Mitochondrial Function. Journal of Clinical Endocrinology & Metabolism, 
90, 984-991. 
ROSSI, P., PEZZOTTI, R., CONTI, M. & GEREMIA, R. 1985. Cyclic nucleotide phosphodiesterases 
in somatic and germ cells of mouse seminiferous tubules. Journal of Reproduction and 
Fertility, 74, 317-327. 
ROWE, P. C., FRANK. HARGREAVE, TIMOTHY. MELLOWS, HEATHER. 1993. WHO Manual for the 
Standardized Investigation and Diagnosis of the Infertile Couple, Cambridge, 
Cambridge University Press. 
SAAD, A. & GUERIN, J. F. 1992. Movement characteristics of human spermatozoa collected 
from different layers of a discontinuous Percoll gradient. Andrologia, 24, 149-153. 
SAGARE-PATIL, V., GALVANKAR, M., SATIYA, M., BHANDARI, B., GUPTA, S. K. & MODI, D. 2012. 
Differential concentration and time dependent effects of progesterone on kinase 
activity, hyperactivation and acrosome reaction in human spermatozoa. International 
Journal of Andrology, 35, 633-644. 
SALICIONI, A. M., PLATT, M. D., WERTHEIMER, E. V., ARCELAY, E., ALLAIRE, A., SOSNIK, J. & 
VISCONTI, P. E. 2007. Signalling pathways involved in sperm capacitation. Society of 
Reproduction and Fertility supplement, 65, 245-59. 
SANTI, C. M., MARTÍNEZ-LÓPEZ, P., DE LA VEGA-BELTRÁN, J. L., BUTLER, A., ALISIO, A., 
DARSZON, A. & SALKOFF, L. 2010. The SLO3 sperm-specific potassium channel plays a 
vital role in male fertility. FEBS Letters, 584, 1041-1046. 
SCHMIDT, L., MÜNSTER, K. & HELM, P. 1995. Infertility and the seeking of infertility treatment 
in a representative population. British journal of obstetrics and gynaecology, 102, 978-
84. 
SCHREIBER, M., WEI, A., YUAN, A., GAUT, J., SAITO, M. & SALKOFF, L. 1998. Slo3, a Novel pH-
sensitive K+ Channel from Mammalian Spermatocytes. Journal of Biological Chemistry, 
273, 3509-3516. 
SCHREIBER, M., YUAN, A. & SALKOFF, L. 1999. Transplantable sites confer calcium sensitivity to 
BK channels. Nature Neuroscience, 2, 416-421. 
SCHUEL, H., BURKMAN, L. J., LIPPES, J., CRICKARD, K., MAHONY, M. C., GIUFFRIDA, A., PICONE, 
R. P. & MAKRIYANNIS, A. 2002. Evidence that anandamide-signaling regulates human 
sperm functions required for fertilization. Molecular Reproduction and Development, 
63, 376-387. 
SERRANO, C. J., TREVIÑO, C. L., FELIX, R. & DARSZON, A. 1999. Voltage-dependent Ca2+ 
channel subunit expression and immunolocalization in mouse spermatogenic cells and 
sperm. FEBS Letters, 462, 171-176. 
SERVIN-VENCES, M. R., TATSU, Y., ANDO, H., GUERRERO, A., YUMOTO, N., DARSZON, A. & 
NISHIGAKI, T. 2012. A caged progesterone analog alters intracellular Ca2+ and flagellar 
bending in human sperm. Reproduction, 144, 101-109. 
SI, Y. & OKUNO, M. 1995. Activation of mammalian sperm motility by regulation of 
microtubule sliding via cyclic adenosine 5'-monophosphate-dependent 
phosphorylation. Biology of Reproduction, 53, 1081-1087. 
SIGNORELLI, J., DIAZ, E. S. & MORALES, P. 2012. Kinases, phosphatases and proteases during 
sperm capacitation. Cell and Tissue Research, 349, 765-782. 
SINGH, J. P., BABCOCK, D. F. & LARDY, H. A. 1983. Motility activation, respiratory stimulation, 
and alteration of Ca2+ transport in bovine sperm treated with amine local anesthetics 
173 
 
and calcium transport antagonists. Archives of Biochemistry and Biophysics, 221, 291-
303. 
SODERLING, S. H. & BEAVO, J. A. 2000. Regulation of cAMP and cGMP signaling: new 
phosphodiesterases and new functions. Current Opinion in Cell Biology, 12, 174-179. 
STONE, B. A., VARGYAS, J. M., RINGLER, G. E., STEIN, A. L. & MARRS, R. P. 1999. Determinants 
of the outcome of intrauterine insemination: Analysis of outcomes of 9963 
consecutive cycles. American Journal of Obstetrics and Gynecology, 180, 1522-1534. 
STRAIN, A. J. 1993. HEPATOCYTE GROWTH-FACTOR - ANOTHER UBIQUITOUS CYTOKINE. 
Journal of Endocrinology, 137, 1-5. 
STRUNKER, T., GOODWIN, N., BRENKER, C., KASHIKAR, N. D., WEYAND, I., SEIFERT, R. & KAUPP, 
U. B. 2011. The CatSper channel mediates progesterone-induced Ca2+ influx in human 
sperm. Nature, 471, 382-386. 
SUAREZ, S. S. 2008. Control of hyperactivation in sperm. Human Reproduction Update, 14, 647-
657. 
SUAREZ, S. S., KATZ, D. F., OWEN, D. H., ANDREW, J. B. & POWELL, R. L. 1991. Evidence for the 
function of hyperactivated motility in sperm. Biology of Reproduction, 44, 375-381. 
SUAREZ, S. S., VAROSI, S. M. & DAI, X. 1993. Intracellular calcium increases with 
hyperactivation in intact, moving hamster sperm and oscillates with the flagellar beat 
cycle. Proceedings of the National Academy of Sciences, 90, 4660-4664. 
SUGIURA, T., KODAKA, T., KONDO, S., NAKANE, S., KONDO, H., WAKU, K., ISHIMA, Y., 
WATANABE, K. & YAMAMOTO, I. 1997. Is the Cannabinoid CB1 Receptor a 2-
Arachidonoylglycerol Receptor? Structural Requirements for Triggering a Ca2+ 
Transient in NG108–15 Cells. Journal of Biochemistry, 122, 890-895. 
SUGIURA, T. & WAKU, K. 2000. 2-Arachidonoylglycerol and the cannabinoid receptors. 
Chemistry and Physics of Lipids, 108, 89-106. 
SUKCHAROEN, N., KEITH, J., IRVINE, D. S. & AITKEN, R. J. 1995. PREDICTING THE FERTILIZING 
POTENTIAL OF HUMAN SPERM SUSPENSIONS IN-VITRO - IMPORTANCE OF SPERM 
MORPHOLOGY AND LEUKOCYTE CONTAMINATION. Fertility and Sterility, 63. 
SUKCHAROEN, N., KEITH, J., IRVINE, D. S. & AITKEN, R. J. 1996. Prediction of the in-vitro 
fertilization (IVF) potential of human spermatozoa using sperm function tests: the 
effect of the delay between testing and IVF. Human Reproduction, 11, 1030-1034. 
TASH, J. S. 1990. Role of cAMP, calcium, and protein phosphorylation in sperm motility. 
Controls of sperm motility: biological and clinical aspects., 229-240. 
TERSTAPPEN, G. C., RONCARATI, R., DUNLOP, J. & PERI, R. 2010. Screening technologies for ion 
channel drug discovery. Future Medicinal Chemistry, 2, 715-730. 
TESARIK, J., MENDOZA, C. & CARRERAS, A. 1992. Effects of phosphodiesterase inhibitors 
caffeine and pentoxifylline on spontaneous and stimulus-induced acrosome reactions 
in human sperm. Fertility and sterility, 58, 1185-1190. 
TESARIKI, J., THÉBAULT, A. & TESTART, J. 1992. Effect of pentoxifylline on sperm movement 
characteristics in normozoospermic and asthenozoospermic specimens. Human 
Reproduction, 7, 1257-1263. 
TESAŘÍK, J., OLTRAS, C. M. & TESTART, J. 1990. Effect of the human cumulus oophorus on 
movement characteristics of human capacitated spermatozoa. Journal of Reproduction 
and Fertility, 88, 665-675. 
THONNEAU, P., MARCHAND, S., TALLEC, A., FERIAL, M.-L., DUCOT, B., LANSAC, J., LOPES, P., 
TABASTE, J.-M. & SPIRA, A. 1991. Incidence and main causes of infertility in a resident 
population (1 850 000) of three French regions (1988–1989)*. Human Reproduction, 6, 
811-816. 
TOMLINSON, M., LEWIS, S. & MORROLL, D. 2013. Sperm quality and its relationship to natural 
and assisted conception: British Fertility Society Guidelines for practice. Human 
Fertility, 16, 175-193. 
174 
 
TOMLINSON, M., TURNER, J., POWELL, G. & SAKKAS, D. 2001. One-step disposable chambers 
for sperm concentration and motility assessment : how do they compare with the 
World Health Organization ’ s recommended methods ? 16, 121-124. 
TOMLINSON, M. J., KESSOPOULOU, E. & BARRATT, C. L. 1999. The diagnostic and prognostic 
value of traditional semen parameters. Journal of Andrology, 20, 588-593. 
TOMLINSON, M. J., POOLEY, K., SIMPSON, T., NEWTON, T., HOPKISSON, J., JAYAPRAKASAN, K., 
JAYAPRAKASAN, R., NAEEM, A. & PRIDMORE, T. 2010. Validation of a novel computer-
assisted sperm analysis (CASA) system using multitarget-tracking algorithms. Fertility 
and sterility, 93, 1911-20. 
TOURNAYE, H. 2012. Male factor infertility and ART. Asian journal of andrology, 14, 103-8. 
TOURNAYE, H. J. & COHLEN, B. J. 2012. Management of male-factor infertility. Best Practice 
&amp; Research Clinical Obstetrics &amp; Gynaecology, 26, 769-775. 
TSIEN, R. W., ELLINOR, P. T. & HORNE, W. A. 1991. MOLECULAR DIVERSITY OF VOLTAGE-
DEPENDENT CA2+ CHANNELS. Trends in Pharmacological Sciences, 12, 349-&. 
UEHARA, Y., MINOWA, O., MORI, C., SHIOTA, K., KUNO, J., NODA, T. & KITAMURA, N. 1995. 
PLACENTAL DEFECT AND EMBRYONIC LETHALITY IN MICE LACKING HEPATOCYTE 
GROWTH FACTOR/SCATTER FACTOR. Nature, 373, 702-705. 
ULLRICH, A. & SCHLESSINGER, J. 1990. Signal transduction by receptors with tyrosine kinase 
activity. Cell, 61, 203-212. 
VAN VOORHIS, B. J., BARNETT, M., SPARKS, A. E., SYROP, C. H., ROSENTHAL, G. & DAWSON, J. 
2001. Effect of the total motile sperm count on the efficacy and cost-effectiveness of 
intrauterine insemination and in vitro fertilization. Fertility and sterility, 75, 661-8. 
VAN WEERT, J. M., REPPING, S., VAN VOORHIS, B. J., VAN DER VEEN, F., BOSSUYT, P. M. M. & 
MOL, B. W. J. 2004. Performance of the postwash total motile sperm count as a 
predictor of pregnancy at the time of intrauterine insemination: a meta-analysis. 
Fertility and Sterility, 82, 612-620. 
VASTA, V., SONNENBURG, W. K., YAN, C., SODERLING, S. H., SHIMIZU-ALBERGINE, M. & BEAVO, 
J. A. 2005. Identification of a New Variant of PDE1A Calmodulin-Stimulated Cyclic 
Nucleotide Phosphodiesterase Expressed in Mouse Sperm. Biology of Reproduction, 
73, 598-609. 
VISCONTI, P. E. 2009. Understanding the molecular basis of sperm capacitation through kinase 
design. Proceedings of the National Academy of Sciences of the United States of 
America, 106, 667-8. 
VISCONTI, P. E., BAILEY, J. L., MOORE, G. D., PAN, D., OLDS-CLARKE, P. & KOPF, G. S. 1995a. 
Capacitation of mouse spermatozoa. I. Correlation between the capacitation state and 
protein tyrosine phosphorylation. Development (Cambridge, England), 121, 1129-37. 
VISCONTI, P. E., JOHNSON, L. R., OYASKI, M., FORNES, M., MOSS, S. B., GERTON, G. L. & KOPF, 
G. S. 1997. Regulation, localization, and anchoring of protein kinase a subunits during 
mouse sperm capacitation. Developmental Biology, 192, 351-363. 
VISCONTI, P. E., KRAPF, D., DE LA VEGA-BELTRÁN, J. L., ACEVEDO, J. J. & DARSZON, A. 2011. Ion 
channels, phosphorylation and mammalian sperm capacitation. Asian journal of 
andrology, 13, 395-405. 
VISCONTI, P. E., MOORE, G. D., BAILEY, J. L., LECLERC, P., CONNORS, S. A., PAN, D. Y., 
OLDSCLARKE, P. & KOPF, G. S. 1995b. CAPACITATION OF MOUSE SPERMATOZOA .2. 
PROTEIN-TYROSINE PHOSPHORYLATION AND CAPACITATION ARE REGULATED BY A 
CAMP-DEPENDENT PATHWAY. Development, 121, 1139-1150. 
VISCONTI, P. E., MOORE, G. D., BAILEY, J. L., LECLERC, P., CONNORS, S. A., PAN, D. Y., 
OLDSCLARKE, P. & KOPF, G. S. 1995c. Capacitation of Mouse Spermatozoa. 2. Protein-
Tyrosine Phosphorylation and Capacitation are Regulated by a cAMP-dependent 
Pathway. Development, 121, 1139-1150. 
VISCONTI, P. E., WESTBROOK, V. A., CHERTIHIN, O., DEMARCO, I., SLEIGHT, S. & DIEKMAN, A. B. 
2002. Novel signaling pathways involved in sperm acquisition of fertilizing capacity. 
Journal of reproductive immunology, 53, 133-50. 
175 
 
VISSER, L., WESTERVELD, G. H., XIE, F., VAN DAALEN, S. K. M., VAN DER VEEN, F., LOMBARDI, 
M. P. & REPPING, S. 2011. A comprehensive gene mutation screen in men with 
asthenozoospermia. Fertility and Sterility, 95, 1020-1024.e9. 
WALENSKY, L. D. & SNYDER, S. H. 1995. Inositol 1,4,5-trisphosphate receptors selectively 
localized to the acrosomes of mammalian sperm. The Journal of Cell Biology, 130, 857-
869. 
WALSCHAERTS, M., BUJAN, L., PARINAUD, J., MIEUSSET, R. & THONNEAU, P. 2013. Treatment 
discontinuation in couples consulting for male infertility after failing to conceive. 
Fertility and Sterility. 
WANG, G., GUO, Y., ZHOU, T., SHI, X., YU, J., YANG, Y., WU, Y., WANG, J., LIU, M., CHEN, X., TU, 
W., ZENG, Y., JIANG, M., LI, S., ZHANG, P., ZHOU, Q., ZHENG, B., YU, C., ZHOU, Z., GUO, 
X. & SHA, J. 2013. In-depth proteomic analysis of the human sperm reveals complex 
protein compositions. Journal of proteomics, 79, 114-22. 
WANG, H., DEY, S. K. & MACCARRONE, M. 2006. Jekyll and Hyde: Two Faces of Cannabinoid 
Signaling in Male and Female Fertility. Endocrine Reviews, 27, 427-448. 
WEIDINGER, S., MAYERHOFER, A., KUNZ, L., ALBRECHT, M., SBORNIK, M., WUNN, E., 
HOLLWECK, R., RING, J. & KOHN, F. M. 2005. Tryptase inhibits motility of human 
spermatozoa mainly by activation of the mitogen-activated protein kinase pathway. 
Human Reproduction, 20, 456-461. 
WELSBY, P. J., WANG, H., WOLFE, J. T., COLBRAN, R. J., JOHNSON, M. L. & BARRETT, P. Q. 2003. 
A Mechanism for the Direct Regulation of T-Type Calcium Channels by 
Ca2+/Calmodulin-Dependent Kinase II. The Journal of Neuroscience, 23, 10116-10121. 
WENNEMUTH, G., CARLSON, A. E., HARPER, A. J. & BABCOCK, D. F. 2003. Bicarbonate actions 
on flagellar and Ca2+-channel responses: initial events in sperm activation. 
Development, 130, 1317-1326. 
WHO, W. H. O. 1987. WHO Laboratory Manual for the Examination of Human Semen and 
Semen-Cervical Mucus Interaction. WHO Laboratory Manual for the Examination of 
Human Semen and Semen-Cervical Mucus Interaction. Cambridge University Press: 
New York, New York, USA; Cambridge, England, Uk. Illus. Paper. 
WHO, W. H. O. 1992. WHO Laboratory Manual for the Examination of Human Semen and 
Sperm-Cervical Mucus Interaction, Cambridge, Cambridge University Press. 
WHO, W. H. O. 2010a. Induced acrosome reaction assay. WHO Laboratory Manual for the 
Examination of Human Semen and Sperm-Cervical Mucus Interaction / Edition 5. 5 ed.: 
World Health Organization. 
WHO, W. H. O. 2010b. Reference values and semen nomenclature. 
WHO, W. H. O. 2010c. Semen Analysis: Preparing the Samples. WHO Laboratory Manual for 
Examintation of Human Semen and Sperm-Cervical Mucus Interaction/ Edition 5. 5 ed.: 
World Health Organization. 
WHO, W. H. O. 2010d. WHO Laboratory Manual for Examination of Human Semen and Sperm-
Cervical Mucus Interaction/ Edition 5. 5 ed.: World Health Organization. 
WHO, W. H. O. 2010e. WHO laboratory manual for the Examination and processing of human 
semen, Switzerland, World Health Organization. 
WHO, W. H. O. 2010f. WHO Laboratory Manual for the Examination of Human Semen and 
Sperm-Cervical Mucus Interaction / Edition 5. 5 ed.: World Health Organization. 
WILLIAMS, A. C. & FORD, W. C. L. 2001. The Role of Glucose in Supporting Motility and 
Capacitation in Human Spermatozoa. Journal of Andrology, 22, 680-695. 
WILTSHIRE, E. J., FLAHERTY, S. P. & COUPER, R. T. L. 2000. Hepatocyte growth factor in human 
semen and its association with semen parameters. Human Reproduction, 15, 1525-
1528. 
WONG, C.-H. & YAN CHENG, C. 2005. Mitogen-activated protein kinases, adherens junction 
dynamics, and spermatogenesis: A review of recent data. Developmental Biology, 286, 
1-15. 
176 
 
XIA, J., REIGADA, D., MITCHELL, C. H. & REN, D. 2007. CATSPER Channel-Mediated Ca2+ Entry 
into Mouse Sperm Triggers a Tail-to-Head Propagation. Biology of Reproduction, 77, 
551-559. 
XIE, F., EDDY, E. M. & CONTI, M. 2013. Chapter Six - Analysis of Signaling Pathways Controlling 
Flagellar Movements in Mammalian Spermatozoa. In: WALLACE, F. M. (ed.) Methods in 
Enzymology. Academic Press. 
XIE, F., GARCIA, M. A., CARLSON, A. E., SCHUH, S. M., BABCOCK, D. F., JAISWAL, B. S., GOSSEN, 
J. A., ESPOSITO, G., VAN DUIN, M. & CONTI, M. 2006. Soluble adenylyl cyclase (sAC) is 
indispensable for sperm function and fertilization. Developmental Biology, 296, 353-
362. 
YAN, C., ZHAO, A. Z., SONNENBURG, W. K. & BEAVO, J. A. 2001. Stage and Cell-Specific 
Expression of Calmodulin-Dependent Phosphodiesterases in Mouse Testis. Biology of 
Reproduction, 64, 1746-1754. 
YANAGIMACHI, R. 1970. The movement of golden hamster spermatozoa before and after 
capacitation. Journal of Reproduction and Fertility, 23, 193-196. 
YANAGIMACHI, R. 1994. Mammalian fertilisation, New York, Raven Press. 
YAO, Y. Q., NG, V., YEUNG, W. S. B. & HO, P. C. 1996. Profiles of sperm morphology and 
motility after discontinuous multiple-step Percoll density gradient centrifugation. 
Andrologia, 28, 127-131. 
YOVICH, J., EDIRISINGHE, W., CUMMINS, J. & YOVICH, J. 1990. Influence of pentoxifylline in 
severe male factor infertility. Fertility and Sterility, 53, 715. 
YOVICH, J. L. 1993. PENTOXIFYLLINE - ACTIONS AND APPLICATIONS IN ASSISTED 
REPRODUCTION. Human Reproduction, 8, 1786-1791. 
YUASA, K., KANOH, Y., OKUMURA, K. & OMORI, K. 2001. Genomic organization of the human 
phosphodiesterase PDE11A gene. European Journal of Biochemistry, 268, 168-178. 
ZHOU, C.-X., WANG, X.-F. & CHAN, H.-C. 2005. Bicarbonate secretion by the female 
reproductive tract and its impact on sperm fertilizing capacity. Shengli Xuebao, 57, 
115-124. 
ZHU, M. X., MA, J., PARRINGTON, J., CALCRAFT, P. J., GALIONE, A. & EVANS, A. M. 2010a. 
Calcium signaling via two-pore channels: local or global, that is the question. American 
Journal of Physiology - Cell Physiology, 298, C430-C441. 
ZHU, M. X., MA, J., PARRINGTON, J., GALIONE, A. & MARK EVANS, A. 2010b. TPCs: 
Endolysosomal channels for Ca2+ mobilization from acidic organelles triggered by 
NAADP. FEBS Letters, 584, 1966-1974. 
 
 
 
 
 
 
 
177 
 
 
 
 
 
CHAPTER 10 
Appendix  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
178 
 
10.1 Components, product list and catalogue numbers for Media and 
Compounds used. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 10.1 Identification of compounds and the product source for media which were utilised in all 
experiments conducted within this project.  
Compound NCM 
(mM) 
CM (mM) Source Catalogue N
o
 
CaCl2 1.8 1.8 Sigma-Aldrich C3306 - 100 
KCl 5.4 5.4 Sigma-Aldrich P5405 – 250g 
MgSO4.7H2O 0.8 0.8 Sigma-Aldrich M2773 - 500g 
Sodium chloride 116.4 116.4 Sigma-Aldrich S5886 – 1Kg 
NaH2PO4.2H2O 1.0 1.0 Sigma-Aldrich 71505 - 250g 
D- glucose 5.55 5.55 Sigma-Aldrich G6152 – 500g 
Sodium lactate 41.75 25 Sigma-Aldrich L7900 – 100ml 
Sodium pyruvate 2.73 2.73 Sigma-Aldrich P2256 – 25g 
HEPES 25 - Sigma-Aldrich H3375 – 1Kg 
Sodium 
bicarbonate 
- 26 Sigma-Aldrich S5761 -500g 
BSA 0.3% 0.3% Sigma-Aldrich A3059 – 100g 
Compound Source Catalogue N
o
 
DMSO Sigma-Aldrich 673439 
PHA665752 Tocris 2693 
Leelamine Hydrochloride Tocris 2139 
GP1a Tocris 2764 
JX401 Tocris 2657 
EO1428 Tocris 2908 
Trequinsin Hydrochloride Tocris 2337 
PureSperm 40% and 80% Hunter Scientific PS40-100 
PS80-100 
SAGE Gamete buffer Origio ART-1005 
Quinns Advantage 
Fertilisation Medium 
Origio ART-1020 
Human Serum Albumin 
(HSA) 
Origio  ART-3001 
Percoll Sigma-Aldrich P1644 
Calcium 3 Molecular Devices  
Methylcellulose Sigma-Aldrich M0512 
PSA FITC Sigma-Aldrich L0770 
Calcium Ionophore Sigma-Aldrich C7522 
PBS Sigma-Aldrich P4417 
Hydromount National Diagnostics HS-106 
D-fructose Sigma-Aldrich F0127 
Sodium citrate dihydrate Sigma-Aldrich W302600 
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10.2 Comparing donor fractions to 80% fraction recovered from patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10-2. Comparison between donor and sub-fertile samples in Curvelinear Velocity (VCL) in Percoll® 
fractions relative to incubation time under capacitating conditions (A) Overview of 20%, 40%, 60%, 80% and 
90% donor fraction compared to 80% sub-fertile fraction (B) 20% donor, 80% sub-fertile (C) 40% donor, 80% sub-
fertile (D) 60% donor, 80% sub-fertile (E) 80% donor, 80% sub-fertile (F) 90% donor, 80% sub-fertile. The result 
shown is the mean ± SEM. N= 5 for both donors and patients, *indicates significant difference (P˂0.05) **indicates 
P˂0.01 (T-test and Kruskall-Wallace test).   
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Figure 10-2. Comparison between donor and sub-fertile samples in amplitude of lateral head displacement 
(ALH) in Percoll® fractions relative to incubation time under capacitating conditions (A) Overview of 20%, 
40%, 60%, 80% and 90% donor fraction compared to 80% sub-fertile fraction (B) 20% donor, 80% sub-fertile (C) 
40% donor, 80% sub-fertile (D) 60% donor, 80% sub-fertile (E) 80% donor, 80% sub-fertile (F) 90% donor, 80% 
sub-fertile. The result shown is the mean ± SEM. N= 5 for both donors and patients, *indicates significant difference 
(P˂0.05) (Mann Whitney test and Kruskall-Wallace test).  
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Figure 10-3. Comparison between donor and sub-fertile samples in linearity (LIN) in Percoll® fractions 
relative to incubation time under capacitating conditions (A) Overview of 20%, 40%, 60%, 80% and 90% donor 
fraction compared to 80% sub-fertile fraction (B) 20% donor, 80% sub-fertile (C) 40% donor, 80% sub-fertile (D) 
60% donor, 80% sub-fertile (E) 80% donor, 80% sub-fertile (F) 90% donor, 80% sub-fertile. The result shown is the 
mean ± SEM. N= 5 for both donors and patients, *indicates significant difference (P˂0.05) ***indicates P˂0.001 (T-
test and Kruskall-Wallace test).  
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Figure 10-4. Comparison between donor and sub-fertile samples in % total motile in Percoll® fractions relative 
to incubation time under capacitating conditions (A) Overview of 20%, 40%, 60%, 80% and 90% donor fraction 
compared to 80% sub-fertile fraction (B) 20% donor, 80% sub-fertile (C) 40% donor, 80% sub-fertile (D) 60% 
donor, 80% sub-fertile (E) 80% donor, 80% sub-fertile (F) 90% donor, 80% sub-fertile. The result shown is the mean 
± SEM. N= 5 for both donors and patients, *indicates significant difference (P˂0.05) (Mann Whitney test and 
Kruskall-Wallace test).  
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Figure 10-5. Comparison between donor and sub-fertile samples in % progressive motility in Percoll® 
fractions relative to incubation time under capacitating conditions (A) Overview of 20%, 40%, 60%, 80% and 
90% donor fraction compared to 80% sub-fertile fraction (B) 20% donor, 80% sub-fertile (C) 40% donor, 80% sub-
fertile (D) 60% donor, 80% sub-fertile (E) 80% donor, 80% sub-fertile (F) 90% donor, 80% sub-fertile. The result 
shown is the mean ± SEM. N= 5 for both donors and patients, *indicates significant difference (P˂0.05) (Mann 
Whitney test and Kruskall-Wallace test).  
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Figure 10-6. Comparison between donor and sub-fertile samples in % hyperactivation in Percoll® fractions 
relative to incubation time under capacitating conditions (A) Overview of 20%, 40%, 60%, 80% and 90% donor 
fraction compared to 80% sub-fertile fraction (B) 20% donor, 80% sub-fertile (C) 40% donor, 80% sub-fertile (D) 
60% donor, 80% sub-fertile (E) 80% donor, 80% sub-fertile (F) 90% donor, 80% sub-fertile. The result shown is the 
mean ± SEM. N= 5 for both donors and patients, *indicates significant difference (P˂0.05) (Mann Whitney test and 
Kruskall-Wallace test).  
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10.3 Determination of the number of aliquots from a single sample that need 
to be taken to assess motility parameters 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10-7 Variation in range of results, 4 aliquots vs 2 aliquots, for the 40% fraction of 
spermatozoa in non-capacitating buffer (A) VAP, (B) VSL, (C) VCL, (D) ALH and (E) % 
hyperactivation.  The result shown is the mean (coloured diamonds) ± the range for A-E, see figure 4-1 
for identifying features of box plots. Motility parameters were measured over a period of 180 min under 
non-capacitating conditions comparing the number of replicates needed to produce a low sampling error 
when measuring sperm motility. Dark Grey boxes = 2 aliquots, 400 cells per aliquot, Light Grey boxes = 
4 aliquots, 200 cells per aliquot. N= 3 for both parameters. Results show no significant differences (Mann 
Whitney test) 
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Figure 10-8 Variation in range of results, 4 aliquots vs 2 aliquots, for the 80% fraction of 
spermatozoa in non-capacitating buffer (A) VAP, (B) VSL, (C) VCL, (D) ALH and (E) % 
hyperactivation.  The result shown is the mean (coloured diamonds) ± the range for A-E, see figure 4-1 
for identifying features of box plots. Motility parameters were measured over a period of 180 min under 
non-capacitating conditions comparing the number of replicates needed to produce a low sampling error 
when measuring sperm motility. Dark Grey boxes = 2 aliquots, 400 cells per aliquot, Light Grey boxes = 
4 aliquots, 200 cells per aliquot. N= 3 for both parameters. Results show no significant differences (Mann 
Whitney test) 
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Figure 10-9 Variation in range of results, 4 aliquots vs 2 aliquots, for the 40% fraction of 
spermatozoa in capacitating conditions (A) VAP, (B) VSL, (C) VCL, (D) ALH and (E) % 
hyperactivation.  The result shown is the mean (coloured diamonds) ± the range for A-E, see figure 4-1 
for identifying features of box plots. Motility parameters were measured over a period of 180 min under 
non-capacitating conditions comparing the number of replicates needed to produce a low sampling error 
when measuring sperm motility. Dark Grey boxes = 2 aliquots, 400 cells per aliquot, Light Grey boxes = 
4 aliquots, 200 cells per aliquot. N= 3 for both parameters. Results show no significant differences (Mann 
Whitney test) 
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Figure 10-10 Variation in range of results, 4 aliquots vs 2 aliquots, for the 80% fraction of 
spermatozoa in capacitating conditions (A) VAP, (B) VSL, (C) VCL, (D) ALH and (E) % 
hyperactivation.  The result shown is the mean (coloured diamonds) ± the range for A-E, see figure 4-1 
for identifying features of box plots. Motility parameters were measured over a period of 180 min under 
non-capacitating conditions comparing the number of replicates needed to produce a low sampling error 
when measuring sperm motility. Dark Grey boxes = 2 aliquots, 400 cells per aliquot, Light Grey boxes = 
4 aliquots, 200 cells per aliquot. N= 3 for both parameters. Results show no significant differences (Mann 
Whitney test) 
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10.4 Determination of slide type required for CASA assessment of motility 
Figure 10-11 Variation in motility between two slide types: Hamilton Thorne glass slides with 
manual glass coverslips and fixed chamber slides (A) VAP, (B) VSL, (C) VCL, (D) % 
hyperactivation. The result shown is the mean ± SE measured at defined time points up to 180 min N= 3 
for both parameters, * indicates a significant increase between manual and fixed slides at independent 
time points for 80% fraction of sperm under capacitating conditions. Significance was considered as 
P˂0.05 
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10.5 Assessment of motility parameters in capacitating and non-capacitating 
media    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10-12 Expression of basal (control) motility values in non-capacitating (NCM) and 
capacitating media (CM) for 40%; (A) VAP (B) VSL (C) VCL and (D) ALH and 80% fractions; (E) 
VAP, (F) VSL, (G) VCL and (H) ALH. The result shown is the mean ± SE. In this study all motility 
parameters were measured over a period of 180 min under non-capacitating and capacitating conditions 
comparing the difference between the two media types. N= 5 for NCM and N= 9 for CM, *** indicates a 
significant increase (P˂0.005 or P˂0.001) between NCM and CM at independent time points (Mann 
Whitney test and Kruskal-Wallace test).   
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10.6 Effect of 1% DMSO on treated sperm samples 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10-13 Expression of basal (control) motility values in non-capacitating media (NCM) treated 
with 1% DMSO in 40% fraction (A) VAP, (B) VSL, (C) VCL, (D) ALH, (E) % HA and 80% fraction 
(F) VAP, (G) VSL, (H) VCL, (I) ALH, (J) % HA. The result shown is the mean ± SE. In this study all 
motility parameters were measured over a period of 180 min under non- capacitating conditions 
comparing the difference between treatment with 1% DMSO and non-treated media. N= 4 for NCM and 
NCM + 1% DMSO, no significant difference noted at any time point.  
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Figure 10-14 Expression of basal (control) motility values capacitating media (CM) treated with 
1% DMSO in 40% fraction (A) VAP, (B) VSL, (C) VCL, (D) ALH and 80% fraction (E) VAP, (F) 
VSL, (G) VCL, (H) ALH. The result shown is the mean ± SE. In this study all motility parameters were 
measured over a period of 180 min under capacitating conditions comparing the difference between 
treatment with 1% DMSO and non-treated media. N= 4 for CM and CM + 1% DMSO, no significant 
difference noted at any time point.  
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Figure 10-15 Expression of basal (control) motility values compared to treated samples (Leelamine 
Hydrochloride) in non-capacitating (NCM) media, 40% fraction (A) ALH, (B) VCL, (C) % total 
motile, (D) % progressively motile and 80% fraction (E) ALH, (F) VCL, (G) % total motile, (H) % 
progressively motile. The result shown is the mean ± SE. In this study all motility parameters were 
measured over a period of 180 min under non-capacitating conditions comparing the difference between 
the control and treated samples. N= 4 for both parameters, * indicates a significant increase (P˂0.05) 
between control and treated samples at independent time points (Mann Whitney test and Kruskall-
Wallace test).   
A 
B 
C D 
194 
 
0 
10 
20 
30 
40 
50 
0 30 60 90 120 150 180 
%
 H
A
 
Time (Mins) 
Control (40% CM) Leelamine Hydrochloride C 
0 
20 
40 
60 
80 
100 
0 30 60 90 120 150 180 
V
C
L 
(µ
m
/s
e
c)
 
 
Time (Mins) 
Control (40% CM) Leelamine Hydrochloride A 
0 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
0 30 60 90 120 150 180 
A
LH
 (
µ
) 
 
Time (Mins) 
Control (40% CM) Leelamine Hydrochloride B 
0 
20 
40 
60 
80 
100 
120 
140 
0 30 60 90 120 150 180 
V
C
L 
(µ
m
/s
e
c)
 
 
Time (Mins) 
Control (80% CM) Leelamine Hydrochloride D 
0 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
0 30 60 90 120 150 180 
A
LH
 (
µ
) 
 
Time (Mins) 
Control (80% CM) Leelamine Hydrochloride E 
0 
20 
40 
60 
80 
100 
0 30 60 90 120 150 180 
%
 P
ro
gr
e
ss
iv
e
ly
 M
o
ti
le
 
Time (Mins) 
Control (80% CM) Leelamine Hydrochloride G 
0 
20 
40 
60 
80 
100 
0 30 60 90 120 150 180 
%
 T
o
ta
l M
o
ti
le
 
Time (Mins) 
Control (80% CM) Leelamine Hydrochloride F 
0 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
0 30 60 90 120 150 180 
A
LH
 (
µ
) 
 
Time (Mins) 
Control (80% CM) Leelamine Hydrochloride 
E 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10-16 Expression of basal (control) motility values compared to treated samples (Leelamine 
Hydrochloride) in capacitating (CM) media, 40% fraction (A) VCL, (B) ALH, (C) % HA and 80% 
fraction (D) VCL, (E) ALH, (F) % total motile, (G) % progressively motile. The result shown is the 
mean ± SE. In this study all motility parameters were measured over a period of 180 min under non-
capacitating conditions comparing the difference between the control and treated samples. N= 4 for both 
parameters, * indicates a significant increase (P˂0.05) between control and treated samples at 
independent time points (Mann Whitney test and Kruskall-Wallace test).   
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Figure 10-17 Expression of basal (control) motility values compared to treated samples (GP1a) in 
non- capacitating (NCM) media (40% and 80% fraction). For 40% fraction (A) VCL, (B) ALH, (C) 
% total motile, (D)  % progressively motile and for 80% fraction (E) VCL, (F) ALH and (G) % 
progressive motility.  The result shown is the mean ± SE for all parameters. In this study all motility 
parameters were measured over a period of 180 min under non- capacitating or capacitating conditions 
comparing the difference between the control and treated samples. N= 3 for all parameters, * indicates a 
significant increase (P˂0.05) between control and treated samples at independent time points (Mann 
Whitney test and Kruskall-Wallace test). 
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Figure 10-18 Expression of basal (control) motility values compared to treated samples (GP1a) in 
capacitating (CM) media (40% and 80% fraction). For 40% fraction (A) VCL, (B) ALH and for 
80% fraction (C) VCL, (D) ALH and (E) % progressive motility.  The result shown is the mean ± SE for 
all parameters. In this study all motility parameters were measured over a period of 180 min under non- 
capacitating or capacitating conditions comparing the difference between the control and treated samples. 
N= 3 for all parameters, * indicates a significant increase (P˂0.05) between control and treated samples 
at independent time points (Mann Whitney test and Kruskall-Wallace test). 
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Figure 10-19. Expression of basal (control) motility values compared to treated samples (EO1428) in 
non-capacitating (NCM) media. Data for 40% fraction under non-capacitating conditions for (A) VCL, 
(B) ALH, (C) % total motile and (D) % progressively motile. Data for 80% fraction; (E) VCL and (F) 
ALH. The result shown is the mean ± SE for motility parameters measured. In this study all motility 
parameters were measured over a period of 180 min under either non-capacitating or capacitating 
conditions comparing the difference between the control and treated samples. N= 4 for all parameters, * 
indicates a significant increase (P˂0.05) between control and treated samples at independent time points 
(Mann Whitney test and Kruskall-Wallace test).   
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Figure 10-20. Expression of basal (control) motility values compared to treated samples (EO1428) in 
capacitating (CM) media. Data for 40% fraction for (A) VCL, (B) ALH, (C) % hyperactivation. Data 
for 80% fraction; (D) VCL, (E) ALH, (F) % total motile and (G) % progressively motile. The result 
shown is the mean ± SE for motility parameters measured. In this study all motility parameters were 
measured over a period of 180 min under either non-capacitating or capacitating conditions comparing 
the difference between the control and treated samples. N= 4 for all parameters, * indicates a significant 
increase (P˂0.05) between control and treated samples at independent time points (Mann Whitney test 
and Kruskall-Wallace test).   
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Figure 10-21. Expression of basal (control) motility values compared to treated samples (JX401) in 
non-capacitating (NCM) media in 40% fractions for (A) VCL, (B) ALH, (C) % total motile, (D) 
hyperactivation and 80% fractions (E) VCL, (F) ALH and (G) % total motile. The result shown is the 
mean ± SE for motility parameters measured. In this study all motility parameters were measured over a 
period of 180 min under non-capacitating conditions comparing the difference between the control and 
treated samples. N= 3 for both parameters, * indicates a significant increase (P˂0.05) between control 
and treated samples at independent time points (Mann Whitney test and Kruskall-Wallace test).   
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Figure 10-22. Expression of basal (control) motility values compared to treated samples (JX401) in 
capacitating (CM) media in 40% fractions for (A) VCL, (B) ALH, (C) % total motile, (D) 
hyperactivation and 80% fractions (E) VCL, (F) ALH, (G) % total motile, (H) % progressively motile 
and (I) hyperactivation. In this study all motility parameters were measured over a period of 180 min 
under capacitating conditions comparing the difference between the control and treated samples. N= 3 for 
both parameters, * indicates a significant increase (P˂0.05) between control and treated samples at 
independent time points.   
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Figure 10-23. Expression of basal (control) motility values compared to treated samples 
(PHA665752) in non-capacitating (NCM) media in 40% fraction for (A) VCL, (B) ALH, (C) % total 
motile, (D) % progressive motility and 80% fraction for (E) VCL, (F) ALH, (G)  % total motile and (H) 
% progressively motile. The result shown is the mean ± SE for motility parameters measured. All motility 
parameters were measured over a period of 180 min under non-capacitating conditions. N= 3 for all 
parameters, * indicates a significant increase (P˂0.05) between control and treated samples at 
independent time points.   
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Figure 10-24. Expression of basal (control) motility values compared to treated samples 
(PHA665752) in capacitating (CM) media in 40% fraction for (A) VCL, (B) ALH, (C)  % total motile 
and (D) % progressively motile and 80% fraction (E) VCL, (F) ALH and (G) % progressively motile. 
The result shown is the mean ± SE for motility parameters measured. In this study all motility parameters 
were measured over a period of 180 min under either non-capacitating or capacitating conditions 
comparing the difference between the control and treated samples. N= 3 for all parameters, * indicates a 
significant increase (P˂0.05) between control and treated samples at independent time points (Mann 
Whitney test and Kruskall-Wallace test).   
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Figure 10-25 Expression of basal (control) motility values compared to treated samples (Trequinsin 
Hydrochloride) in non-capacitating (NCM) media for 40% fraction (A) ALH, (B) VCL and (C) % 
total motile and 80% fraction (D) VCL, (E) ALH and (F) % total motile. The result shown is the mean ± 
SE for motility parameters measured. In this study all motility parameters were measured over a period of 
180 min under either non-capacitating or capacitating conditions comparing the difference between the 
control and treated samples. N= 6 for all parameters, * indicates a significant increase (P˂0.05), ** 
indicates P˂0.005 between control and treated samples at independent time points (T-test, Mann Whitney 
test and Kruskall-Wallace test).   
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Figure 10-26 Expression of basal (control) motility values compared to treated samples (Trequinsin 
Hydrochloride) in non-capacitating (NCM) media for 40% fraction (A) VCL, (B) ALH, (C) % total 
motile, (D) % progressively motile and (E) hyperactivation and 80% fraction (F) VCL, (G) ALH, (H) % 
total motile and (I) % progressively motile. In this study all motility parameters were measured over a 
period of 180 min under capacitating conditions comparing the difference between the control and treated 
samples. N= 6 for all parameters, * indicates a significant increase (P˂0.05), ** indicates P˂0.005 
between control and treated samples at independent time points (T-test, Mann Whitney test and Kruskall-
Wallace test).   
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Figure 10-27. Comparing basal (control) motility values under capacitating conditions to 
Trequinsin treated non-capacitated samples for 40% fraction (A) VCL, (B) ALH and 80% fraction 
(C) VCL and (D) ALH. The result shown is the mean ± SE for motility parameters measured. In this 
study all motility parameters were measured over a period of 180 min.  N= 6 for both parameters, * 
indicates a significant increase (P˂0.05), ** indicates P˂0.005 between control and treated samples at 
independent time points (T-test, Mann Whitney test and Kruskall-Wallace test).   
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10.13 Treatment with Novel Ion Channel Compounds (A1-H1) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10-28. Expression of basal (control) motility values compared to treated samples in non-
capacitating (NCM) media, 40% fraction (A) VCL, (B) ALH (C) % hyperactivation. The result shown 
is the mean ± SE. In this study all motility parameters were measured over a period of 180 min under 
non-capacitating conditions comparing the difference between the control and treated samples. N= 3 for 
all compounds, * indicates a significant increase (P˂0.05) between control and treated samples at 
independent time points (Mann Whitney test and Kruskall-Wallace test).   
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Figure 10-29. Expression of basal (control) motility values compared to treated samples in non-
capacitating (NCM) media, 40% fraction (A) % total motile and (B) % progressively motile. The result 
shown is the mean ± SE. In this study all motility parameters were measured over a period of 180 min 
under capacitating conditions comparing the difference between the control and treated samples. N= 3 for 
all compounds, * indicates a significant increase (P˂0.05) between control and treated samples at 
independent time points (Mann Whitney test and Kruskall-Wallace test).   
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Figure 10-30 Expression of basal (control) motility values compared to treated samples in 
capacitating media (CM), 80% fraction (A) VCL, (B) ALH and (C) % hyperactivation. The result 
shown is the mean ± SE. In this study all motility parameters were measured over a period of 180 min 
under capacitating conditions comparing the difference between the control and treated samples. N= 3 for 
all compounds, * indicates a significant increase (P˂0.05) between control and treated samples at 
independent time points (Mann Whitney test and Kruskall-Wallace test).   
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10.14 Progesterone Metabolites (Neurosteroids) 
10.14.1 Introduction 
Progesterone induces hyperactivation, stimulates the acrosome reaction and increases 
binding and penetrating capabilities of spermatozoa in hamster oocytes (Uhler et al., 
1992, Calogero et al., 1996, Bronson et al., 1999, Sueldo et al., 1993). The 
physiological relevance of this has been proven through sperm incubation with 
follicular fluid which controls sperm function in relation to the steroid content. When 
steroids were removed from the follicular fluid the related sperm functional effects 
(hyperactivation and the acrosome reaction) disappeared (Calogero et al., 2000). 
Progesterone has been found to significantly increase the number of hyperactivated 
spermatozoa and is capable of generating an almost three-fold increase in the percentage 
of hyperactivated sperm in a sample even at low concentrations (Uhler et al., 1992, 
Calogero et al., 2000, Calogero et al., 1996). A large number of studies have shown that 
progesterone is capable of modulating sperm function by interacting with a membrane 
binding site similar to the neuronal γ-aminobutyric acid (GABAA) receptor (Calogero et 
al., 2000). Activation of the neuronal GABAA receptor results in an influx of chloride 
ions through open chloride channels leading to hyperpolarization in the neuron. 
Progesterone and its metabolites have been implicated in the interaction of GABA with 
its GABAA receptor in the central nervous system (Calogero et al., 2000, Lan et al., 
1991, Majewska et al., 1986). The presence of GABA in human semen and specifically 
the identification of GABAA binding sites on human sperm plasma membranes had not 
been elucidated until 1995 however in 1993 Wistrom and Meizel observed the 
involvement of a putative GABAergic receptor in the progesterone induced acrosome 
reaction (Aurell and Meizel, 1993, Aanesen et al., 1995). However, the GABAA 
receptor identified on sperm is different to the neuronal GABAA receptor and results in 
an efflux of chloride ions rather than an influx as seen in neuronal tissue (Aurell and 
Meizel, 1993). The presence of GABAA receptors and their biological competences has 
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been substantiated by a numerous studies and it has been shown that GABA 
independently is capable of initiating the acrosome reaction in human sperm (Aurell and 
Meizel, 1993, Aanesen et al., 1995, Ritta et al., 1998). Calogero et al identified that 
GABA is also able to modulate sperm kinematic parameters in normal men and this 
modulation involved the GABAA receptor specifically (Calogero et al., 1996).  
However, the effect of GABA on sperm motility is still controversial with Aanesen et al 
not being able to identify any effect of GABA on sperm motility (Aanesen et al., 1995). 
 
The Dundee drug discovery unit had previously produced a library similar to the 
Chemogenomics library (chapter 5 and 6) which consisted of neurosteroids which are 
metabolites of progesterone.  These compounds are also allosteric modulators of 
GABAA receptors which included the GABAA agonist muscimol and the modulator 
diazepam along with DHEA, 5α-pregnan-3α-ol-20-one and 5β-pregnan-3α-ol-20-one 
and DHEA sulphate. From the knowledge of the effect of GABA and progesterone on 
sperm function via the GABAA receptor it was decided to include some compounds 
from this library in the motility assessment. These compounds were evaluated 
identically to the compounds from the Chemogenomics library and were selected for 
their ability to increase intracellular Ca
2+
.    
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10.14.2 Results 
Prepared sperm cells were collected from the 40% fraction after density gradient 
centrifugation and placed in appropriate incubators under non-capacitating conditions. 
Following this, cells were treated with the appropriate compound and motility analysis 
conducted on addition of compound and then at 30 min intervals over a period of 3 hrs 
(see chapter 2, methods).  
No significant changes were identified from treatment at any time point, in any of the 
kinematic parameters assessed (VCL, ALH, total motile and progressively motile) for 
DHEA, 5β-pregnan-3α-ol-20-one and diazepam (figures 10-31 A-C and 10-32 A). 
However, muscimol and 5α-pregnan-3α-ol-20-one were found to significantly increase 
ALH instantaneously (0 min, P˂0.05, figure 10-31 B) although this effect was not 
sustained past this point.  5α-pregnan-3α-ol-20-one and DHEA sulphate were then 
found to significantly decrease ALH after 120 min incubation (P˂0.05, figure 10-31 B). 
No other significant changes were noted for these compounds in any other parameter at 
any other time point.        
 
 
 
 
 
 
 
 
 
 
 
 
212 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10-31. Expression of basal (control) motility values compared to treated samples in non-
capacitating (NCM) media, 40% fraction (A) VCL, (B) ALH and (C) % total motile. The result shown 
is the mean ± SE. In this study all motility parameters were measured over a period of 180 min under 
non-capacitating conditions comparing the difference between the control and treated samples. N= 3 for 
all compounds, * indicates a significant increase (P˂0.05) between control and treated samples at 
independent time points (Mann Whitney test and Kruskall-Wallace test).   
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Figure 10-32. Expression of basal (control) motility values compared to treated samples in non-
capacitating (NCM) media, 40% fraction (A) % progressive motility. The result shown is the mean ± 
SE. In this study all motility parameters were measured over a period of 180 min under non-capacitating 
conditions comparing the difference between the control and treated samples. N= 3 for all compounds, * 
indicates a significant increase (P˂0.05) between control and treated samples at independent time points 
(Mann Whitney test and Kruskall-Wallace test).   
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10.14.3 Discussion 
As mentioned previously the effect of compounds affecting sperm motility through 
GABAA receptors is controversial. The results from this study overall corroborate the 
results from Aanesen et al (1995) identifying very few significant changes in motility 
(Aanesen et al., 1995). However, muscimol was found to stimulate ALH in this study 
which is similar to the results observed by Calogero et al (1996) (Calogero et al., 1996).  
The study by Calogero et al (1996) found treatment with muscimol also increased VCL, 
the percentage of active sperm and hyperactivation which was not seen in this study 
(Calogero et al., 1996). Ritta et al (1998) also identified significant increases in 
hyperactivation as a result of muscimol treatment suggesting under the correct 
conditions this compound has the potential to promote hyperactivated motility (Ritta et 
al., 1998).  The reason for this discrepancy is most likely owing to the difference in 
experimental protocol with samples in this study being from the 40% fraction under 
non-capacitating conditions.  
  
Numerous studies have linked compounds that act via GABAA receptors to the 
acrosome reaction and a proposed model for this suggests the chloride flux in 
spermatozoa, plays a role in the regulation of the secondary Ca
2+
 transient, essential for 
the acrosome reaction (Tesarik, 1996, Aurell and Meizel, 1993, Shi and Roldan, 1995). 
The chloride induced depolarization which results from binding to the GABAA receptor 
is thought to open an additional set of channels that are voltage regulated, leading to a 
secondary Ca
2+
 transient and the initiation of the acrosome reaction (Tesarik, 1996, 
Meizel et al., 1997). Meizel et al (1997) were the first group to detect a ligand mediated 
Ca
2+
 wave in sperm and they proposed that the efflux of chloride ions as a result of 
GABAA receptor binding of progesterone influences Ca
2+ 
influx during the acrosome 
reaction (Meizel et al., 1997). This Ca
2+ 
influx could explain the increased [Ca
2+
]i 
measured by the Flexstation when spermatozoa were treated with these compounds. It 
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would be beneficial to complete acrosome studies on these compounds to confirm this 
theory.  Further analysis was not conducted on these compounds owing to the minimal 
changes in motility expressed as a result of incubation with these compounds.       
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10.15 Clinic A and B datasets 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10-33 Scatter plots identifying correlations for Clinic A for the lower limit group (≤15 
million/ml). 2-D plots looking at correlations between motility and morphology (A), motility and 
concentration (B) and morphology and concentration (C).    
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Figure 10-34 Scatter plots identifying correlations for Clinic B for the lower limit group (≤15 
million/ml). 2-D plots looking at correlations between motility and morphology (A), motility and 
concentration (B) and morphology and concentration (C).    
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Figure 10-35 Scatter plots identifying correlations for Clinic A for the upper limit group (≤100 
million/ml).2-D plots looking at correlations between motility and morphology (A), motility and 
concentration (B) and morphology and concentration (C).    
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Figure 10-36 Scatter plots identifying correlations for Clinic B for the upper limit group (≤100 
million/ml). 2-D plots looking at correlations between motility and morphology (A), motility and 
concentration (B) and morphology and concentration (C).    
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10.16 Consent form for patient/donor participation in research 
 
CONSENT FORM FOR PATIENTS/DONORS  
[producing extra semen samples]   
Title of research: Understanding the regulation of human sperm function and the development 
of novel treatments for male infertility. 
First of all we would like to thank you very much for taking part in our research project. 
The aim of this study is to understand how a sperm cell is activated in response to secretions 
from the female tract - progesterone and nitric oxide and to understand if this activation is 
abnormal in some men. In addition we would like to test enzyme inhibitors to see if we can 
enhance sperm motility and hope that in the future we may be able to develop drugs which may 
be able to improve IVF success. 
You may decline to take part, or withdraw at any time without this affecting, in any way, your 
treatment and care now or in the future. 
I have fully understood what will be involved in the project.  This study involves me producing 
a semen (sperm) sample by masturbation in the Assisted Conception Unit or by arrangement at 
home, for the research purposes of the project.  In the future there may be requests for further 
semen samples. 
 
Signed……………………………………………………………………………………. 
Name (block capitals)…………………………………………………………………….. 
Date………………………………………………………………………………………… 
Witnessed…………………………………(name)………………………………Signature 
 
If you have any further queries or questions you can contact either: Mr Steven Mansell (01382 
660111 ext. 33605) or Nurse Evelyn Barratt,  e.barratt@dundee.ac.uk 
 
 
 
ASSISTED CONCEPTION 
UNIT 
NHS TAYSIDE 
WARD 35 NINEWELLS HOSPITAL 
 DUNDEE DD1 9SY 
 
 Direct line (01382) 632111 
Fax (01382) 633853 
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Patient/donor consent form 
Research to improve our understanding of how human sperm function 
I have read the research study information sheet and have had the opportunity to 
ask questions                                                                                 YES / NO                                                                                
I understand that I can withdraw consent or change my mind at any time 
                                                                                                         YES / NO 
Whether I participate or not, I understand that this will have no impact on my 
treatment or care either now or in the future                YES / NO 
I consent to allowing researchers to use left-over semen following diagnosis or 
treatment           YES / NO 
I am prepared to be contacted for a further sample, if required     YES / NO 
If yes: contact details 
 
SIGNED………………………………………………………………………………………………………………………….. 
NAME (BLOCK CAPITALS)……………………………………………………………………………………….. 
DATE…………………………………………………………………………………….. 
WITNESSED……………………………………(NAME)……………………………………(SIGNATURE) 
If you have any further questions or queries you can contact either nurse Evelyn 
Barratt (07528 558624 or email e.barratt@dundee.ac.uk) or Dr Sarah Martins da 
Silva (01382 660111 bleep 4535 or email s.martinsdasilva@dundee.ac.uk)  
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